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General introduction and aims 
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Trauma to a limb (often minor) is occasionally followed by severe pain and trophic changes 
characteristic of sympathetic algodystrophy (Sudeck's atrophy). The pathophysiology of 
the condition is unknown. Even more rarely minor trauma may provoke not only Sudeck's 
atrophy but also involuntary movements. The clinical picture is so unusual that such 
patients may be labeled as "hysterical," particularly when compensation is being 
considered. We, however, have seen four similar cases of muscle spasms associated with 
Sudeck's atrophy after mild trauma in three different countries. We believe this to be a 




These words date back to 1984. Since this recognition by professor C. David Marsden and 
colleagues, a number of case series
2-7
 were reported on what is nowadays called 'complex 
regional pain syndrome (CRPS) related dystonia'. 
 
Dystonia 
In general, dystonia is characterized by an abnormal control of movement, with 
involuntary muscle contractions causing twisting movements and abnormal postures.
8
 In 
CRPS, dystonia typically presents with predominant flexor postures of the fingers (in less 
severe cases only the third to fifth finger), wrists, and feet. Progression to the proximal 
part of the extremity as well as spread to muscles outside the affected limb may occur. 
Because of the presence of postures, which are typically not mobile, this dystonia is called 
'fixed'.  
 
What is CRPS? 
In 1994, the International Association for the Study of Pain (IASP) introduced the term 
CRPS, which was the new name for sympathetic algodystrophy (or Sudeck's atrophy or 
reflex sympathetic dystrophy).
9
 It was defined by a combination of sensory and autonomic 
disturbances which are often preceded by a limb trauma (Table 1.1). It is noteworthy that 
the presence of a preceding trauma is not a necessary requirement. The IASP made a 
distinction between two types of CRPS: without nerve injury (type 1) and with nerve injury 
(type 2). In 2003, new diagnostic criteria for CRPS were proposed by an international 
consensus group (Table 1.2).
10,11
 The validity of these criteria were reconfirmed in a recent 
study,
11
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1 The presence of an initiating noxious event, or a cause of immobilization 
2 Continuing pain, allodynia, or hyperalgesia with which the pain is disproportionate 
to any inciting event 
3 Evidence at some time of oedema, changes in skin blood flow, or abnormal 
sudomotor activity in the region of the pain 
4 This diagnosis is excluded by the existence of conditions that would otherwise 
account for the degree of pain and dysfunction 
Note: criteria 2-4 must be satisfied. 
 
 




1 Continuing pain, which is disproportionate to any inciting event 
2 Must report at least one symptom in three of the four following categories: 
- Sensory: reports of hyperesthesia and/or allodynia 
- Vasomotor: reports of temperature asymmetry and/or skin colour 
changes and/or skin colour asymmetry 
- Sudomotor/oedema: reports of oedema and/or sweating changes and/or 
sweating asymmetry 
- Motor/trophic: Reports of decreased range of motion and/or motor 
dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, 
nail, skin) 
3 Must display at least one sign at time of evaluation in two or more of the 
following categories: 
- Sensory: evidence of hyperalgesia (to pinprick) and/or allodynia (to light 
touch and/or deep somatic pressure and/or joint movement) 
- Vasomotor: evidence of temperature asymmetry and/or skin colour 
changes and/or asymmetry 
- Sudomotor/oedema: evidence of oedema and/or sweating changes 
and/or sweating asymmetry 
- Motor/trophic: evidence of decreased range of motion and/or motor 
dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, 
nail, skin) 
4 There is no other diagnosis that better explains the signs and symptoms 
 
 
The pathophysiology of CRPS-related dystonia 
The pathophysiology of both CRPS and its dystonia is only partly understood. Each (micro-) 
trauma that leads to activation of local nociceptors results in neurogenic inflammation, i.e. 
the release of inflammatory mediators. This process causes inflammatory signs, induces 
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sensitisation of the nociceptors as well as sensitisation at the spinal cord level.
12
 It is 
supposed that this process is out of balance in both type 1 and 2 CRPS. Against this 
background, it was suggested that inflammatory mediators are involved in the 
pathophysiology of CRPS. Indeed, increased levels of the pro-inflammatory interleukin-6 
(IL-6) and tumor necrosis factor-α (TNF-α) were found in artificially obtained blister fluid of 
CRPS patients with a mean disease duration of 8 months (range 4-12 months).
13
 At three 
years follow-up,
14
 but not at six years follow-up,
15
 these levels remained elevated. 
Neurogenic inflammation induces functional changes at the spinal cord level which play a 
key role in the maintenance of the pain (central sensitisation).
16
 
Dystonia is considered to be a consequence of perturbed sensorimotor processing.
8
 Lack 
of central inhibition plays a key role in the pathophysiology of dystonia in general.
17
 In 
CRPS, the altered processing of noxious, tactile and thermal input has been suggested to 
be an important factor in the development of fixed dystonia.
18
 Central sensitisation is 
associated with disinhibition of sensory circuits leading to spontaneous pain, allodynia and 
hyperalgesia. In CRPS patients with and without dystonia, pathophysiological studies have 
provided evidence of central disinhibition on different levels of the nervous system, 
ranging from the spinal cord
19
 to cerebral cortex
20,21
. The role of central disinhibition in 
CRPS-related dystonia is further supported by a small placebo-controlled study in which 
about half of the patients had a marked and sustained reduction of the dystonia severity 
after administration of intrathecal baclofen, a specific gamma aminobutyric acid (GABA) B 
agonist. This drug enhances the presynaptic and postsynaptic inhibition of afferent input 




CRPS-related tremor and myoclonic jerks 
In CRPS, tremor and myoclonic jerks have also been reported, however, information on 




A hysterical label? 
To date, there are a number of neurologists who consider CRPS-related dystonia a 
psychogenic movement disorder.
23,24
 Though these are expert opinions, and as such 
meaningful, a scientific approach would be more appropriate. In a study with 27 CRPS-
related dystonia patients, no psychological abnormalities were found in comparison with a 
control population.
25
 In a recent study, that was performed at the Leiden University 
Medical Centre, no unique disturbed psychological profile was found in 46 CRPS patients 
with dystonia.
26
 Nevertheless, in comparison to patients with affective disorders, the level 
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of somatoform dissociative experiences (medically unexplained analgesia, anesthesia, 
motor disturbance, alternating preferences for tastes and smells, pain, and loss of 
consciousness) was elevated. Early traumatic experiences were found to be moderately 
related to somatoform dissociative experiences which may indicate that early traumatic 
experiences are a predisposing factor for the development of CRPS-related dystonia.
26
 Of 
course, if psychological or psychiatric abnormalities are present, they also might be part of 
the syndrome instead of the cause. 
 
Epidemiology 
A recent Dutch population-based study
27
 found an estimated overall incidence rate of 
CRPS of 26.2 per 100,000 person years (95% CI 23.0-29.7). Women are affected 3.4 times 
more often than men. The highest incidence occurred in women in the age category of 61-
70 years. Considering a life expectancy at birth of 77.6 years for men and 81.9 years for 
women (Statistics Netherlands, 2006), the life time risk for CRPS is 0.9% for men and 3.3% 
for women. 
Generally, it is assumed that 14-30% of the CRPS patients may develop dystonia.
28
 In 
comparison with CRPS, the female to male ratio is further increased in patients with CRPS-






Of 74 CRPS patients that were identified in a population study in the United States, 55 
patients (74%) underwent resolution, often spontaneously.
29
 In a more recent Dutch 
study, it was shown that at a minimum of 2 years since onset 65 of 102 CRPS patients 
(64%) still fulfilled the IASP criteria for CRPS.
30
 The course of CRPS-related dystonia was 
studied in the 185 patients who visited the Department of Neurology of the Leiden 
University Medical Centre between 1998 and 2004.
6
 It was found that the presence of 
dystonia in the affected limb increased the hazard of developing dystonia in a second limb 
with 2.29 (95% CI 1.67-3.14). Furthermore, dystonia in two extremities increased the 
hazard of developing dystonia in the third to 2.15 (95% CI 1.33-3.48), and dystonia in three 
extremities increased the hazard of developing dystonia in the fourth to 7.4 (95% CI 3.74-
14.65). In contrast, as the number of extremities with only non-motor CRPS symptoms 
increased, which occurred in 21 patients (11.4%), the hazard of developing dystonia 
decreased. However, this study investigated a highly selected population, and these 
findings may not be generalised.  
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Treatment 
The Dutch Institute for Healthcare Improvement (CBO) developed the evidence-based 
'Guideline Complex Regional Pain Syndrome type I'.
31
 The scientific support for most 
treatments in CRPS is limited. Figure 2.1 shows the proposed treatment algorithm which 
includes the treatment of dystonia. Clearly, the treatment of CRPS-related dystonia is still 
in its infancy. Intrathecal baclofen is considered a promising therapy for severe dystonia.
22
 
However, until now, treatment was restricted to the experimental setting. 
 
Aims of this thesis 
 
First aim was to study the pathophysiology of CRPS-related movement disorders. 
Neurologists differ in their opinions on whether CPRS-related dystonia is psychogenic or 
not. Chapter 2 describes, from a historical point of view, the sway between organic and 
psychogenic explanations for dystonia including CRPS-related dystonia. The sensory 
system in CRPS-related dystonia patients was evaluated by means of quantitative 
somatosensory thermotesting, which is described in chapter 3. Chapter 4 describes the 
clinical characteristics of CRPS-related dystonia. These findings were used in a 
neuromuscular model of the wrist to investigate a possible role of disrupted 
proprioceptive reflexes. The results from cerebrospinal fluid analysis are described in 
chapter 5. We used coherence analysis to investigate myoclonic jerks that occurred in 
CRPS patients with or without dystonia. The findings are described in chapter 6. 
Second aim was to find new treatments for CRPS-related movement disorders. Two 
chapters describe studies that evaluated continuous administration of intrathecal baclofen 
(chapter 7) and glycine (chapter 8). Both these agents have the potential to reverse the 
lack of inhibition in the central nervous system. A study that evaluated intrathecal 
methylprednisolone in CRPS is described in chapter 9. We found a high incidence and 
prolonged course of post-dural puncture headache after implantation of the pump for 
intrathecal administration. This observation and, moreover, its implications, are described 





Figure 2.1 (next page). CBO treatment algorithm for CRPS in adults (printed with 
permission from Van Zuiden Communications).
31
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 Primary prevention:  
• in the case of wrist fractures, vitamin C  
Secondary prevention (for existing or past CRPS-I):  
• postpone surgery until CRPS-I symptoms have almost disappeared  
• keep the operation as short as possible and try to prevent to operate without removing blood from the operated 
extremity  
• adequate pre- and perioperative pain control  
Consider:  
• perioperative stellate ganglion block or administer regional i.v. anaesthesia (clonidine)  
• anaesthesia with sympathicolytic effect  




according to a 
protocol  
• occupational 
therapy according to 
a protocol 
In the case of 
allodynia/hyperalgesia:  
• gabapentin  
• carbamazepine  
• amitriptyline/nortriptyline  
In the event of a discrepancy 
between symptoms that can be 
objectively described and the 
patient's pain-related behaviour, 
if treatment stagnates, or if the 
patient is experiencing extreme 
suffering:  
• consult a psychologist  
In the case of cold CRPS-I:  
• vasodilating medication 
In the case of dystonia, 
myoclonia or muscle spasms:  
• oral baclofen, diazepam or 
clonazepam  
Treatment of children with CRPS-
I:  
• In addition to drug treatment, 
physiotherapy and/or 
occupational therapy  
• if necessary, psychological 




If ineffective:  
• intrathecal baclofen at a 
specialised clinic 
If ineffective:  
• percutaneous sympathetic 
block  
Communication and information:  
• verbal and written  
• involve relatives  
• put patients in touch with patient association for CRPS-I  
CRPS-I and work:  
• have the patient's working conditions assessed by the company 
doctor  
• consult the patient's company doctor / doctor treating him or her 
to establish how much strain he or she can bear  
Other therapies:  
If other therapies prove 
ineffective, you may consider:  
• spinal cord stimulation at a 
specialised clinic  
If recurrent infections occur, 
you may consider:  
• amputation at a specialised 
clinic  
Drug treatment:  
• pain medication 
according to the 
WHO ladder (up to 
step 2)  
• 50% DMSO / n-
acetylcysteine 
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Abstract 
In the last few centuries there has been a constant sway between organic and psychogenic 
explanations for dystonia. In the current study we investigate this history, assuming the 
perspective of a spectrum from organic to psychogenic, between which ideas were 
moving. We have focussed on (i) primary generalised dystonia; (ii) cervical dystonia; (iii) 
writer's cramp; and (iv) fixed dystonia related to complex regional pain syndrome. We 
have studied medical texts published since the 19
th
 century and their references. Jean-
Martin Charcot advocated the concept of hysteria: disorders in which, besides 
predisposition, environmental factors were involved in its pathogenesis. Sigmund Freud 
introduced psychoanalysis as an explanatory therapy for psychic disorders. Previous 
theories, together with the lack of an organic substrate for dystonia, made a strong case 
for psychogenic explanations. Consequently, many dystonia patients were told that they 
suffered from psychological conflicts and were treated for them. However, after the 
description of new hereditary cases in the 1950s, the limited efficacy of psychotherapy in 
torsion dystonia, the effects of surgical treatments and the lesion studies in the 1960s, 
more physicians became convinced of the organic nature. The culminating point was the 
discovery of the DYT1 gene in 1997. In the meantime, experts had already convinced the 
neurological community that cervical dystonia and writer's cramp were focal dystonias, 
i.e. minor forms of generalised dystonia, and therefore organic disorders. In contrast, the 
pathophysiology of fixed dystonia related to complex regional pain syndrome remained 
controversial. Knowledge of this history, which played on the border between neurology 
and psychiatry, is instructive and reflects the difficulty in discriminating between them. 
Today, new insights from functional imaging and neurophysiological studies again 
challenge the interpretation of these disorders, while the border between psychogenic 
and organic has become more blurred. Abnormalities of sensorimotor integration and 
cortical excitability that are currently supposed to be the underlying cause of dystonia 
bring us back to Sherringtonian physiology. We suggest that this may lead to a common 
explanation of the four afflictions of which we have traced the history. 




For many years, physicians have observed and discussed the remarkable signs of what we 
nowadays call dystonia. The introduction of the term dystonia as an abnormality of tone 
with coexistent hypo- and hypertonia goes back to 1911 when the well-known Berlin 
neurologist Hermann Oppenheim (1858-1919) introduced dystonia musculorum 
deformans, which was later renamed early-onset generalised torsion dystonia.
1
 In 1967, 
Wolfgang Zeman (1921-2001) and Paul Dyken reported the presence of milder forms of 
dystonia in dystonia musculorum deformans families, including cases of isolated writer's 
cramp.
2
 In 1976, David Marsden (1938-1998) proposed the term focal dystonia for 
blepharospasm, oromandibular dystonia, dystonic writer's cramp, and torticollis, as well as 
for axial dystonias, arguing that these were closely related to generalised dystonia.
3
 Up to 
the present, this view has not changed. Over the years, however, there has been a 
discussion on whether the aetiology of dystonia is either organic or psychogenic. In this 
paper we study the evolution of ideas with respect to dystonia, in particular whether or 
not it was considered an organic or psychogenic affliction. We will put the historical 
evolution against the background of present-day knowledge resulting from functional 





We started our search on dystonia history using two standard books on the history of 
medicine.
4,5
 Furthermore, we used the PubMed database by entering the term 'dystonia' 
with limitation to 'history of medicine'. In addition, we used medical and neurological 




 century written in English, French, German, or Dutch.
6-16
 
In the tables of contents and subject indexes we searched for dystonia, spasm(s), 
spasmodic contortion or contraction, torticollis, wryneck, (writer's) cramp, scrivener's 
palsy, occupational neurosis (English); dystonie, torticolis (mental), spasme clonique (du 
sterno-mastoïdien), spasme fonctionel (du sterno-mastoïdien), crampe fonctionelle, 
crampes des écrivains (French); Dystonie, Torticollis, Schreib(e)krampf, Funktionskrämpfe, 
Beschäftigungsneurose (German); dystonie, torticollis, (ver)kramp(ing), and schrijvers-
kramp (Dutch). In addition, we searched for relevant literature in the reference lists of 
consulted books and papers. As many nineteenth- and early twentieth-century primary 
textbooks refer to the work of Duchenne and Bell, we chose to discuss their descriptions 
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in more detail. When dealing with the question whether a particular author considered a 
disorder psychogenic or organic, we assumed a spectrum from organic to psychogenic 
between which ideas of the individual authors could be placed, as far as could be derived 
from the text.  
 
Definition of dystonia 
The word dystonia was introduced in 1911.
1
 Later its meaning was changed several times. 
For example, Derek Denny-Brown (1901-1981) considered dystonia a disorder with a fixed 
posture or oscillation between two or more fixed postures (Denny-Brown, 1965; Denny-
Brown, 1966). The modern definition is "a syndrome of sustained muscle contractions, 
frequently causing twisting and repetitive movements, or abnormal postures".
17
 In this 
article, we use the latter definition. 
 
Definitions of neurosis and hysteria 
In the late 18
th
 and early 19
th
 century, neurosis was defined as the category of clinically 





 century, this category became smaller when neuropathological 
substrates of several of these diseases were established.
20
 Hysteria was a subcategory 
within the neuroses, in which neurological signs were similar to those in patients who 
suffered from nervous diseases with known anatomic lesions, although somewhat 
different and usually more extensive. In the late 19
th
 century, Charcot assumed that 
hysteria arose from a lesion of an undetermined structural or functional nature and he 
expected that the pathological basis would be found in due course. The neurological 
defect was believed  to result from a combination of hereditary predisposition and an 
environmental, provocative factor, which usually was a physical or emotional shock.
21
 
Therefore, throughout history the term psychogenic cannot always be considered equal to 
non-organic, in particular in the pre-Freudian period. After this period non-organic mostly 
did mean psychogenic. The meanings of neurosis and hysteria changed and finally the 
terms were used solely in descriptions of psychiatric diseases. At present, the terms are 
used less often, and no longer listed in the Diagnostic and Statistical Manual of Mental 
Disorders.
22









Primary generalised dystonia 
In 1871 William Hammond (1828-1900) reported on three patients "in which the most 
characteristic symptoms are an inability to retain the fingers and toes in any position in 
which they may be placed, and their continual motion".
23
 He mentioned the acquired 
disorder 'athetosis' and hypothesised on a striatal lesion. Hammond's patients may not be 
considered dystonic patients – although today most authors consider athethosis part of 
the dystonia spectrum
24
 but it is important to mention Hammond's coining of the term 
athetosis. In 1897, the Spanish physician Lluis Barraquer I Roviralta (1855-1928) reported 
another patient with athetosis, which later was considered the first description of 
generalised torsion dystonia.
25,26
 In 1908, the German Marcus Walter Schwalbe (1883-
1927) described hysterical symptoms in the siblings Fanny, Heimann, and Wulf Levin, 
suffering from tonic cramps, which is now recognised as early-onset generalised torsion 
dystonia (Figure 2.1).
27,28
 Among the most important hysterical characteristics there was 
the presence of pressure points (called 'hysterogenic zones' in Charcot's work
21
), i.e. body 
areas in which cramps may be provoked by pressure. 
Familial involvement was another feature. In 1911 Oppenheim launched the term 
dystonia musculorum deformans for the same disorder.
1
 He reported on four patients, 
who were Jewish children. Illustrative  is the description of a 14-year old girl with a 
'dromedary gait' "indem der sättelformige ausgebuchtete Rücken in eine fast horizontale 
Lage kommt, und zwar fällt die Rumpfbeugung zusammen mit dem Aufsetzen des linken 
Beins, während der Rumpf sich hebt beim Schwingen des linken Beins" [because the 
saddle-shaped back acquires an almost horizontal position, in which the left leg posture 
phase is accompanied by trunk flexion, and the swing phase by trunk elevation]. He was 
convinced that it was an organic disease without concomitant hysteria. 
Subsequently, dystonia musculorum deformans became a collective term for a variety of 
neurologic disorders.
29
 There was a continuing discussion on the characteristics of the 
disorder, and a pathological substrate was still unknown. For these reasons, the concept 
of dystonia as a disease was demolished during the tenth Réunion Neurologique 
Internationale Annuelle in Paris (1929). Subsequently, the Danish physician Auguste 
Wimmer (1872-1937) concluded that dystonia was no more than a syndrome.
30
 In the 
meantime, a psychogenic explanation had emerged for various nervous disorders without 
anatomic lesions. One of the founders of psychogenesis was Sigmund Freud (1856-1939). 
From 1888 to 1910 he described several patients who suffered from hysteria and in whom 
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symptoms were related to conflicts and psychological defence.
31
 The effectiveness of 
psychological intervention supported this new and revolutionary theory. Exploring and 
resetting the unconscious mind, by means of 'psychoanalysis', became a successful 
therapy in many cases of hysteria. Since then, many patients with generalised dystonia 
underwent this or other forms of psychotherapy. 
In 1944, Ernst Herz (1900-1965) published three frequently cited articles on his studies of 
dystonia cases. He considered dystonia a "clinical entity" with "characteristic irregular, 
involuntary motor phenomena", "a peculiar distribution of 'excess of motion' and 'excess 
of tension'", and "without recognizable etiologic factors at onset".
32-34
 In 1959 the 
hereditary nature of dystonia musculorum deformans was demonstrated
35
 and ten years 
later a report was published on the limited efficacy of psychotherapy in 44 patients with 
torsion dystonia.
36
 In the same year, Irving Cooper (1922-1985) reported on a 77% success 
rate after unilateral or bilateral surgery of the thalamus or globus pallidus in 144 dystonia 
musculorum deformans patients.
37
 In the 1960s Denny-Brown reported his landmark 
studies on dystonia. He caused selective lesions in monkey brains which led to 
uncontrollable abnormal postures and movements resembling dystonia. It was remarkable  
 
 
Figure 2.1. Developments on generalised dystonia in the 20
th
 century. See the text for 
references. 
*
Not for the first time but more convincing than ever before. 
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report on the 
efficacy of 
neurosurgery 
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to observe that damage in different anatomical structures might have the same 
consequences. Denny-Brown assumed that dystonia resulted from an imbalance of reflex 
responses in the central nervous system.
38-40
 In 1975, an International Symposium on 
Dystonia was organised. In the preface of the conference book, Eldridge and Fahn wrote: 
 
In the past, many victims of dystonia and their families have been caused anguish 
and hardship over and above that caused by the disease itself owing to the 
frequent misdiagnosis of the symptoms as manifestations of a psychiatric 
ailment. We hope that the present volume will facilitate accurate diagnosis, assist 
practicing physicians in treating their dystonic patients, encourage them to report 
their observations and results, and stimulate clinical and basic research workers 





At this symposium, Marsden emphasised the existence of sporadic torsion dystonia.
42
 
Fahn and Eldridge stated that psychologically based dystonia was a rare or non-existent 
condition.
43
 However, three years after the symposium (1978), the "first case of 
psychogenic dystonia" was reported
44
 and in 1983, at the 35
th
 annual meeting of the 
American Academy of Neurology, another five followed.
45
 The first patient was a 15-year-
old girl who had simulated her dystonic symptoms and signs. She was admitted after a 
failed suicide attempt and told that she had faked her symptoms: "she discarded her leg 
brace, and the sustained contractions in her leg and arm immediately improved". The 
histories of the other five patients were not included in the publication. 
In 1984, an ad hoc committee, consisting of members of the Scientific Advisory Board of 
the Dystonia Medical Research Foundation, re-defined dystonia as "a syndrome of 
sustained muscle contractions, frequently causing twisting and repetitive movements, or 
abnormal postures".
17
 Four years later a classification for psychogenic dystonia followed 
(Table 2.1).
46
 The first locus (9q32-34 region) for idiopathic dystonia (DYT1) was found in 
1989
47
 and ten years later the same group identified the gene, describing a unique 3-base 
pair deletion in the coding region, which was responsible for almost all their cases with 
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Documented Persistent relief by psychotherapy, by the clinician utilizing psychological 
suggestion including physiotherapy, or by administration of placebos 
(again with suggestion being a part of this approach), or the patient must 




The dystonia is inconsistent over time or is incongruent with classical 
dystonia, plus at least one of the following features: 
- other neurologic signs are present that are definitely psychogenic, e.g. 
false weakness, false sensory findings, and self-inflicted injuries 
- multiple somatizations are present 
- an obvious psychiatric disturbance is present 
Probable - The dystonia is inconsistent over time or is incongruent with classical 
dystonia, but there are no other features, or 
- The dystonia is consistent and congruent with organic dystonia, 
however at least one of the following features is present:  
- other neurologic signs are present that are definitely psychogenic, 
e.g. false weakness, false sensory findings, and self-inflicted 
injuries 
- multiple somatizations are present 
Possible The dystonia is consistent and congruent with organic dystonia, however, 
an obvious emotional disturbance is present 
 
 
Cervical dystonia (Table 2.2) 
One of the earliest descriptions of cervical dystonia was given by the Swiss physician Felix 
Platerus, also known as Plater (1536-1614).
49,50
 He described a case of 'spasmi species, in 
qua caput in sinistrum latus torquebatur' [a kind of spasm in which the head was turned to 
the left side]. The Dutch Nicolaas Tulp, or Tulpius (1593-1674), well-known from the 
famous Rembrandt painting The Anatomy Lesson of 1632, described dissection of the 
sternocleidomastoid muscle as a therapy for what he called 'obstipi capitis' [crooked head] 
in his Observationes medicae.
51,52
 However, this patient had had torticollis from childhood  
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Table 2.2 (continued on next pages). Historical descriptions on cervical dystonia 
Year Author City Terminology O/P Comments 
1614 Plater
49,50
 Basel (CH) spasmi species, in 
qua caput in 
sinistrum latus 
torquebatur 
O case report; explained 







obstipi capitis O probably mechanic 




 Paris (FR) colli singularem 
omninò 
distortionem 
P case report in a 
monography on 
melancholia; 
explained as due to 
boredom and 
therefore aversion to 
life 

















 Paris (FR) torticolis, caput 
obstipum 







London (UK) spasmodic 
affection of the 
muscles of the 
neck 
U case report 
1825 Gilby
58
 Bristol (UK) contraction of the 
muscles of the 
neck 
O? efficaciously used 
















contortion of the 
head and neck 




 Berlin (DE) Halsmuskelkrampf U in most cases 
unknown cause, 
sometimes due to 
physical strain; 
described that some 
think that it may be 
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 Paris (FR) spasme du 
sternomastoïdien 
O may be cured by 
continuous stretch to 
the antagonists by 
means of an 






London (UK) spasmodic 
contraction of 
cervical muscles 
O? case report; spinal 





 Paris (FR) hyperkinésie de 
l'accessoire de 
Willis 
O clonic form: rare, 
unknown cause; tonic 
form: either 
congenital, vertebral 
disorder or due to 
pressure on sensible 
nerve (reflex cramp) 











 Paris (FR) spasme clonique 
du sterno-
















(= hysterical = partly 
moral, partly physical) 
tends to spread from 
the neck to the trunk 
1889 Freud
67
 Vienna (AT) Genickkrämpfe O case report (Frau 












U divided the dorsal 
rami of the C1-C3 
spinal nerves in a 
patient in whom 
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 Paris (FR) torticolis mental P believed that torticolis 
was a tic (P), not a 
spasm (O); the touch 
that was able to 




 Paris (FR) torticolis 
intermittent 












of kinetic centres in 








O? efficaciously dissected 
involved muscles and 
nerves (method from 
Kocher); treatment 
effect might be due to 




 Paris (FR) torticolis 
spasmodique 
O case report with 
extensor toe response 








observation is needed 











 Mainz (DE) spasmodischen 
torticollis 





 Koblenz (DE) Torticollis mental O < 
P 
often in neuropathic 
patients; organic 
causes must be 
excluded (ocular, 
auricular; cervical 
spine, or brain 
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disease) 







mental torticollis P Clark reported on the 
efficacy of 
psychotherapy; was 
criticised by others 
1923 Wartenberg
79
 Freiburg im 
Breisgau 
(DE) 
Torticollis O > 
P 
pathophysiological 
description on the 




the geste antagoniste) 
1923 Cushing
80
 Boston (US) spasmodic 
torticollis 
U performed surgery 
with unilateral 
division of the spinal 
accessory nerve and 
































associated with an 
extrapyramidal 
disease; and 












hysterical (P) and 
congenital torticollis 
and torticollis tic (P) 






















psychotherapy is the 
treatment of choice 








O 43 cases; though 
organic in nature, the 
clinical picture may be 








Boston (US) torticollis O performed 
experiments in 
monkeys; described 
that torticollis arises 
from damage to the 
pretectal region, and 























treatments in 60 
patients; >5,000 
hours; severe ego-
regression in all cases 






torticollis O? improvement with 
sensory feedback 
therapy (13 cases); 




 London (UK) torticollis O focal dystonia; 
suspected an 
abnormality in the 
extrapiramidal system 






O first report on the 
efficacy of botulinum 
toxin 








stated that in some 
cases psychotherapy 
is indicated 
O = organic; P = psychogenic; O > P = majority of cases is organic; O or P = cause is organic 
in some cases and psychogenic in other cases; O + P = cause is a combination of organic 
and psychogenic factors in every; U = unknown cause. 
 
 
The well-known Scottish surgeon-anatomist Charles Bell (1774-1842) stated that the origin 
of 'spasmodic contortion of the head and neck' was nerve rather than muscle 
dysfunction.
60
 One of his patients, Mary Preston, developed the disease following a hard 
and protracted labour. In Bell's view, a disorder of the accessory nerve but not other 
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nerves, due to strain, might lead to unbalanced muscle drive and thus to the disease. 
Interestingly, the same case was also reported elsewhere,
57
 but according to these 
authors, the disease was not limited to the distribution of the accessory nerve. Their 
disagreement with Bell was underlined by their commentary "We have frequently had 
occasion to notice the very ingenious manner in which Mr. Bell perverts facts, in order to 
meet his own particular views of a case". The French physician Guillaume-Benjamin 
Duchenne (1806-1875), who applied electricity for a variety of disorders in Paris hospitals, 
reported that 'spasme fonctionnel du sterno-mastoïdien' is quite resistant to treatment.
62
 
Instead, he advised therapy by applying continuous stretch of the antagonists with the use 
of an instrument. 
During one of his well-known Tuesday Lessons, on June 26, 1888, Charcot presented a 63-
year old man with 'spasme clonique du sterno-mastoïdien et du trapèze' [clonic spasm of 
the sternocleidomastoid and the trapezius muscles], which had been present for eight 
months.
66
 The disorder started after the patient, who was a stockbroker, had lost all his 
money. On July 10, 1888, he was presented again after being successfully treated with 
electricity. Five years later, one of Charcot's former students, Edouard Brissaud (1852-
1909), introduced the term 'torticolis mental'.
70
 In his view, the condition was 
psychogenic, which was evident from the fact that the patient was able to correct the 
powerful muscle activity by simply touching the head, later named the 'geste antagoniste 
efficace'.
74
 Emphasizing the psychogenic nature again, the Hungarian Jenö Kollarits (1870-
1940) reported on six 'torticollis hystericus' cases in 1905.
75
 Therapeutic dissection of the 
involved muscles or nerves, as performed by the Swiss surgeon Fritz de Quervain (1868-
1940),
72
 was considered malpractice according to Kollarits, who, instead, stated that 
therapy should be based on suggestion. 
In this period, there was much discussion on torticollis in the scientific community. At the 
New York Neurological Society (1914), Pierce Clark (1870-1933) presented an adult man 
with 'mental torticollis' which, he said, was the consequence of pleasurable stroking 
movements by his mother, before the age of six.
78
 In reaction, Bernard Sachs (1858-1944) 
said, "if this indicated the future trend for our present-day neurology, then the less we 
hear of it, the better". The debate went on for several decades. In 1935 Joseph Yaskin 
(1891-1955) wrote that before surgery, every case of 'spasmodic torticollis' should receive 
a trial of psychotherapy.
81
 In 1943 Patterson and Little reported on 103 cases with 
spasmodic torticollis,
83
 stating that the aetiology was usually organic and that surgery, 
intradural rhizotomy in particular, was very satisfactory. However, in 1945 the Scottish 
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physician Paterson presented 21 cases, concluding that psychotherapy was the treatment 
of choice unless gross signs of neurological disease were present.
84
 
At the 1975 International Symposium on Dystonia (vide supra), Marsden presented 
arguments that spasmodic torticollis, as well as blepharospasm, oromandibular dystonia 
and dystonic writer's cramp (vide infra), were focal dystonias with an organic aetiology. He 
summarised the reasons why they had been regarded psychogenic (Table 2.3),
3
 and 
subsequently explained his ideas about functional abnormalities in the extrapyramidal 
motor system.
3
 Obvious arguments were their occurrence in early-onset generalised 
torsion dystonia and the similarities with late-onset generalised torsion dystonia: both 
focal dystonia and late-onset generalised torsion dystonia had a comparable age of onset 
and were usually neither progressive nor hereditary. A new name was introduced in the 
1980s: 'cervical dystonia'. In 1985 the Canadian Tsui reported for the first time the 
successful use of botulinum toxin injections in 12 patients,
89
 which eventually became the 
standard treatment. During the past few decades hardly any reports on psychogenic 
cervical dystonia cases have been published. 
 
 
Table 2.3. Seven reasons why focal dystonias were regarded as psychogenic
3
 
1 The bizarre nature of the dyskinesias 
2 Their appearance frequently only on certain actions, other motor acts employing the 
same muscles being carried out normally 
3 Their relief by certain inexplicable trick actions 
4 Their exquisite sensitivity to social and mental stress 
5 The failure so far to find any anatomical, physiological, or biochemical abnormality in 
any of these conditions 
6 The belief that such patients show overt psychiatric disturbance 





In 1713 the Italian physician Bernardino Ramazzini (1633-1714) recognised intense fatigue 
of the hand and arm, which resulted in failure of power, as an occupational disorder in 
professional writers.
91
 In 1844 (published posthumously), Bell most probably described 
writer's cramp when he reported on an ambiguous condition in which writing had become 
impossible while the arm strength remained normal.
60
 In 1861 Duchenne reported on 
'crampe des écrivains' in which electricity was not a very successful therapy. However, he 
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advised an ingenious prosthesis.
62
 He preferred the names 'spasme fonctionnel' and 
'paralysie musculaire fonctionelle' because the disorder was not restricted to cramps and 
could be provoked not only by writing but also by other manual actions. 
 
En résumé, les faits et les considérations exposés précédemment démontrent, 
comme je l'ai dit au commencement de cette note, qu'il existe une maladie 
caractérisée par un spasme douloureux ou indolent (contracture, contractions 
clonique, tremblements), ou par une paralysie musculaire; que ces troubles se 
manifestent seulement pendant l'exercice de certains mouvements volontaires 
ou instinctifs; enfin, qu'ils peuvent siéger dans des régions fort diverses.
62
 [In 
summary, the former findings and considerations show, as I described in the 
beginning of this report, that there is a disease which is characterised by painful 
or painless spasms (contracture, jerks, tremor) or paralysis in which the signs 
only occur during certain (in-)voluntary actions; the involved body parts are 
diverse.] 
 
Similar to the situation in cervical dystonia, the debate on aetiology started in the early 
20
th
 century. In 1914 the German Fritz Mohr (1874-1957) summarised the two conflicting 
theories in Lewandowsky's Handbuch der Neurologie.
12
 Writer's cramp was explained by 
some authors as a purely organic disorder, e.g. as a reflex cramp through motor nerves 
that was initiated by painful sensory input. The German physician Moritz Romberg (1795-
1873) was mentioned as one of the early advocates (with reference to the 1853 edition of 
Rombergs Lehrbuch der Nervenkrankheiten des Menschen
92
). Others, including Mohr 
himself, believed that only people with certain personality characteristics were prone to 
develop the disorder, a psychological factor possibly being involved. From that view, 
accurate psychoanalysis would be the best therapy for patients with writer's cramp. 
Kinnier Wilson's (1878-1937) 1940 edition of Neurology, described 'writers' cramp' as an 
occupational neurosis, physiologically akin to hysteria, and assumed a cortical 
dysfunction.
11
 Prevention by excluding people prone to develop 'spasms' from certain 
occupations, was considered the best treatment. 
As in other focal dystonias, Marsden advocated the organic nature of writer's cramp (vide 
supra),
3
 which he and Sheehy further demonstrated in a report on 29 patients, (1982).
93
 
However, in 1983 Cottraux (France) et al. reported on the success of behavioural therapy 
and biofeedback in 9 of 15 patients with writer's cramp,
94
 and the 1985 edition of John 
Walton's Brain's Diseases of the nervous system stated:  
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I find the conclusions of Sheehy and Marsden inherently implausible and 
unacceptable. In my experience even subtle physical signs are absent in the many 
'simple' cases that I have seen and neither focal dystonia nor any other organic 
disorder could in my view impair movements only when they take part in one co-
ordinated act while leaving totally unaffected all other precise and complex 




The 1993 edition stated that writer's cramp had "in the past been attributed to 
psychological factors, but there is now good evidence that this is not so". Interestingly, the 
author referred to the same single publication of Sheehy and Marsden.
93,96
 In 1991 Rivest 
et al. reported for the first time on the use of botulinum toxin for writer's cramp,
97
 which 
is currently considered the most effective treatment. 
 
Fixed dystonia related to complex regional pain syndrome 
In 1864 Silas Weir Mitchell (1829-1914) described a series of American Civil War (1861-
1865) victims with gunshot wounds who developed burning pain and a shiny red skin after 
nerve injury.
98,99
 He suspected that traumatic nerve irritation was the cause and named 
the condition 'causalgia'. He recognised that patients might come into an unendurably 
painful hyperaesthetic state. In 1892, Charcot demonstrated another entity in two 
patients: 'oedème bleu des hystériques', a painful condition with oedema and blue 





L'historique de cette affection n'est pas bien long. Je l'ai pour la première fois 
mentionnée et distinguée à propos d'un malade de cet hospice [with reference 
to the Leçons du Mardi from 1889], que je suis d'ailleurs à même de vous 
présenter de nouveau. Puis, à plusieurs reprises je l'ai observée chez des 
personnes de la ville, combinée tantôt avec des altérations de la sensibilité 
(anesthésie ou hyperesthésie), tantôt avec des troubles du mouvement 
(paralysies et contractures). Il s'agissait presque toujours de sujets marqués, par 
la présence des stigmates, au sceau de l'hystérie la mieux caractérisée.
100
 [This 
disorder has a short history. For the first time [in 1889], I reported on a patient 
from this hospital [Hospice de la Salpêtrière]. From then, I recognised more 
cases. In a number of them, I observed sensory abnormalities (anesthesia or 
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hyperesthesia) or movement disturbances (paralysis and contractures). Mostly, 
patients were extraordinary persons having characteristics which may be 
considered hysterical.] 
 
In 1946, Evans renamed the latter disorder 'reflex sympathetic dystrophy', because he 
suspected involvement of spinal reflexes as well as sympathetic efferent fibres.
101
 It was 
different from causalgia in that it occurred in the absence of major nerve trauma. 
However, in 1994, the International Association for the Study of Pain introduced the name 
CRPS for both conditions: type 1 (reflex sympathetic dystrophy) and type 2 (causalgia).
102
 
The diagnostic criteria for CRPS type 1 were: (i) presence of an initiating noxious event, or 
a cause of immobilization (not obligatory item); (ii) continuing pain, allodynia, or 
hyperalgesia with which the pain is disproportionate to any inciting event; (iii) evidence at 
some time of oedema, changes in skin blood flow, or abnormal sudomotor activity in the 
region of the pain; and (iv) no other condition that would account for the degree of pain 




In 1984  Marsden et al. reported on four 'reflex sympathetic dystrophy' patients who had 
dystonia, characterised by fixed, predominantly flexion, postures.
103
 They believed it to be 
'a distinct clinical syndrome'. Six years later Schwartzman et al. reported on motor 
disturbances in 43 patients with 'reflex sympathetic dystrophy', in whom the most 
dramatic characteristic was a dystonic posture in all patients.
104
 The authors hypothesised 
on a spinal cause. In 1993, a series of 18 patients with similar characteristics was 
reported.
105
 However, it was remarkable that many patients met the criteria for 
psychogenic dystonia from 1988 (vide supra) (Table 2.1). They concluded that the 
aetiology of this disorder, psychogenic or organic, was unknown.
105
 In 2004 it was 
reported that many patients with features of CRPS and dystonia also had features of 
psychogenic dystonia.
106
 In the same year it was stated that a very large proportion had a 
primary psychogenic disorder.
107
 In a more recent paper on 110 CRPS type 1 patients with 
dystonia predominantly characterised by tonic flexion postures, the authors hypothesised 






There has been a continuous vacillation between psychogenic and organic explanations 
for (i) primary generalised dystonia; (ii) cervical dystonia; (iii) writer's cramp; and (iv) CRPS-
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related fixed dystonia. Although at first sight the attributions of the terms psychogenic 
and organic in Table 2.2 seem quite obvious, it seems more realistic to assume a spectrum 
with two ends between which attributions were moving. Moreover, the discussion 
between an organic and psychogenic aetiology has not always been explicit (particularly in 
the 19
th
 century). The opinions of several authors could only be derived or interpreted 
from their hypotheses on aetiology and their therapies. 
An example is Schwalbe's description of hysterical symptoms in siblings with generalised 
dystonia. In the late 19
th
 century, Charcot considered hysteria a neurosis, similar to 
paralysis agitans, epilepsy and chorea, which were diseases without known pathology. For 
paralysis agitans he expected that the lesion would be discovered.
109
 Hysteria appeared a 
more difficult obstacle for Charcot's clinical-anatomic method and, when describing male 
traumatic neurosis, he moved towards a psychological conception of hysteria.
109
 This was 
further elaborated by Freud and his followers.
110
 Hysteria evolved from a disease in which 
an organic pathophysiology was suspected but not found, to a psychogenic disease in the 
late 19
th
 and early 20
th
 century. Recent functional imaging studies in these patients have 
shown specific cerebral abnormalities.
111,112
 From these studies, it is suspected that 
affective or stress-related factors modulate cerebral sensorimotor representations 
through interactions between limbic and sensorimotor networks. It is hypothesised that 
primitive reflexive mechanisms of protection and alertness, which are partly independent 
of conscious control, are involved. 
 
Primary generalised dystonia 
The patients of Oppenheim made him move to the organic end of the spectrum, whereas 
Freud and his followers in psychoanalysis, moved in an opposite direction. The improved 
description of the 'clinical entity' in the 1940s (Herz), the new hereditary cases described 
in the 1950s (Zeman), and the limited efficacy of psychotherapy in torsion dystonia, as 
well as the effects of surgical treatments and the lesion studies in the 1960s (Eldridge, 
Cooper, and Denny-Brown respectively) pushed the explanatory ideas back into the 
organic again. This culminated in Eldridge's & Fahn's 1975 statement (published in 1976). 
However, a new movement towards psychogenesis soon followed with the recognition of 
psychogenic dystonia. Meanwhile, the remaining dystonias kept their position on the 
organic side of the spectrum, not in the least because of the discovery of the DYT1 gene. 
Nevertheless, one cannot be too rigid because dystonic disorders with a genetic origin can 
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Cervical dystonia 
Bell and Duchenne probably assumed an organic cause for cervical dystonia (Table 2.2). 
Not much later Charcot, and certainly his student Brissaud, moved to the psychogenic 
view, in which the interpretation of observing the 'geste antagoniste' played an important 
role. At the time, such terms as 'torticolis mental' and 'torticollis hystericus' were used on 
both sides of the Atlantic and dealt with likewise. Psychological and surgical treatments 
were applied simultaneously in different patients at different places around the 1940s. 
After Marsden's 1975 presentation, the aetiological ideas on cervical dystonia clearly 
moved away from the psychogenic to the organic side of the spectrum.  
 
Writer's cramp 
To explain writer's cramp, Ramazzini used such terms as 'fatigue' and 'failure of power'. 
These should be interpreted in the humoral pathophysiological concepts of the time, i.e. 
animal spirits that flow through the nerves with less power than usual. One would be 
inclined to consider an organic aetiology here; however, we may question whether 
Ramazzini was concerned with this question at all. From Bell's description a century later 
and also from Romberg's work, an organic viewpoint may be recognised. Duchenne again 
used the term 'functional', which, however, does not necessarily imply that he meant a 
psychogenic aetiology. A clearer distinction came about in the early 20
th
 century, when 
Mohr mentioned personality characteristics and a psychological factor, and suggested 
psychoanalysis for treatment. An interesting position was taken by Kinnier Wilson, 
assuming cortical dysfunction but comparing it to hysteria. Once more, Marsden's 1975 
presentation pushed the aetiology of writer's cramp toward the organic side, with a few 
exceptions in the 1980s. 
 
Fixed dystonia related to complex regional pain syndrome  
Charcot's demonstration of two patients with 'oedème bleu des hystériques' occurred in a 
period in which he was moving towards a psychological explanation of hysteria. Marsden 
et al. expressed the opinion that the similarities between CRPS cases with dystonia over 
the world suggested its existence as a distinct clinical syndrome.
103
 In contrast, Sa et al. 
stressed that most cases satisfied the criteria for psychogenic dystonia, and should, 
therefore, be considered as such.
107
 But these are based on expert opinion. Such 
statements are not like a gold standard and should, therefore, be used with caution. 
Moreover, it is remarkable that the reasons why CRPS-related fixed dystonia is considered 
psychogenic are at least partly the same as the arguments that were used in the past to 
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explain why focal dystonia was psychogenic (Table 2.3): (i) the dystonia in CRPS may be 
considered incongruent with classical dystonia; (ii) may be inconsistent over time; (iii) 
weakness, described in the majority of CRPS cases, might be interpreted as false; (iv) 
sensory abnormalities, which fit the diagnosis of CRPS, might be interpreted as false 
sensory findings; and (v) sometimes, psychiatric abnormalities are present. In recent times 




It is clear that the discussions on the psychogenic or organic aetiology of dystonia have 
been emotional. In some of the periods, particularly during the 20
th
 century, strong 
believers as well as non-believers may be recognised. Charcot isolated hysterical disorders 
from other neurologic diseases. In his view, environmental factors ('agents provocateurs') 
were involved in its pathogenesis. The rise of the psychoanalytic movement, following the 
work of Freud at the beginning of the 20
th
 century, caused important disagreements 
between supporters of organic and psychogenic explanations. This was not specific to the 
interpretation of dystonia, but more generally reflected the division between biologically 
and psychoanalytic oriented neuropsychiatrists at the time. The success and popularity of 
psychoanalysis, as well as the lack of an organic substrate for dystonia, encouraged 
psychogenic theories. As the 20
th
 century proceeded, knowledge in favour of a somatic 
origin of early-onset generalised dystonia accumulated. Marsden, a leading neurologist in 
movement disorders, convinced the neurological community in the 1970s and 1980s that 
both generalised and focal dystonia were somatic entities. However, psychogenic dystonia 
re-emerged, but as a special category. Nowadays, psychogenic dystonia is thought to be 
"common" in specialised movement disorders clinics.
116
 
The recognition of the hereditary character of dystonia played an important role in 
attributing an organic nature in the first as well as the last decades of the 20
th
 century. If 
dystonia had existed as an entity and its hereditary character had been recognised 
previously, it would probably have been interpreted in a different way, because of the 
particular concepts of the late 19
th
 century. In this period several neuroses were 
considered hereditary, in fact a favourite subject in the interpretation models of 
Charcot.
117
 Similar to contemporary psychiatrists (the French Benedict-Augustin Morel 
(1809-1873) and Valentin Magnan (1835-1916)), he assumed that degeneration was a 
constitutional factor in certain families ('neuropathic families') in which neuroses including 
hysteria, alcoholism, and epilepsy could be transformed during the passage from one 
generation to the next. Hysteria in a parent could be inherited as epilepsy in the 
child.
109,118
 In the 20
th
 century, following delineation of dystonia as an entity and following 
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new discoveries in genetics, the hereditary character led to new insights. Today it is 
recognised that more than 14 genes are implicated in different monogenic dystonia 
syndromes, which are frequently inherited as autosomal dominant conditions with 
reduced penetrance. Most cases of early-onset torsion dystonia are associated with the 
DYT1 gene mutation.
113
 Familial occurrence of cervical dystonia or writer's cramp has been 
described but appears to be rare.
119
 
Medical problems nearly always unravel because of the advent of a new technology, skill, 
or understanding of a hitherto unknown system of disease. One example is the unravelling 




 century. Ideas on whether or not 
animal electricity existed and played a role in the nature of nerve conduction, were put 
forward at the end of the 18
th
 century by Galvani and denied by Volta.
120,121
 The 
confirmation had to await more sophisticated sensitive measuring devices such as the 
galvanometer invented by Du Bois-Reymond in the 1840s, after which observation of the 
action potential became possible.  
What will be the future 'sophisticated sensitive measuring device' that will finally lead to 
the understanding of dystonia? We believe that the increasing knowledge resulting from 
neurophysiological and imaging studies, combined with genetic methods, will provide the 
insight that the explanation of dystonia cannot just be interpreted in terms of organic or 
psychogenic. These modern methods may show that the interaction of genetic and 
environmental factors is more complex than was previously thought. When reviewing the 
pathophysiology of primary adult-onset focal dystonia, Defazio et al. suggest that in 
human focal dystonia there may be an overload of a predisposed sensory system resulting 
from peripheral injury or repetitive motor activity in a certain part of the body, or both, 
causing sensory receptive changes in the corresponding cortical brain areas and leading to 
abnormal regulation of inhibitory interneuronal mechanisms at brainstem or spinal cord 
level.
119
 There seems to be an abnormality of sensorimotor integration and cortical 
excitability beyond the symptomatic body part. In both generalised and focal dystonia 
neurophysiological and functional imaging studies indeed point towards abnormalities in 
the sensorimotor circuitry, which result in a vulnerable central nervous system. Some of 
these phenomena have been found in asymptomatic gene carriers, as well as in 
representations of unaffected body parts. It is suspected that a 'second hit' is needed to 
bring the central nervous system out of balance, which leads to dystonia.
113,119
 Musician's 
dystonia is an interesting example. In a transcranial magnetic stimulation study, cortical 
changes were found in musicians compared to healthy controls, and these changes were 
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more marked in those with musician's dystonia. It is hypothesised that musician's dystonia 
is a form of training-induced dystonia.
122
  
These suggestions, in particular the assumption of abnormal regulation of inhibitory 
interneuronal mechanisms at brainstem or spinal cord level, bring us back to 
Sherringtonian neurophysiology as already suggested by Denny-Brown in the 1960s, when 
he found that damage in different anatomical structures could have the same 
consequence, pointing to a basic neurophysiological principle, the final common path, that 
had been conceived around the turn of the 19
th
 to the 20
th
 century by his teacher Charles 
Scott Sherrington (1857-1952).
123,124
 This may still be a valid explanation of the 
phenomenology, if not the underlying causation of dystonia in modern terms. 
Today, psychogenic dystonia is considered a disorder that results from an underlying 
psychiatric illness. Its diagnostic criteria have remained unchanged for decades (Table 2.1). 
In the meantime, however, the border between neurology and psychiatry has been less 




 and primary dystonia
113
 are now 
considered neurofunctional disorders. Additionally, it has been shown recently that 
patients with cervical dystonia or blepharospasm have distinct neuropsychiatric and 
personality profiles of the anxiety spectrum.
127
 Another study shows high psychiatric 
comorbidity in cervical dystonia, which is unlikely to be a mere consequence of chronic 
disease and disfigurement.
128
 It is attractive to see psychogenic disorders as the 
consequence of functional crashes in anatomically normal brains. In these disorders, 
abnormalities found in neurophysiological and functional imaging studies may be 
interpreted as signs of organic dysfunction. We have only traced two transcranial 
magnetic stimulation studies on psychogenic dystonia. Interestingly, one of these found 
similar abnormalities in both organic and psychogenic dystonia: reduced short and long-
interval intracortical inhibition and cortical silent period, and an increased cutaneous 
silent period.
116
 The other detected difference: patients with organic dystonia had an 
increased response to paired associative stimulation compared to patients with 
psychogenic dystonia.
129
 The authors of the latter study concluded that abnormal 
plasticity is a hallmark of organic dystonia in contrast to psychogenic dystonia. 
If we hypothesise further, assuming abnormal regulation of inhibitory interneuronal 
mechanisms as mentioned above, neurophysiological and functional imaging studies may 
help to explain dystonia in CRPS due to peripheral injury leading to similar sensory 
receptive changes. Such mechanisms may also be in play in dissociation disorders, 
including conversion disorder,
111,112,130-132
 thereby associating primary dystonia, CRPS-
related fixed dystonia, and sensory and motor disorders in conversion disorder. 




Opinions on whether dystonia is either organic or psychogenic continuously changed on a 
spectrum between the two extremes over the described period. Genetic studies, the 
limited efficacy of psychotherapy, the effects of surgical treatments, lesion studies, and 
the recognition that focal dystonias may be minor forms of generalised dystonia pushed 
the explanatory ideas in the direction of organic. We have seen how insights were 
influenced by contemporary general pathophysiological concepts (humoral 
pathophysiology in the pre-1800 period, solid pathophysiology reflected by the clinical-
anatomical method thereafter, psychological pathophysiology after about 1900, and 
genetic and molecular pathophysiology in recent decades), as well as by various research 
methods, from which we have learn to be prudent with the interpretation of results and 
to reflect on epistemological mechanisms. Nevertheless, with these reservations in mind, 
modern neurophysiological and imaging studies may open new ways for the 
interpretation of dystonia. In both generalised and focal dystonia, studies point towards 
abnormalities in the sensorimotor circuitry, resulting in a vulnerable central nervous 
system. They indicate that the old distinction between psychogenic and organic is not 
easily applicable and perhaps should be abandoned. Similar mechanisms may be in play in 
CRPS-related fixed dystonia and sensory and motor disorders in conversion disorder. 
Hypotheses made on the basis of neurophysiological and functional imaging studies need 
further testing in these groups of patients. In addition, genetic studies may provide further 
insight. Until more knowledge is available, we must keep in mind the lessons from history 
and remember 1975: 
 
In the past, many victims of dystonia and their families have been caused anguish 
and hardship over and above that caused by the disease itself owing to the 





Once hurt, twice shy. 
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The quantitative thermal test showed cold and warmth hypesthesia without increased 
heat pain sensitivity in the affected limbs of complex regional pain syndrome (CRPS) 
patients with tonic dystonia (n=44) in comparison with healthy controls with a similar age 
and gender distribution (n=35). The degrees of cold and warmth hypesthesia were 
strongly correlated. We conclude that dysfunction in small nerve fiber (i.e., C and Aδ) 
processing is present in patients with CRPS. 
 




Complex regional pain syndrome (CRPS) is characterised by various combinations of 
sensory, autonomic and motor disturbances, and is usually preceded by a trauma. Patients 
with CRPS often experience spontaneous pain along with allodynia, hyperalgesia and 
hyperesthesia.
1,2
 In addition, negative sensory phenomena, such as hypesthesia and 
hypalgesia may be present, especially in chronic cases with longer disease duration.
1,3-5
 
Autonomic signs include changes in skin temperature and colour, and hyperhidrosis.
1,2
 
About 25% of the patients develop movement disorders, especially dystonia.
6-8
 In contrast 
to the twisting and repetitive movements generally encountered in primary dystonia, 
dystonia in CRPS is typically characterised by fixed flexion postures of the distal 
extremities. 
In primary dystonia, there is compelling evidence of altered sensory processing
9
 which 
includes abnormalities in temporal and spatial discrimination and vibration-induced 
illusion of movements as well as higher-order sensory processing. In CRPS-related 
dystonia, sensory integration of proprioceptive afferent input was found normal.
10
 Until 
now, small nerve fiber (i.e., C and Aδ) as opposed to large nerve fiber function, has not 
been studied in this type of dystonia. 
The quantitative thermal test is a non-invasive clinical test which assesses the function of 
small fibers and their central connections.
11,12
 The technique quantifies temperature 
sensation by testing minimally detectable temperature changes ('thresholds') for cold (CDT) 
and warmth detection (WDT), as well as for heat-induced (HPT) and cold-induced pain 
(CPT). 
In this study we applied the quantitative thermal test to evaluate C and Aδ fiber 
dysfunction in CRPS patients with dystonia. Since CRPS patients with dystonia may 
sometimes have three or even four affected extremities, and because an unaffected 
extremity may be involved on a subclinical level, we chose to compare results primarily 
with those of healthy controls. Whenever possible, comparisons were also made between 
affected and unaffected sides 
 
Patients and methods 
 
We studied 44 consecutive CRPS patients (41 women; mean age (SD) 36 (13) years; mean 
disease duration (SD) 10 (6) years) who were candidates for a study on intrathecal 
baclofen treatment (Table 3.1). This study was published in detail elsewhere.
13
 Severity of 
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pain was evaluated with a numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst 
imaginable pain). Severity of dystonia was assessed with the Burke-Fahn-Marsden (BFM) 
dystonia rating scale,
14




Table 3.1. Characteristics of the 44 CRPS patients with dystonia 
Characteristic Value 
Gender (F/M) 41/3 
Age (yr; mean, SD) 36 (13) 
Duration of CRPS (yr; mean, SD) 10 (6) 
Severity of pain (NRS; mean, SD) 7.7 (1.4) 
Number of affected extremities, n (%)  
 1 0 
 2 8 (18) 
 3 7 (16) 
 4 29 (66) 
Number of affected arms, n (%)  
 1  9 (20) 
 2  33 (75) 
Number of affected legs, n (%)  
 1  9 (20) 
 2  34 (77) 
Number of extremities with dystonia, n (%)  
 1 2 (4) 
 2 11 (25) 
 3 9 (21) 
 4 22 (50) 
Severity of dystonia (BFM; mean, SD) 50 (21) 
Sensory abnormalities, n (%) 43 (98) 
 Mechanical hypesthesia or hypalgesia 37 (84) 
 Mechanical hyperesthesia, hyperalgesia or allodynia 25 (57) 
BFM = Burke-Fahn-Marsden dystonia rating scale (range 0 - 120, with 0 = no dystonia)
14
; 
CRPS = complex regional pain syndrome; IQR = interquartile range; NRS = numeric rating 
scale (range 0 - 10, with 0 = no pain). 
 
 
For control purposes, 35 healthy controls with a similar age and gender distribution, who 
had no diseases of the central nervous system and did not receive any neuroactive drugs 
were also investigated (35 women; mean age (SD) 40 (13) years). Controls were partners, 
relatives or friends of patients, or were recruited among the hospital staff. Informed 
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consent was obtained from all subjects according to the Declaration of Helsinki. The study 
protocol was approved by the Institutional Review Board of the Leiden University Medical 
Centre. 
 
Quantitative thermal test 
A TSA-II NeuroSensory Analyzer (Medoc Ltd., Ramat Yishai, Israel) was used to determine 
CDT, WDT and HPT of both hands (thenar eminence) and both feet (dorsal aspect of the 
first metatarsal bone). CPT was not tested to minimize discomfort. These tests were 
performed by trained technicians in a quiet room at a temperature of 20 - 22°C. Subjects 
were measured in supine position and were not allowed to watch the computer screen. 
The 'method of levels' algorithm was used, in which the thermode returns to its baseline 
temperature (32°C) after each temperature change. After each stimulus period subjects 
are asked whether a change was perceived. The amplitude of the next temperature 
change is based on the response given after a stimulus: when no change of temperature 
has been perceived, the temperature change for the next step is doubled. If a change was 
perceived, the amplitude for the next step was halved. The procedure was continued until 
the step size reached 0.1°C. To alert the subject that a stimulus was imminent each 
stimulus was preceded by an auditory cue. Lower and higher temperature limit were 15.0° 
and 50.0°C, respectively; rate of temperature change 1.0°C/s (CDT, WDT) and 4.0°C/s 
(HPT); stimulus duration 5 s; return rate 10°C/s; and interstimulus interval 5 s (CDT, WDT) 
and 9 s (HPT). 
 
Statistical analysis 
The data were not distributed normally (Kolmogorov-Smirnov statistics for raw and log-
transformed CDT and WDT data, and raw HPT data, P<0.05) and therefore non-parametric 
tests were used. The significance threshold was set at P<0.05. For all tests, the SPSS 




Patients versus controls 
Thermal thresholds were evaluated in 37 hands of 28 patients, and in 48 feet of 37 
patients; testing on the other sites was not feasible due to dystonia or pain. The CDT and 
WDT were abnormal in the patients' affected limb in comparison with the controls' non-
dominant limbs (Table 3.2). There was a strong positive correlation between CDT and WDT 
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in patients (Spearman rho = 0.66, P<0.001) and a trend towards significant association in 
controls (Spearman rho = 0.33, P=0.05). HPT did not differ between patients and controls 
(HPT hand: P=0.50, HPT foot: P=0.53). 
 
Compared with the non-dominant limbs of controls, CDT and WDT of patients' unaffected 
limbs were increased, although the difference was not significant (Table 3.2). There were 
no significant differences in thresholds between non-dominant and dominant limbs in 
controls (data not shown). 
 
Within and between patients comparisons 
Nine patients had one affected arm, and also nine patients had one affected leg (Table 3. 
1). The affected limbs showed elevated CDT and WDT in comparison with their unaffected 
counterparts, but this was only significant for WDT in the hands (Table 3.2). 
 
 
Table 3.2. Comparison of thermal thresholds between CRPS patients' affected and 
controls' non-dominant extremities and between patients' affected and unaffected side 
 













   
 





























P value <0.0005 <0.0005 0.50  <0.0005 <0.0005 0.53 
Patients
a





























 P value 0.24 0.01 0.46  0.25 0.18 0.46 
Data represent median values (°C) with interquartile ranges shown in parentheses. 
CDT = cold detection threshold (difference from baseline temperature); CRPS = complex 
regional pain syndrome; HPT = heat-induced pain threshold; WDT = warmth detection 
threshold (difference from baseline temperature); ∆T = difference with baseline 
temperature. 
a
Note that most patients were excluded because they had two affected hands or two 
affected feet; number of patients is slightly different from Table 3.1 because testing was 
impossible in two patients due to dystonia or pain (both for hands and feet). 
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Relations between clinical characteristics and thermal thresholds 
There was no significant correlation between the severity of pain (NRS) and any threshold 
(data not shown), nor between dystonia (BFM) and any threshold. Although disease 
duration varied considerably between patients, none of the thresholds showed significant 
associations with this variable. There were no significant differences in thermal thresholds 
between patients who used analgesics versus those who did not. 
 
Discussion 
Although thermal thresholds have previously been examined in CRPS patients without 
dystonia,
3,15-17
 this issue has not been addressed in CRPS patients with dystonia. These 
earlier studies have yielded variable findings that most likely are explained by differences 
in applied methods and population characteristics. The general picture that arises from 
these studies is that CDT and WDT are elevated in patients with disease durations up to 4 
years, with the possible exception of CDT in patients with short disease duration (6 
months); findings on CPT and HPT are contradictory. In the present study we found cold 
and warmth hypesthesia together with normal HPT in the affected arms and legs of CRPS 
patients with dystonia. 
Thermal hypesthesia may be caused by disturbances at multiple levels of the nervous 
system. First, small fiber pathology has been demonstrated in CRPS
18-20
 and may explain 
our findings. In addition, it is known that impairment of C and Aδ fibers typically leads to 
thermal hypesthesia while sparing heat-induced pain, due to differences in spatial 
summation requirement.
11
 Second, C fiber activation by capsaicin injection elicited 
reversible tactile hyperalgesia and hypesthesia at the site of injection, but also in the 
adjacent tissue.
21
 This was attributed to rerouting of somatosensory input from non-
nociceptive into nociceptive pathways in the spinal dorsal horn. Therefore, plasticity-
related changes of sensory processing at the spinal level may also be an explanation for 
our findings. Third, in a population of 40 CRPS patients with one affected extremity, 
neurological examination showed hemisensory deficits including the face in 15 (38%).
17
 
The authors suggested that functional changes in the thalamus may play an important role 
in the pathogenesis of sensory abnormalities. Fourth, a shrunk representation area of the 
affected hand was found in the primary somatosensory cortex of CRPS patients.
22-24
 
Reduced activation of the contralateral primary and secondary somatosensory cortex after 
tactile stimulation has also been reported in CRPS
24
 and similar cortical changes may 
underlie thermal hypesthesia.  
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In conclusion, we found thermal hypesthesia in CRPS patients with dystonia. Whether this 
sensory abnormality is a secondary phenomenon or is in fact involved in the causal 
pathway to dystonia is uncertain. For a further understanding, clinical studies on the 
efficacy of sensory rehabilitation in CRPS-related dystonia are warranted. 
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Abstract 
Complex regional pain syndrome (CRPS) may occur after trauma, usually to one limb, and 
is characterised by pain and disturbed blood flow, temperature regulation and motor 
control. Approximately 25% of cases develop fixed dystonia. Involvement of dysfunctional 
GABA (gamma aminobutyric acid)-ergic interneurons has been suggested, however the 
mechanisms that underpin fixed dystonia are still unknown. We hypothesised that 
dystonia could be the result of aberrant proprioceptive reflex strengths of position, 
velocity or force feedback. We systematically characterised the pattern of dystonia in 85 
CRPS patients with dystonia according to the posture held at each joint of the affected 
limb. We compared the patterns with a neuromuscular computer model simulating 
aberrations of proprioceptive reflexes. The computer model consists of an antagonistic 
muscle pair with explicit contributions of the musculotendinous system and reflex 
pathways originating from muscle spindles and Golgi tendon organs, with time delays 
reflective of neural latencies. Three scenarios were simulated with the model: (i) increased 
reflex sensitivity (increased sensitivity of the agonistic and antagonistic reflex loops); (ii) 
imbalanced reflex sensitivity (increased sensitivity of the agonistic reflex loop); and (iii) 
imbalanced reflex offset (an offset to the reflex output of the agonistic proprioceptors). 
For the arm, fixed postures were present in 123 arms of 77 patients. The dominant 
pattern involved flexion of the fingers (116/123), the wrists (41/123) and elbows (38/123). 
For the leg, fixed postures were present in 114 legs of 77 patients. The dominant pattern 
was plantar flexion of the toes (55/114), plantar flexion and inversion of the ankle 
(73/114) and flexion of the knee (55/114). Only the computer simulations of imbalanced 
reflex sensitivity to muscle force from Golgi tendon organs caused patterns that closely 
resembled the observed patient characteristics. In parallel experiments using robot 
manipulators we have shown that patients with dystonia were less able to adapt their 
force feedback strength. Findings derived from a neuromuscular model suggest that 
aberrant force feedback regulation from Golgi tendon organs involving an inhibitory 
interneuron may underpin the typical fixed flexion postures in CRPS patients with 
dystonia.  
  




Dystonia is characterised by sustained muscle contractions, frequently causing repetitive 
twisting movements or abnormal postures.
1
 The aetiological classification of dystonia 
discriminates primary (idiopathic) dystonia, in which dystonia is the only clinical sign 
without any identifiable exogenous cause, from secondary forms in which dystonia is a 
symptom of an identified neurological condition, such as a focal brain lesion, exposure to 
drugs or chemicals.
2
 Primary dystonia is associated with disturbances of higher order 
processing including sensory temporal-spatial discrimination, multisensory integration for 
example between visual and tactile input, and movement representation.
3
 These 




One example of secondary dystonia is the so-called peripherally-induced dystonia which 
may develop following peripheral tissue or nerve injury.
7
 Whereas primary dystonia is 
typically characterised by prolonged twisting and repetitive movements, peripherally-




These fixed dystonias occur in about 25% of the patients with complex regional pain 
syndrome (CRPS) which is usually triggered by a limb injury. CRPS is characterised by 
persistent pain, autonomic and trophic features
9–11
 which reflect the various involvement 
of mechanisms that underlie inflammation
12,13
 and vasomotor dysfunction.
14,15
 Fixed 
dystonia in CRPS may spread to other limbs
16,17
 and its prognosis is poor
18,19
. Psychological 
or personality-based factors have been proposed as predisposing factors for CRPS-related 




One hypothesis underpinning CRPS-related fixed dystonia is that noxious input might 
interfere with joint and muscle proprioception of the affected body part, which in turn 
distorts segmental and polysegmental muscle activation during voluntary and reflex 
movements.
21
 Disturbed proprioceptive reflexes have been found in patients with CRPS-
related dystonia demonstrated by impaired inhibition of H-reflexes on tendon vibration,
22
 
and disturbed proprioceptive reflexes in posture maintenance experiments using a robot 
manipulator.
23
 We therefore hypothesised that fixed dystonia may result from aberrant 
proproceptive reflex strengths of position, velocity or force feedback. Although several 
independent reports appear to describe similar postures,
24–26
 a formal categorisation of 
CRPS-related dystonia has not been undertaken. We aimed to fill this critical gap by 
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characterising the nature of CRPS-related dystonia in 85 patients with CRPS-related 
dystonia. We subsequently used a neuromuscular model to evaluate whether specific 
disruptions of the musculotendinous system and reflex loops originating from muscle 
spindles and Golgi tendon organs (GTO) could produce fixed dystonia as observed in 





Eighty-five patients with arm or leg pain who presented to the Neurology department of 
the Leiden University Medical Centre and were diagnosed with CRPS type 1 and dystonia 
in one or more extremities, participated (Table 4.1). CRPS was diagnosed according to the 
criteria of the International Association for the Study of Pain: patients must have (i) 
continuing pain, allodynia or hyperalgesia, in which the pain is disproportionate to any 
inciting event; (ii) evidence at some time of oedema, changes in skin blood flow or 
abnormal sudomotor activity in the region of the pain; and (iii) no condition that would 
otherwise account for the degree of pain and dysfunction.
27
 It is convention to categorise 
patients as having CRPS type 2 if a nerve lesion is demonstrable and CRPS type 1 if a lesion 
is not demonstrable. This study involved only CRPS type 1 patients with dystonia of at 
least one extremity. 
None of the patients had a history of birth trauma or abnormal development. Other 
causes of dystonia had been excluded using appropriate blood and imaging studies 
(computed tomography, magnetic resonance imaging) of the spinal cord and brain. 
All patients provided informed consent before they were filmed in sitting or standing so 
that footage of each limb, sufficient to characterise its posture, was obtained. Footage of 
CRPS patients who exhibited fixed dystonia at rest on clinical examination between 1994 
and 2007 was examined by one investigator (T.M.). The severity of dystonia in the affected 
extremities was evaluated using the severity factor of the Burke-Fahn-Marsden scale 
(slight, mild, moderate or severe).
28
 Patterns of fixed posture were evaluated in four joints 
of the arms (fingers, wrist, elbow and shoulder) and legs (toes, ankle, knee and hip). 
Medical records were evaluated to verify that the posture observed in the footage was 
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Table 4.1. Demographic and clinical characteristics (n=85) 
Characteristic Value 
Gender, n (%)  
  Female  80 (94.1) 
  Male 5 (5.9) 
Age (yr; mean, SD) 41.3 (13.5) 
Duration of CRPS (yr; mean, SD) 11.7 (8.6) 
Preceding psychiatric history, n (%) 8 (9.4) 
Duration of dystonia (yr; mean, SD) 9.9 (8.6) 
Number of extremities with dystonia, n (%)  
  1 8 (9.4) 
  2 26 (30.6) 
  3 26 (30.6) 
  4 25 (29.4) 
Severity dystonia most affected extremity, n (%)  
  Slight 10 (11.8) 
  Mild 35 (41.2) 
  Moderate 21 (24.7) 
  Severe 19 (22.3) 
Sensory abnormalities, n (%)  
  Mechanical hypesthesia or hypalgesia 74 (87.1) 
  Mechanical hyperesthesia, hyperalgesia or allodynia 51 (60.0) 
 
 
Neuromuscular model simulation of fixed dystonia 
The neuromuscular model used to simulate dystonia consists of two antagonistic muscles 
attached to hand inertia, with Hill-type activation & contraction dynamics
29
 based on the 
Winters and Stark muscle model.
30
 Two parameter sets for the wrist and shoulder muscles 
were adopted from Winters and Stark.
30
 The model contains explicit contributions of the 
musculotendinous system and reflex pathways originating from muscle spindles and GTO 
with subsequent time delays to represent neural latencies. In the model, three reflex 
pathways are included that excite the contractile element of the muscle: (i) velocity-
dependent pathways initiated by activation of type Ia afferents from the muscle spindles; 
(ii) position-dependent pathways initiated by activation of type II afferents from the 
muscle spindles; and (iii) force-dependent pathways initiated by activation of type Ib 
afferents (GTO) (Table 4.2). The model enables determination of the contribution of each 
of these pathways to muscle activity in the arm. 
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There was one reference scenario with normal reflexes and three scenarios with abnormal 
reflexes (Figure 4.1): (i) increased reflex sensitivity, increased sensitivity of both the 
agonistic and antagonistic reflex loops, i.e. 'hyperreflexia'; (ii) imbalanced reflex sensitivity, 
increased sensitivity of only the agonistic reflex loop; and (iii) imbalanced reflex offset, an 
offset to the reflex output in only the agonistic proprioceptors. Each scenario was applied 
to each of the three reflex pathways to produce nine aberrant conditions. 
Although under normal conditions, reflex strength adapts during external force and 
voluntary movement
31
 and reflexes are suppressed to enable unimpeded voluntary 
movements, we excluded reflex adaptation so that both external forces and voluntary 
movements elicited reflexes. Each simulation had the same set-up: five seconds of 
continuous external force were followed by five seconds of rest, and then, five seconds of 
continuous voluntary contraction followed by again five seconds of rest.  
Figure 4.1 shows that the model reflex strengths were set up as (over) excitatory to agree 
with neurophysiologic studies in patients with CRPS that have demonstrated reduced 
central inhibition - so-called 'disinhibition'.
17,22,32,33
 Behaviour of the resultant model in 
each of the aberrant reflex scenarios was scored (0-5) according to the following 
characteristics, which are typical of CRPS-related dystonia:
17,34
 (i) abnormal posture; (ii) 
sustained contraction; (iii) increased stiffness; (iv) worsening with activity; and (v) loss of 
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Figure 4.1. Schematic representation of the aberrant reflex scenarios tested with the 
neuromuscular model. 
Increased reflex sensitivity, i.e. increased sensitivity of both the agonistic and antagonistic 
reflex loops; imbalanced reflex sensitivity, i.e. increased sensitivity of only the agonistic 
reflex loop; and imbalanced reflex offset, i.e. an offset to the reflex output in only the 





Eighty-five patients with CRPS and fixed dystonia (80 female) participated. Mean (SD) age 
was 41 (13) with a range from 16-69 years. Mean duration of CRPS was 11.7 (8.6) years, 
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Fixed dystonia was apparent in 123 arms of 77 patients (both arms were affected in 46/77 
patients). The dominant pattern of fixed dystonia was flexion. This fixed flexion dystonia 
was more often present in distal joints than in proximal joints, affecting mostly the fingers 
(116/123) but also the wrist (41/123), and elbow (38/123). Shoulder adduction was 
observed in 12/123 arms (Figure 4.2). One or more of these joint postures were found in 
118 arms (Table 4.3A). Other fixed dystonias were observed, although they were much 
less common. Extension of the fingers was observed in 5/123 arms, extension of the wrist 
in 1/123, and pronation of the elbow in 3/123.  
The extent and nature of fixed dystonia did not vary between left and right arms (P=0.95, 
Fisher's exact test). The 60 arms in which at least two segments were involved showed a 




Figure 4.2. Most common postures in arm and leg in CRPS-related dystonia arranged to 
the severity from left to right. Drawings were made by S. Blankevoort. 
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Flexion fingers Flexion wrist Flexion elbow Adduction 
shoulder 
60 X    
20 X X X  
15 X X   
9 X  X  
4 X  X X 
4 X X X X 
3 X   X 
1 X X  X 
1  X   
1   X  







Plantar flexion or 
inversion ankle 
Flexion knee Endorotation 
hip 
42  X   
24 X X   
17 X X X  
6 X    
6  X X  
6  X  X 
4   X  
3 X X  X 
3 X  X  
2 X X X X 
113 55 100 32 11 
Most common arm postures were present in 74 patients and most common leg postures 
in 77 patients. Column totals are presented in the bottom row. Note that for clarity 





Fixed dystonia was present in 114 legs of 77 patients. Only the right leg was involved in 
21/77, only the left in 19/77 and both legs in 37/77. Also in the legs, fixed dystonia was 
more often seen in distal than in proximal joints. The most common postures were plantar 
flexion and inversion of the ankle (73/114 legs); plantar flexion without inversion (11/114 
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legs), and inversion without plantar flexion (16/114 legs). Other common postures were 
plantar flexion in the toes (55/114 legs), flexion of the knee (32/114), and internal rotation 
in the hip (11/114) (Figure 4.2). One or more of these postures were observed in 113 legs 
(Table 4.3B). 
Other postures were rarely observed: dorsal flexion of the ankle (2/114 legs), eversion 
(2/114), dorsal flexion and inversion (1/114), and plantar flexion and eversion (2/114); 
dorsiflexion of the toes (4/114), and knee extension (7/114).  
As for the arm, there was no difference in the number or nature of fixed dystonias 
between the left and right legs (P=0.90, Fisher's exact test). The 73 legs in which at least 
two segments were involved showed also a gradual spread of dystonia from distal to more 
proximal regions of the limb. 
 
 
Simulating CRPS-related dystonia by modelling aberrant proprioceptive reflexes 
We used a neuromuscular model to simulate the dominant postures observed in patients. 
This model incorporates the interaction between mechanical properties of the limb and 
spinal proprioceptive reflexes. Figure 4.3 shows the movement and muscle torques of the 
wrist in the reference condition with (arbitrary) normal reflexes. Figure 4.1 shows the 
aberrant reflex scenarios, i.e. (i) increased reflex sensitivity; (ii) imbalanced reflex 
sensitivity; and (iii) imbalanced reflex offset, which were successively applied to 
proprioceptive feedback pathways originating from muscle spindles and GTO (Table 4.2). 
The increased reflex sensitivity scenario (i.e. 'hyperreflexia') resulted in motor dysfunction, 
varying from rigidity (in case of increased reflex sensitivity to force) to fast oscillatory 
movements (in case of increased reflex sensitivity to velocity or position), but did not 
cause an abnormal posture (Figure 4.4). The imbalanced reflex offset scenario resulted in 
abnormal postures, however, without other characteristics of fixed dystonia such as 
sustained contraction, increased stiffness and loss of voluntary control (Figure 4.4). For 
both the wrist and the shoulder parameter sets the simulation of the imbalanced reflex 
sensitivity to muscle force was the only condition that resulted in behaviour that closely 
resembled all clinical characteristics of fixed dystonia (Figure 4.4). The upper plot in Figure 
4.5 shows the deviant joint angles (abnormal posture) that resulted from imbalance of 
muscle force feedback. The degree of imbalance determined the severity of the deviation, 
since the force imbalance is counteracted by force contributions from muscle stretch in 
the antagonist. The increased co-contraction is evident from the high muscle torques in 
agonist and antagonist in Figure 4.5. After attaining the abnormal posture, the joint 
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movement induced by external force and voluntary contraction is smaller due to the co-
contraction and excitatory force feedback. 
 
 
Figure 4.3. Model simulation results with normal reflexes. 
Joint angle (top panel) and muscle torques (bottom panel) at the wrist in response to 
external force (0-5 s) and voluntary contraction (10-15 s) with normal reflexes. In periods 
of rest (5-10 and 15-20 s) the muscle contractions subside and the hand returns to its 
neutral position. 




Figure 4.4. Model simulation results with the three aberrant reflex scenarios applied to 
the three reflex pathways. 
Joint angles (top panels) and muscle torques (bottom panels) at the wrist in response to 
external force (0-5 s) and voluntary contraction (10-15 s) with the three aberrant reflex 
scenarios applied to the three reflex pathways. Left panels show the increased reflex 
sensitivity scenario, middle panels show the imbalanced reflex sensitivity scenario, and 
right panels show the imbalanced reflex offset scenario. The three traces within a panel 














Figure 4.5. Model simulation results with several degrees of imbalanced reflex sensitivity 
to muscle force. 
Joint angles (top panel) and muscle torques (bottom panel) at the wrist in response to 
external force (0-5 s) and voluntary contraction (15-20 s) with several degrees of 
imbalanced reflex sensitivities to muscle force. The motor behaviour resembles fixed 
dystonia. 
 




By systematically evaluating 123 affected arms and 114 affected legs, of 85 patients with 
CRPS-related dystonia, we identified a dominant pattern of fixed dystonia that would be 
predicted on the basis of proprioceptive disruption as an underlying cause. Symptoms are 
more often present in distal than in proximal joints, and more in flexor than in extensor 
muscles. In fact, Table 4.3A shows that proximal joint involvement was always found to be 
accompanied by more distal dystonia. From the 12 arms with an affected shoulder joint all 
had affected fingers. In legs the same relation was found between the hip and ankle, from 
the 11 legs with an affected hip joint all had affected ankles. In contrast, distal dystonias 
without involvement of proximal joints occurred often: only the fingers were affected in 
60 out of 118 arms and only the ankle in 42 out of 113 legs.  
The conspicuous involvement of flexor muscles in fixed dystonia in CRPS has been 
attributed to disinhibition of spinal circuitry involved in mediating nociceptive withdrawal 
reflexes (NWR).
17
 The character of the NWR represents the most appropriate movement 
for a withdrawal of the stimulated area from an offending stimulus.
35
 If disinhibition of 
NWR played a role in our findings, one would generally expect a stereotypical pattern of 
multi-segmental muscle involvement. However, only in the most severely affected cases 
did we encounter such multi-segmental patterns. In the majority of cases there was a 
selective distal muscle involvement which thus raises the need for an alternative 
explanation for fixed dystonia.  
Flexor motor neurons and associated interneurons which mediate depolarisation of 
primary afferent fibres, receive more sensory input than their extensor counterparts. The 
release of gamma aminobutyric acid (GABA) by spinal interneurons produces primary 
afferent depolarisation and reduces transmitter release (presynaptic inhibition), which in 
turn modulates reflex gains. The synaptic effectiveness of Ib afferent feedback ending in 
the spinal cord of vertebrates can thus be modulated by means of specific sets of GABA-
ergic interneurons.
36
 Dysfunction of GABA-ergic interneurons, which is a key component 
of central sensitisation, has been shown to compromise the specificity of afferent 
processing.
37
 Several studies have found evidence of disinhibition along the neuraxis in 
CRPS patients with and without dystonia.
22,33
 Dystonia in CRPS patients responds to the 
GABAB receptor agonist, baclofen, which enhances spinal GABA-ergic inhibition
38,39
 but not 
to the administration of the inhibitory neurotransmitter glycine.
40
 Collectively, these 
findings highlight a specific role of GABA-ergic mechanisms in CRPS patients with dystonia. 
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Since separate sets of GABA-ergic interneurons allow for selective control of muscle length 
and muscle tension, the predominant flexor postures in dystonia of CRPS may implicate 
imbalanced control of functionally coupled muscles.
41
  
We tested three types of aberrant reflex patterns using a neuromuscular model that 
captures the interaction between proprioceptive reflexes, the mechanical properties of 
the limb and its load. The aberrant reflex pattern that most closely mimicked the fixed 
dystonia in patients with CRPS was imbalanced reflex sensitivity to muscle force feedback. 
The severity of the abnormal posture varied according to the degree of imbalance. In 
contrast, increased and imbalanced reflex sensitivity to position and velocity feedback 
only caused oscillatory motions, which likely can be explained by consecutive reflexive 
contractions leading to decreased stretch in one of the antagonistic muscles, but 
increased stretch in the other. Increased reflex sensitivity to muscle force caused 
behaviour that exhibited all the characteristics of dystonia, except for the abnormal 
posture due to the balanced force feedback. Our findings therefore implicate possible 
involvement of GTO afferent input. GTO functions as the sensor in the feedback system 
that regulates muscle force and accurately signals active contractile force.
42–44
 Stretch of 
the tendon, which is proportional to the force in the muscle during active contraction, 
activates GTO and thereby increases type Ib afferent input onto inhibitory interneurons 
subserving primary afferent depolarization. These in turn inhibit α-motor neurons that 
supply the muscle from which they arise.
45
 Finally, since time delays destabilise feedback 
systems and the delay is greater distally than proximally, disruption of GTO feedback 
would most likely be associated with fixed dystonias that arise distally and then progress 
proximally. Hence, central sensitisation may impair the processing of GTO afferent input 
and thus contribute to the development of fixed dystonia.  
Alternatively, peripheral factors that influence the torque at the joint, such as changes of 
the contractile properties of the muscles, may introduce imbalances in force feedback 
independent of reflex settings. In fact, differences in agonistic and antagonistic muscle 
strength and moment arms may already introduce imbalances and possibly only become 
symptomatic with disturbed feedback control. Speculatively adequate control of reflexes 
may be required to actively balance feedback control. The most common ankle postures in 
our patients were plantar flexion or inversion, and indeed, the contributing muscles have 
greater strength compared to their antagonists. It may also explain the greater diversity in 
shoulder and hip postures, because the proportional strength of the contributing muscles 
is more variable between subjects and postures. 
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In conclusion, findings derived from a neuromuscular model suggest that aberrant force 
feedback regulation from GTO involving an inhibitory interneuron may underpin the 
typical fixed flexion postures in CRPS patients with dystonia.  
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Abstract 
There is compelling evidence of central nervous system involvement in neuropathic pain 
and movement disorders in patients with complex regional pain syndrome (CRPS). 
Previously, elevated cerebrospinal fluid (CSF) levels of interleukin-1β and interleukin-6 
were found in CRPS patients with and without movement disorders. The aim of the 
present study was to replicate these findings and to search for additional CSF biomarkers 
in chronic CRPS patients with dystonia. CSF samples of 20 patients and 29 subjects that 
underwent spinal anaesthesia for surgical interventions were used. We measured 
interleukin-1β, interleukin-6, interferon-γ inducible protein-10, RANTES (regulated upon 
activation, normal T-cell expressed and secreted), complement C3, mannose-binding 
lectin, complement C1q, soluble intercellular adhesion molecule-1, endothelin-1, nitric 
oxide, human lactoferrin and hypocretin-1 levels in these samples. No differences in the 
CSF levels of these effector mediators between patients and controls were found. Our CSF 
findings do not support a role of a variety of inflammatory mediators or hypocretin-1 in 
chronic CRPS patients with dystonia.  




Complex regional pain syndrome (CRPS) is a disorder that usually occurs after trauma and 
is more common in women.
1-3
 The initial clinical features of CRPS, which include persistent 
pain, changes in skin colour and temperature, sweating and swelling, have led several 
investigators to suggest an aberrant inflammatory response to trauma in these patients.
3,4
 
Various studies have reported involvement of a perturbed function of both C and Aδ fibres 
of sensory nerves (neurogenic inflammation) and the local immune system in the skin.
5-8
 
Following the acute phase of CRPS, patients may develop chronic pain, allodynia, 
hyperalgesia and movement disorders, which may include dystonia, myoclonus and 
tremor.
2,9
 There is compelling evidence that these clinical features are associated with 
aberrant processing of spinal and supraspinal sensorimotor neural networks.
10
  
In recent years evidence was obtained indicating that the immune system influences 
central sensitisation. A wide range of inflammatory mediators including cytokines, 
chemokines, adhesion molecules, endothelins, nitric oxid and complement are involved in 
the cascade of central events that play a role in the development and maintenance of 
pain.
11,12
 Furthermore, several lines of evidence have implied involvement of lactoferrin 
and hypocretins in nociceptive processing.
13,14
  
Because cerebrospinal fluid (CSF) is in close proximity of the central nervous system, it 
may reflect biochemical changes that are associated with mechanisms that underlie 
immune system involvement in central sensitisation. In this perspective, increased levels 




In the present study we first aimed to confirm our earlier findings of increased levels of IL-
1β and IL-6 in patients with CRPS and secondly searched for additional inflammatory 
mediators involved in chronic CRPS with dystonia. 
 
Materials and methods 
 
Patients and controls 
We used CSF from patients with CRPS-related dystonia who participated in clinical trials 
with intrathecal administration of medication. CRPS was diagnosed if patients met the 
CRPS type 1 criteria of the International Association for the Study of Pain,
16
 either at the 
time of disease onset or at the time of presentation at the clinic. Because we focussed on 
CRPS type 1, nerve conduction studies were performed in those cases where on the basis 
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of history or the distribution of sensory abnormalities, dystonia was possibly associated 
with CRPS type 2. Additionally, imaging studies were performed in those cases where 
history or neurological exam yielded atypical findings. 
 
CSF acquisition and processing 
CSF samples (5 mL) of 20 patients were collected prior to the administration of intrathecal 
medication. Control CSF samples (1-2 mL) were obtained from subjects who underwent 
spinal anaesthesia for surgical interventions including urologic (e.g. transurethral resection 
of urinary bladder tumour), orthopaedic (e.g. total knee prosthesis), vascular 
(femoropopliteal bypass), gynaecologic (vulvectomy) and general (e.g. lipoma excision) 
surgery. Otherwise, controls did not suffer from pain or neurological diseases. CSF was 
always sampled before surgery had started. Neither patients nor controls had any ongoing 
or recent infection at the time of the sample collection. 
After CSF was obtained, a small amount was used for leukocyte and erythrocyte count. 
Subsequently, CSF was centrifuged at 1790 xg for 5 min and the supernatant collected. 
Thereafter, supernatants were frozen in aliquots and stored at -80° C. The complete 
procedure was performed within 2 h. CSF containing >1000 erythrocytes/μL was excluded 
from the study. The medical ethics committee approved the study (MEC P01.098 and 
P03.027) and all subjects gave written informed consent. 
 
Assays 
Each test was performed on thawed aliquots, which were not re-frozen for further testing. 
If available, commercial assays were used and performed following the manufacturer's 
protocol. IL-1β and IL-6 concentrations were measured using enzyme-linked 
immunosorbent assays (ELISA; respectively R&D Systems, Minneapolis, MN, USA, high 
sensitivity assay, and BioSource, Nivelles, Belgium, ultrasensitive assay). Furthermore, 
ELISA (R&D Systems) were used to determine CSF levels of chemokines interferon-γ 
inducible protein-10 (IP-10) and RANTES (regulated upon activation, normal T-cell 
expressed and secreted). Complement C1q and C3 levels were determined by radial 
immunodiffusion using monospecific polyclonal rabbit antisera. Concentrations of 
mannose-binding lectin (MBL), involved in the lectin pathway of the complement system, 
were measured using ELISA as described in an earlier study.
17
 Soluble intercellular 
adhesion molecule-1 (sICAM-1) as well as endothelin-1 (ET-1) levels were measured by 
ELISA (R&D Systems) and nitric oxide (NO) levels were measured using a colorimetric 
activity assay (R&D Systems). Lactoferrin concentrations were quantified with a human 
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lactoferrin-specific ELISA as described by Van Berkel et al.
18
 using a microplate reader 
(BioTek Instruments, Winooski, VT, USA). Detection limits of these assays are reported in 
the table. Hypocretin-1 was measured with a standardised radioimmunoassay with a 
detection limit of 100
 
pg/mL (Phoenix Pharmaceuticals Inc, Belmont, CA, USA); levels were 
measured in unextracted samples.  
 
Statistics 
Group differences were analysed using a Mann-Whitney U test (SPSS version 12.0). P 




Twenty female patients with a mean (range) age of 42 (22-57) years and mean (range) 
disease duration of 10 (2-20) years were included. They reported mean visual analogue 
scale pain scores of 8 on a scale of 0-10 (range 4-9) and most of them used analgesics as 
medication. Allodynia and hyperalgesia were present in 13/20, hypesthesia and hypalgesia 
in 13/20; spread of CRPS to other limbs occurred in 18/20 and spread of dystonia in 16/20 
patients. Controls (13 females, 16 males) had a mean age of 59 (range 31-78 years). 
Median leukocyte count was 1/μL (range 0-10) in patients and 0/μL (0-9) in controls; 
median erythrocyte count was 11/μL (0-587) in patients and 1/μL (0-501) in controls. 
 
Control levels for IL-1β ranged from <0.125-0.83 pg/mL (median <0.125). This was not 
significantly different from that published earlier (Figure 5.1A). While in our earlier study a 
significant increase of IL-1β in CRPS patients was found, in the present study these 
differences between patients and controls were not obvious (P=0.10). In a similar fashion, 
IL-6 was analysed and again not significantly different between the two groups (Figure 
5.1B). Elevated CSF levels of IL-1β (4.6 and 7.4 pg/mL) were measures in two patients and 
in none of the controls. CSF IL-6 was elevated in one other patient (5.9 pg/mL) and in none 








Figure 5.1. Dot plots of CSF levels of IL-1β (A) and IL-6 (B) in CRPS patients and controls in 
the current study (study 2). For comparison, levels measured in an earlier study
15
 (study 1) 
are also shown. According to the ELISA manuals, inter-assay coefficient of variation is 8.2-
19.2% for IL-1β and 6.7-10.0% for IL-6. The dotted lines mark the lowest detectable levels 
of the ELISAs. 
A 
B 
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IL-1β pg/mL 0.125 0.14 <0.125 
– 7.43 
(n=15) 




IL-6 pg/mL 0.16 0.89 0.23 – 
5.98 
(n=15) 




IP-10 pg/mL 7.8 70.7 29.4 – 
385.6 
(n=20) 









C3 ng/mL 10 2213 1511 – 
3271 
(n=15) 




C1q ng/mL 0.1 184 132 – 
293 
(n=15) 









sICAM-1 ng/mL 0.35 2.1 1.3 – 
3.6 
(n=15) 











NO μmol/L 0.54 3.0 0 - 
15.0 
(n=15) 




Lactoferrin ng/mL 0.4 4.9 <0.4 – 
15.8 
(n=15) 




ND = not detectable. 
  
 
CSF levels of C3 and C1q in patients were not significantly different from controls. MBL 
was undetectable in both groups. sICAM-1, ET-1, NO and lactoferrin CSF levels were not 
significantly different between patients and controls (Table 5.1). Hypocretin-1 (orexin A) 
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levels were measured in 15 patients and were all in the normal range (197-391 pg/mL, 




The clinical spectrum of CRPS is heterogeneous and most likely reflects a mixture of 
symptoms and signs that are linked to differentially involved peripheral and central 
biological pathways. Identification of biomarkers that are related to particular biological 
pathways may provide clues to the pathogenesis of CRPS and perhaps contribute to 
improving therapeutic strategies. In this study we found no differences between patients 
and controls for any of the evaluated mediators of inflammation or hypocretin-1. 
Although patients and controls had a different age and gender distribution, these variables 
were not controlled because they were not related to the various mediators and could 
therefore not have acted as confounders. 
 
Recently, in a collaborative study, we found elevated CSF levels of IL-1β and IL-6 in chronic 
cases of CRPS.
15
 In the current study we could not confirm these findings, which may have 
at least two reasons. First, IL-1β and IL-6 levels in the controls of the present study were 
more heterogeneous (Figure 5.1A and B). This finding was unexpected because, contrary 
to the controls in the previous study, our controls did not have a history of neurological 
disease. Review of the medical records of the three controls with an elevated level of IL-1β 
(Figure 5.1A) revealed no explanation for these findings. Controls in the present study did 
not have neurological symptoms or signs and consequently are unlikely to have CSF 
abnormalities; therefore they better represent a normal population than those in the 
previous study. Second, inter-assay variation (IL-1β 8-19%; IL-6 7-10%) may have 
contributed to the different findings. Nonetheless, inspection of the IL-1β and IL-6 data of 
both studies shows that the majority of patients have values in the same range as 
controls. 
 
We additionally evaluated the presence of several other inflammatory molecules in CSF of 
patients and controls, because of their presumed role in neuropathic pain.
7,12,15,19-21
 
Unfortunately, the results again revealed no difference in CSF levels between both groups. 
RANTES and MBL were not detectable in both patients and controls. Hence, our study 
does not support a role of a variety of inflammatory mediators in these patients, but 
absence of evidence is not evidence of absence.
22
 Because our patients represent an 
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extreme dystonic phenotype with long disease duration, we cannot exclude a role of these 
inflammatory mediators in the early inflammatory phase where they may be a 
prerequisite to develop CRPS
23,24
 For both neuropathic pain and dystonia aberrant 
neuroplasticity is considered to be the pivotal underlying mechanism.
25-28
 Hence, a search 
for CSF biomarkers involved in molecular pathways that play a role in the ability of the 




Finally, neuroplasticity may involve a coordinated up and down-regulation of multiple 
protein complexes within the activated circuits.
30
 As a consequence, in future research a 
more global proteomics-based approach may be more informative than studies that focus 
on changes in CSF levels of inflammatory proteins.  
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Abstract 
The origin of myoclonus in patients with complex regional pain syndrome (CRPS) is 
unknown. Eight patients with CRPS-related myoclonus were clinically evaluated and 
studied with intermuscular and corticomuscular coherence analysis. Jerks were present at 
rest, aggravated during action and were frequently associated with tremulousness or 
dystonia. Electromyography demonstrated a burst duration ranging from 25-240 ms with 
burst frequencies varying from <1 jerk/s during rest to 20 Hz during action. Coherence 
studies showed increased intermuscular coherence in four patients in the 6-12 Hz band, as 
reported in patients with enhanced physiological tremor. In two patients side-to-side 
coherence was observed, pointing to a central oscillatory drive. Significant coherence 
entrainment was detected in 5 patients. We conclude that the characteristics of 
myoclonus in CRPS are different from other forms of myoclonus. 
                   




Complex regional pain syndrome (CRPS) may follow trauma and is characterised by 
sensory and autonomic features. Symptoms and signs of the acute phase reflect aberrant 
inflammation.
1,2
 Subsequently, patients may develop chronic pain, allodynia, or 
hyperalgesia, and movement disorders.
3





The nature of CRPS and its associated movement disorders has been subject of debate. 
Views supporting a role of somatic
3,5,6
 and  psychogenic
7-9
 factors have been reported. 
Currently, for dystonia in CRPS there is compelling evidence implicating disinhibition on 




In the present study, eight CRPS patients with myoclonus as a predominant movement 
disorder were clinically characterised and evaluated. Electromyography (EMG) was 
performed and analysed using coherence analysis, including entrainment during tapping. 
Coherence analysis is used for the evaluation of functional coupling between cerebral 
cortex and muscles (corticomuscular coherence) and central circuits linking individual 
muscles (intermuscular coherence).
10
 Abnormal or increased normal oscillatory drives 
have been described in different types of hyperkinetic movements, and are thought to 




Subjects and methods 
 
Subjects 
All CRPS patients with myoclonus of at least one extremity were selected from the CRPS 
database (399 records) of the Leiden University Medical Centre (department of 
Neurology). Thirteen patients had myoclonus as predominant movement disorder. Of 
them, three were lost to follow-up and two refused participation. The remaining eight 
patients (seven women; mean age 41 years, range 35 - 59 years) were investigated (Table 
6.1). CRPS was diagnosed according to the definition of the International Association for 
the Study of Pain: patients must have (i) continuing pain, allodynia or hyperalgesia, in 
which the pain is disproportionate to any inciting event; (ii) evidence at some time of 
oedema, changes in skin blood flow or abnormal sudomotor activity in the region of the 
pain; and (iii) no condition that would otherwise account for the degree of pain and 
dysfunction.
11
 Medication use was stable over a period of a month prior to the 
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investigations. The ethics committee of the Academic Medical Centre of Amsterdam 
approved the study and all participants gave written informed consent. 
 
Clinical evaluation 
Nature, distribution and severity of movement disorders were assessed by two authors 
(A.M. and M.T.) at the day of coherence analysis using items 5-8 of the abnormal 
involuntary movements scale (AIMS),
12
 which rates severity of dyskinesia on a scale of 0-4 




Recordings were performed at the Academic Medical Centre Amsterdam. Surface electro-
encephalogram (EEG) and EMG were recorded with silver-silver chloride electrodes. EEG 
electrodes were placed according to the international 10-20 electrode system. Bipolar 
EMG was recorded from three muscles of both the symptomatic extremity and the 
asymptomatic or less symptomatic contralateral arm. A typical montage in the arm was 
first dorsal interosseus (FDI) and wrist extensor (Ext) and flexor (Flex) muscles, and in the 
leg gastrocnemius (GA), vastus medialis (VM) and tibialis anterior (TA) muscles. 
Measurements were performed with BrainlaB (OSG, Rumst, Belgium). Sampling rate was 1 
kHz. Involuntary movements were recorded with uniaxial accelerometry (CPU gauge 9500 
series, Aikoh Engineering, Japan). 
 
Participants were measured in the supine position during: (1) rest; (2) posture: in case of a 
most affected arm, both arms were simultaneously extended; in case of a most affected 
leg only that leg was raised; (3a) force 1: 25 percent of maximal voluntary contraction 
against resistance of the most affected extremity and; (3b) force 2: 25 percent of maximal 
voluntary contraction against resistance of the unaffected or less affected hand; and (4) 
entrainment test: tapping with the unaffected or less affected hand at a metronome-
guided rate during rest and posture of the most affected extremity. The metronome 
frequency was set between 2 and 4 Hz, at a rate different from the patient's involuntary 
movements. Each condition had a total duration of 3 min; conditions (2) to (4) were 
performed in periods of 30-60 s separated by 10 s of rest. 
 
Data were processed off-line using BrainVision Analyzer software (Brain Products GmbH, 
München, Germany). Bipolar derivations were calculated for EEG data. EEG was high-pass 
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filtered at 2 Hz, and EMG at 10 Hz, and a 50 Hz notch filter was applied. Subsequently, 
EMG was rectified thus enhancing the firing rate information of the signal.
13
 Frequency 
analysis was performed using Matlab (The MathWorks Inc., Cambridge, UK) and 
NeuroSpec software (http://www.neurospec.org). Fourier transform of disjoint sections of 
1,024 data points, applying a Hanning window, was used to construct autospectra of EEG 
and EMG. Coherence is an extension of Pearson's correlation coefficient. It measures the 
correlation between autospectra and ranges from 0 (no linear association) to 1 (perfect 
linear association) and is the absolute square of the cross-spectrum normalized by the 
autospectra. Coherence was estimated between EEG and EMG and between EMG and 
EMG in the 2-50 Hz range. Cumulant density estimates (inverse Fourier transform of the 
cross-spectrum) and phase plots (defined as the argument of the cross-spectrum) were 
calculated, providing information on the time delay between two signals (lags and leads). 
Confidence limits were calculated.
14
 Phase plots were visually inspected; phase was 
formally assessed when there was a constant slope over the band of significant coherence 
that extended over at least five data points. Only significant findings (exceeding the 95% 
confidence level) are reported. Coherence entrainment is considered to be present when 
significant intermuscular coherence exists between affected extremity and contralateral 






Results for the individual patients are described below and listed in Table 6.1. The interval 
between onset of CRPS and hyperkinetic movements ranged from 0-10 years. There were 
no particular events preceding the onset of the hyperkinetic movements. In four patients, 
therapy with oral baclofen, diazepam, tiapride or magnesium had led to a reduction of 
severity. At neurological examination, all patients showed hyperkinetic movements at rest 
that increased during action. All patients had combinations of irregular jerks with 
tremulousness or dystonia in the affected extremities as specified below and in Table 6.1. 
Dystonia spread to other extremities in two of them (patient D and E). Myoclonus was 





Table 6.1 (next pages). Characteristics of the CRPS patients 
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A 54/F/7 L CTS surgery LA 6 months LA > RA; 
dist > prox 
Y Y 
B 45/F/12 L + R hallux 
valgus surgery 
RA, LA, RL + 
LL 
10 years RA > LA Y N 
C 59/M/5 Contusion R 
hand 
RA + RL 1 week RL > RA Y N 
D 35/F/10 Strain/sprain RA, LA, RL + 
LL 
6 years LA N Y 
E 51/F/5 Strain/sprain RA + RL Immediate RA + LA; 
dist > prox 
N Y 
F 48/F/11 Strain/sprain RA + RL 7 years RL Y Y 
G 43/F/14 R wrist 
fracture 
RA + LA 10 years RL Y Y 
H 51/F/8 Spontaneously LA + LL 3 years LA Y Y 
AIMS = abnormal involuntary movements scale; CRPS = complex regional pain syndrome; 
CTS = carpal tunnel syndrome; dist = distal; LA = left arm; LL = left leg; prox = proximal; RA 
                   


















LA > RA; dist 
> prox 
Y Y 90-130/4-5 6 Meloxicam, Metoclopramide, 
Distigmine, Bisacodyl, Macrogol 
RA > LA Y N 120-180/ 
5-6 
4 Tiapride, Diazepam, Baclofen, 
Oxycodone, Acetaminophen, 
Furosemide, Magnesium, 
Bisacodyl, Conjugated estrogens 
RL > RA Y N 120-150/6-
8 
3 Propranolol, Magnesium 
LA N Y 30-60/10-
14 
5 Morphine, Amitriptyline, 
Metoclopramide, Naproxen, 
Ketanserin, Pantoprazole 




8 Baclofen, Pantoprazole, 
Ethinylestradiol/Levonorgestrel 
RL Y Y 25-75/14-
16 
9 Magnesium, Amlodipine, 
Levothyroxine, Furosemide 
RL Y Y 40-100/8-
11 
8 Acetaminophen, Codeine, 
Naproxen, Amitriptyline 
LA Y Y 25-50/15-
20 
2 Amitriptyline 
= right arm; RL = right leg. 
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EMG recording and coherence studies were feasible in all patients. Five patients (A, C, D, E 
and G) had difficulty to tap rhythmically with their contralateral hand, nevertheless, EMG 
autospectrum peaks of the tapping muscles were at the metronome frequency. It was 
noticed that coherence was predominantly seen in a lower, 6-12 Hz band, and a higher 15-
30 Hz band. Table 6.1 summarises EMG findings and Table 6.2 summarises the maximum 
coherence values per patient for the different channels per condition for these two bands. 
 
 
Table 6.2. Significant intermuscular coherence in 5 patients 
Subject Muscle pairs Intermuscular coherence 
 Frequency band (Hz) Rest Posture Force 1 Force 2 
B FDI R-Ext R 











FDI R-FDI L 
FDI R-Ext L 
Ext R-FDI L 
Ext R-Ext L 


























FDI L-Ext L 6-12 - + (0.10) + (0.04) + (0.12) 
E Ext R-Tri R 6-12 - - + (0.04) - 
FDI R-FDI L 
Ext R-FDI L 
Ext R-Ext L 





















Ext L-Tri L 15-30 - - - + (0.02) 
F GA R-VM R 











G GA R-VM R 











H FDI R-Ext R 











Ext R-Ext L 











FDI L-Ext L 











Force 1 = 25% maximal voluntary contraction of the (most) affected extremity; Force 2 = 
25% maximal voluntary contraction of the contralateral extremity; FDI = first dorsal 
interosseus; Ext = forearm extensor; Flex = forearm flexor; GA = gastrocnemius; VM = 
vastus medialis; TA = tibialis anterior; NP = not possible.  
 
 
                   




Figure 6.1. Raw EMG data from patient A (A), patient D (B) and patient E (C), at rest. ECR = 
extensor carpi radialis, FDI =first dorsal interosseus. 
 
 
Patient A showed jerks, tremulousness and dystonia in both arms, left more than right. 
The raw EMG showed 90-130 ms bursts with frequency 4-5 Hz during action (Figure 6.1A). 
During rest, bursts were present, but less frequently. Intermuscular and corticomuscular 
coherence were not detected. There was no coherence entrainment (Figure 6.2). 
Patient B showed jerks and tremulousness in both arms, right more than left. 
Intermuscular coherence in the 5-10 Hz range was found between muscles of the right 
arm, between muscles of the left arm and between muscles of both arms (Table 6.2). 
Corticomuscular coherence was found around 6 Hz (C3Cz-Ext R and C3Cz-Flex R; posture); 
phase was ambiguous. During tapping with the left hand, the frequency was adopted by 
the right arm. This patient showed coherence entrainment between both forearm 
extensors with a coherence of 0.45 (Figure 6.2). 
Patient C showed jerks and tremulousness in the right leg and, to a lesser extent, in the 
right arm. Intermuscular and corticomuscular coherence were not detected. Left hand 
tapping altered the frequency of the hyperkinetic movements on visual inspection and 
coherence entrainment with magnitude 0.06 was found. 
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Figure 6.2 (continued on next page). Results of coherence entrainment test is shown for 
patients A and B: EMG autospectrum of the affected forearm extensor (Ext) during 
posture of both arms (A) and during posture of the affected arm and tapping with the 
contralateral hand (B), EMG autospectrum of the Ext of the tapping arm (C), coherence 
spectrum between (B) and (C) with 95% confidence limit (D), phase between them with 




Patient D showed jerks in the left arm, increasing during action and less in rest (Figure 
6.1B), and dystonia in both arms. Intermuscular and corticomuscular coherence were not 
detected. Right hand tapping altered the frequency of the hyperkinetic movements on 
visual inspection and coherence entrainment (0.17) was found. 
                   






Patient E showed jerks and dystonia in both arms. During rest jerks decreased (Figure 
6.1C). Coherence in the 7-11 Hz range was found between muscles of the right arm and 
between muscles of both arms (Table 6.2). Furthermore, intermuscular coherence was 
present in the 15-16 Hz range. Left hand tapping altered the frequency of the hyperkinetic 
movements on visual inspection and coherence entrainment (0.29) was found. 
Patient F showed jerks, tremulousness and dystonia in the right leg. Coherence ranging 
from 9-10 Hz was found between muscles of the right leg (Table 6.2). Corticomuscular 
coherence was found around 9-10 Hz (C3F3-GA R, C3Cz-GA R, C3Cz-TA R, C3F3-VM R and 
C3Cz-VM R; posture); phase was ambiguous. The coherence entrainment test failed 
because of the occurrence of dystonia. 
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Patient G showed jerks, tremulousness and dystonia in the right leg. Coherence between 8 
and 10 Hz was found between muscles of the right leg (Table 6.2). Left hand tapping 
altered the frequency of the hyperkinetic movements on visual inspection and coherence 
entrainment (0.03) was found. 
Patient H showed jerks, tremulousness and dystonia in the left arm. Both intermuscular 
(Table 6.2) and corticomuscular coherence were detected in the 17-23 Hz range. The 





CRPS is associated with presence of movement disorders like tremor and dystonia.
3
 
Myoclonus is also frequently mentioned but detailed information is scarce. In the current 
study, we investigated the clinical and electrophysiological characteristics in eight patients 
with CRPS-related myoclonus. 
 
Clinically, the myoclonus in our eight patients was diverse. Jerks were present at rest and 
worsened during action in all patients. Combination with tremulousness was present in 
most of them. Five of our patients developed myoclonus only several years after the onset 
of CRPS, as also described in dystonic features in CRPS patients.
16
 EMG registration 
revealed burst durations ranging from 25 ms-240 ms with a frequency ranging from 4-20 
Hz during action. 
 
Significant intermuscular coherence was detected most often during isometric contraction 
of the affected extremity (posture, force 1; Table 6.2). In patients B, E, F and G, 
intermuscular coherence in the 6-12 Hz band was detected. Furthermore, significant 
corticomuscular coherence in the 6-10 Hz range was present in two of them (B and F) 
during the posture condition. Both these coherence bands are most likely related to the 
hyperkinetic movements recorded in the same muscles, as the accelerometer peak 
frequency was in the same range. In dystonia, an abnormal drive can be detected in the 4-
7 Hz frequency band.
17
 The detected coherence in the current patients did not, however, 
correlate with clinical dystonic features. Moreover, in our dystonia patients, coherence 
was present at another frequency band. 
 
                   





 performed tremor recordings in 21 CRPS patients and found enhanced 
physiological tremor (EPT) with a mean tremor frequency of 7.2 (SD 0.4) Hz in 12 of them. 
The rhythmic hyperkinetic movements in our CRPS patients share some characteristics 
with EPT. However, two of them also showed side-to-side intermuscular coherence, which 
is uncommon for EPT.
19
 Side-to-side coherence has been reported in three patients with 
bilateral postural and kinetic tremors resembling EPT; in those patients there was no 
known cause for their tremor and there was a significant asymmetry in tremor amplitude 
in two of them.
19
 It was suggested in that study that these unclassified tremors originated 
from brainstem generators. Side-to-side coherence has also been described in three 
patients with persistent mirror movements, possibly originating at the level of 
corticospinal tracts projecting both contra- and ipsilaterally.
20
 A common drive for the 
bilateral involuntary movements in our patients seems likely.  
 
Coherence around 20 Hz was seen in patient E during both force conditions, and in patient 
H during rest and posture. Significant coherence in this band is considered physiological 




Coherence entrainment was present in five patients. Entrainment has been suggested as 
clue for psychogenic movement disorders.
21
 However, none of our patients had a 
psychiatric history before the onset of CRPS or otherwise indications of psychogenic 
movement disorders
21
 in line with a previous study on CRPS patients with dystonia.
22
 In 
general, phase and frequency of oscillatory movements are prone to entrainment by 
rhythmic movements occurring elsewhere in the same individual.
23
 Coupling between 
spinal pattern generators has been implicated in interlimb entrainment by movement-
elicited afference.
24
 Therefore, presence of entrainment may reflect a normal 
physiological phenomenon. On the other hand, entrainment may share similarities with 
mirror movements, which are defined as visible involuntary movements of the relaxed 
hand that appear to replicate the timing and type of movement being carried out by the 
voluntary activated hand.
25
 Overflow of central motor drive as occurs in mirroring may 
support the concept of central disinhibition in CRPS and its movement disorders. Further 
studies towards the value of detected entrainment are warranted. 
 
On visual inspection five patients were unable to tap rhythmically with their contralateral 
hand, suggesting a more elaborate impaired voluntary motor control. Ribbers et al.
26
 
performed kinematic analysis on the nonaffected dominant arm in CRPS patients. During a 
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drawing task, CRPS patients showed poorer execution of movement and impairment of 
temporospatial coding, suggesting impairment of central motor processing. 
 
To summarise, myoclonus in CRPS has a distinct clinical presentation. Clinically, jerks are 
associated with tremulousness and dystonia, are present at rest and aggravate during 
action. The current study shows some similarities and differences with other movement 
disorders, highlighting the need for future studies to clarify the mechanism underlying 
motor dysfunction of CRPS. 
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Abstract   
Dystonia in complex regional pain syndrome (CRPS) responds poorly to treatment. 
Intrathecal baclofen (ITB) may improve this type of dystonia, but information on its 
efficacy and safety is limited.  A single-blind, placebo-run-in, dose-escalation study was 
carried out in 42 CRPS patients to evaluate whether dystonia responds to ITB. Thirty-six of 
the 38 patients who met the responder criteria received a pump for continuous ITB 
administration and were followed for 12 months to assess long-term efficacy and safety 
(open-label study). Primary outcome measures were Global Dystonia Severity (both 
studies) and Dystonia-related Functional Limitations (open-label study). The dose-
escalation study showed a dose-effect of baclofen on dystonia severity in 31 patients in 
doses up to 450 µg/day. One patient did not respond to treatment in the dose-escalation 
study and three patients dropped out. Thirty-six patients entered the open-label study. 
Intention-to-treat analysis revealed a substantial improvement in patient and assessor-
rated dystonia scores, pain, disability and quality
 
of life (QoL) at 12 months. The response 
in the dose-escalation study did not predict the response to ITB in the open-label study. 
Eighty-nine adverse events occurred in 26 patients and were related to baclofen (n=19), 
pump/catheter system defects (n=52), or could not be specified (n=18). The pump was 
explanted in 6 patients during the follow-up phase. Dystonia, pain, disability and QoL all 
improved on ITB and remained efficacious over a period of one year. However, ITB is 
associated with a high complication rate in this patient group and methods to improve 
patient selection and catheter-pump integrity are warranted. 
                   






Complex regional pain syndrome (CRPS) is a poorly understood disorder that 
predominantly affects women and usually is preceded by an injury or surgery.
1,2
 Early 
clinical features of CRPS include persistent pain, swelling, increased sweating, and changes 
in skin colour and temperature and may reflect an aberrant inflammatory response to 
trauma.
2,3
 Various studies have reported the involvement of perturbed functions of both C 
and Aδ fibers of sensory nerves (neurogenic inflammation) and also a perturbed function 
of the local immune system in the skin.
4-7
 Several other studies have reported axonal 
degeneration in small distal nerve fibers of patients with CRPS.
8-10
 Aberrant processing of 
spinal and supraspinal sensorimotor neural networks are held responsible for the 
development of chronic pain, allodynia, hyperalgesia, and movement disorders.
11,12
 
Approximately 20% of patients with CRPS develop dystonia,
2,13,14
 which is defined as 
abnormal involuntary muscle contractions that cause twisting or repetitive movements or 
sustained postures.
15
 Dystonia in CRPS is predominantly characterised by fixed flexion 
postures, frequently has a delayed onset and may spread to other extremities.
14,16,17
 
Dystonia in CRPS is generally refractory to treatment
18
 and therefore adds considerably to 
the disease burden, leaving some patients severely disabled. 
Knowledge of the mechanism that underlies dystonia in CRPS is a prerequisite for the 
development of a treatment. In 2000, we reported on the beneficial effects of continuous 
administration of intrathecal baclofen (ITB) in six CRPS patients with multifocal or 
generalised dystonia.
19
 Baclofen stimulates the presynaptic gamma aminobutyric acid B 
(GABAB) receptor, which inhibits sensory input to spinal neurons,
20
 but may also act post-
synaptically.
21
 The aim of the current study was (i) to further elucidate the efficacy of ITB 
in a dose-escalation study of a large group of patients with CRPS-related dystonia and (ii) 
to evaluate whether ITB is effective and safe in this population over a 12-month period. 




All patients who visited our clinic with a diagnosis of CRPS 1 and dystonia in at least one 
extremity and who fulfilled the CRPS criteria of the International Association for the Study 
of Pain (IASP)
3
 were considered for inclusion in the study. The IASP criteria include a 
combination of (i) the presence of an initiating noxious event or a cause of immobilization; 
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(ii) continuing pain, allodynia or hyperalgesia with which the pain is disproportionate to 
any inciting event; (iii) evidence at some time of oedema, changes in skin blood flow or 
abnormal sudomotor activity in the region of the pain; and (iv) absence of a condition that 
would otherwise account for the degree of pain and dysfunction. Criteria ii-iv are 
necessary for a diagnosis of CRPS.
3
 We increased the homogeneity of the population by 
only including CRPS patients in whom a noxious event triggered the onset of the syndrome 
in the first affected extremity. Patients were only eligible if they experienced no benefit of 
oral baclofen up to a minimum daily dose of 60 mg or if this treatment caused dose-limiting 
side effects. Exclusion criteria were other causes of dystonia (birth injury, head trauma, 
neuroleptic treatments), other medical or psychiatric concomitant disorders that could 
affect the surgical risk or completion of the trial, pregnancy and spinal deformities that 
could interfere with implantation of the pump/catheter system. Physicians throughout the 
Netherlands referred patients to our department. Patient consent was obtained in 




A single-blind, placebo-run-in, dose-escalation study with continuous infusion of baclofen 
was conducted. This design was chosen for the following reasons. Firstly, our increasing 
experience of ITB in CRPS patients with dystonia indicates that bolus injections may result 
in effects lasting several days. These prolonged effects suggest that the previously used 
cross-over design
19
 with baclofen and placebo on alternate days is inappropriate. We 
therefore chose to administer placebo before baclofen. Patients were blind as to which 
days they received placebo. Secondly, bolus injections with ITB are less effective than 
continuous infusions with ITB.
22
 
Baclofen or placebo was administered via a percutaneous catheter that was introduced 
into the subarachnoid space (L3-4) and advanced to the lower thoracic region. The other 
end of the catheter was tunneled subcutaneously to the flank and connected to an 
external micro-infusion pump. Two days of placebo infusion were followed by the start of 
ITB infusion on the third day at a rate of 200 µg per day, which was increased daily 
according to a fixed schedule (200-250-300-375-450-525-600-700-800 µg) until the 
responder criteria (see below) were reached. If a baclofen-related side effect occurred, the 
dose was decreased or maintained, depending on the severity of the side effect.  
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Open-label study  
A programmable pump (SynchroMed Infusion system, Medtronic INC, Minneapolis, MN) 
for ITB administration was implanted subcutaneously in the lower abdominal wall in 
patients who met the responder criteria. The catheter was introduced in the subarachnoid 
space (L2-L3) under X-ray guidance with placement of the distal tip of the catheter in the 
midthoracic region. The catheter was placed in the same position in all patients, 
irrespective of upper or lower extremity involvement of dystonia. The catheter was then 
tunneled subcutaneously and connected to the pump.  
ITB was started at a rate of 150 µg per day and increased in 10-20% steps until (i) patients 
experienced a satisfactory reduction of dystonia; (ii) a maximum daily dose of 1300 µg was 
reached;  or (iii) dose-limiting side effects occurred. Pump-catheter system integrity was 
verified postoperatively in all patients and again in patients who showed no effect when a 




Patients completed Global Dystonia Severity (GDS) and Dystonia-related Functional 
Limitations (DFL) ratings at hourly intervals at home for five consecutive days and also for the 
duration of the dose-escalation study. GDS was assessed using a numeric rating scale (NRS) 
ranging from 0 (absent) to 10 (most severe). DFL involved four items (transfers, general 
mobility, left/right arm functions) with four response options, ranging from 0 (no limitations) 
to 3 (severe limitations).  
Patients participating in the open-label study were evaluated at baseline and 3, 6, 9, and 
12 months after surgery. Primary outcome measures included the GDS and DFL scores. All 
other outcome measures were considered secondary. Dystonia severity was rated using 
the Burke-Fahn-Marsden (BFM) dystonia rating scale,
23
 which is the sum of the scores of 
the individual body regions. Pain severity was evaluated using a numeric rating scale, 
ranging from 0 (no pain) to 10 (worst possible pain). The Rivermead Mobility Index (RMI) 
was used to assess mobility and includes 15 questions addressing a wide range of 
activities, from turning over in bed to running. The items are scored dichotomously (0-1) 
and summated, with a higher score reflecting better mobility (0-15).
24
 Activities of daily 
living were scored using the Barthel Index (range 0-20),
25
 while the Rankin Scale was used 
to determine global disability (0: no symptoms to 4: severe disability).
26
 Health-related 
quality of life (QoL) was assessed with the EuroQol-5D.
27
 The EuroQol-5D includes five items 
with three response options, from which a health state value (EQ-Tariff) is calculated, which 
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ranges from 0 (death) to 1 (perfect health), although negative values for health states 
considered worse than death are possible. It also includes a visual analog scale for general 
health (ranging from 0; worst imaginable to 100; best imaginable). Higher scores in the RMI, 
the Barthel Index and the EuroQol-5D correspond to better mobility, ADL and QoL, 
respectively. Higher scores in all other measures indicate symptoms with a higher degree 
of severity or poorer function.  
Safety was evaluated by recording the frequency and severity of adverse events, which 
included any new symptom or worsening of a pre-existing symptom.  
 
Statistical analysis  
Dose-escalation study. The scores of six hourly intervals from the home evaluation (11:00-
16:00) were summed (range 0-60) for each of the five days. The selection of these six time 
points was based on the fact that these were the hours that patients were active and able 
to record their evaluations. Sleeping, bathing and other activities often caused a larger 
number of missing values in the earlier and later parts of the day. The mean of these 5 
days was used as the baseline score. A mean sum score was similarly calculated for the 
two placebo days and each baclofen day. Missing values in the diary were replaced with 
the value of the previous hour if this concerned two scores or less per day. A day was 
excluded from analysis if three or more values were missing. The placebo and baclofen 
responses were expressed as the percentage change from baseline (i.e, home evaluation). 
The GDS score was used as the primary outcome. The responder criteria were set at a 
≥25% difference between the GDSbaclofen and GDSplacebo responses on two consecutive 
baclofen days.  
Open-label study. The primary outcome measures were the changes in the GDS and DFL 
from baseline to 12 months. Missing data in the primary outcome measures were handled 
in the same way as in the dose-escalation study. Secondary outcome was defined as 
changes from baseline on all other scales. Data from any particular patient's scale were 
excluded from statistical analyses if 25% or more of the data were missing from the scale. 
The results were analyzed both on an 'intention-to-treat' and on an 'on-treatment' basis. 
Score differences between baseline and 12 months were compared using the paired-samples 
t-test or Wilcoxon-signed-rank test. The relationship between the results from the various 
scales was assessed using a Spearman's rho test. A logistic regression analysis was 
performed to evaluate which patient characteristics or screening parameters predicted 
responsiveness to treatment in the open-label study, where a ≥25% reduction in patient-
reported dystonia was considered a positive response. Statistical analyses were performed 
                   
I n t r a t h e c a l  b a c l o f e n  i n  d y s t o n i a  i n  C R P S | 111 
 
 
using SPSS (version 14.0). A 95% CI excluding 0 indicated a significant difference at an α 





Fifty-seven CRPS patients were assessed for eligibility between January 2002 and January 
2007, of which 42 patients (40 women) with a mean (SD) disease duration of 10.3 (6.1) 
years participated in the study (Tables 7.1 and 7.2). Nineteen percent of study patients 
had CRPS in two extremities, another 19% in three extremities and 62% had symptoms in 
four extremities. Three percent of patients suffered from dystonia in one extremity while 
two, three and four extremities were affected by dystonia in 31, 21 and 45 percent of 
patients, respectively. Demographic and dystonia characteristics of the 15 excluded 




Table 7.1.  Demographic and clinical characteristics of patients (n=42) 
Characteristic Value 
Gender (F/M) 40/2 
Age (yr; mean, SD) 35.7 (12.8) 
Duration of CRPS (yr; mean, SD) 10.3 (6.1) 
Trauma preceding first affected extremity (%)  
 Soft tissue injury 23 (55) 
 Fracture 11 (26) 
 Surgery 8  (19) 
Number of affected extremities (%)  
 2 8 (19) 
 3 8 (19) 
 4 26 (62) 
Number of extremities with dystonia (%)  
 1 1 (3) 
 2 13 (31) 
 3 9 (21) 
 4 19 (45) 
Dystonia in upper and lower extremities (%)  
 Only upper 3 (7) 
 Only lower 1 (2) 
 Upper and lower 38 (91) 
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Three patients dropped-out due to intolerable side effects (n=1), CSF leakage (n=1) and 
because the study was considered too demanding (n=1). The number of missing data from 
the primary outcome never exceeded 2 scores per day. Thirty-seven patients followed the 
fixed-dose schedule; side effects required adjustment of the schedule for 5 patients. Blinding 
in the dose-escalation study was generally successful until patients perceived an 
improvement in their dystonia, after which blinding could not be maintained successfully. 
 
 
Table 7.2. Signs and symptoms of CRPS in affected extremities 










Pain     
 Present / absent / unknown, n 42 / 0 / 0 42 / 0 / 0 34 / 0 / 0 26 / 0 / 0 
Hypalgesia     
 Present / absent / unknown, n 38 / 4 / 0 32 / 9 / 1 26 / 8 / 0 19 / 5 / 2 
Hyperalgesia/allodynia     
 Present / absent / unknown, n 28 / 14 /  0 22 / 20 / 0 17 / 17 / 0 11 / 15 / 0 
Oedema     
 Present / absent / unknown, n 39 / 3 / 0 29 / 13 / 0 17 / 17 / 0 12 / 14 / 0 
Temperature changes     
 Present / absent / unknown, n 40 / 2 / 0 36 / 4 / 2 25 / 8 / 1 18 / 6 / 2 
Colour changes     
 Present / absent / unknown, n 40 / 1 / 1 38 / 3 / 1 24 / 10 / 0 19 / 6 / 1 
Hyper-/hypohidrosis     
 Present / absent / unknown, n 31 / 10 / 1 25 / 15 / 2 19 / 14 / 1 13 / 11 / 2 
Hair and nail growth changes     
 Present / absent / unknown, n 35 / 6 / 1 32 / 8 / 2 23 / 8 / 3 15 / 9 / 2 





                   




Figure 7.1. Enrollment of patients in dose-escalation and open-label studies. 
 
 
The mean GDSplacebo response was 7% (95% CI 3-12). One patient did not respond to ITB. A 
dose-effect of baclofen on dystonia severity was observed in doses up to 450 µg/day. 
Thirty-one patients reached the responder criteria at this dose (Figure 7.2). A total of 38 
patients showed a ≥25% difference between the baclofen and placebo responses on two 
36 entered open-label  
     study 
2 withdrawn 
     1 catheter-induced back pain 
     1 partial improvement/declined 
30 reached 
endpoint 
6 explanted  
   2 pump pocket infections 
   2 local pain at pump site 
   2 severe ITB side effects   
15 excluded  
    5 declined to participate  
    2 pregnant 
    4 unstable psychiatric disease 
    2 interfering somatic co-morbidity 
    1 deceased 
    1 lumbar osteosynthesis 
 
1 negative    
   response 
38 positive 
     responses
  
3 discontinued 
  1 intolerable ITB side effects 
  1 leakage 
  1 screening too burdensome 
 
57 assessed for eligibility  
36 included in intention-to-treat analysis 
30 included in on-treatment analysis 
42 entered dose-escalation study  
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subsequent baclofen days.  The mean difference between placebo and baclofen response was 
38% (95% CI 34-43) in favor of baclofen for responders on the first response day and 41% 
(95% CI 36-46) on the second day. The responder criteria were reached at a mean baclofen 
dose of 415 µg/day (SD 139, range 200-800). The total DFLplacebo response score showed a 
worsening of 2% (95% CI -3-7). The mean difference between DFLplacebo and DFLbaclofen 
response was 25% in favor of baclofen (95% CI 17-33) on the first response day and 25% (95% 
CI 17-31) on the second day. 



























Figure 7.2. Dose-escalation study: baclofen dose at which the responder criteria were 
reached. 
Kaplan-Meier curve of 42 patients showing the baclofen dose at which patients reached 
the responder criteria. ◊ denotes three patients that dropped out because of intolerable 
side effects, aanpassen. *denotes one patient who did not respond to ITB. 
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Open-label study   
Thirty-six of the 38 patients who met the responder criteria participated in the open-label 
study.  Two patients declined to proceed to implantation, due to catheter-induced back pain 
and persistent partial improvement of dystonia after the dose-escalation study. Missing data 
never exceeded the predefined criteria. All dystonia scores had improved significantly 
between baseline and 12 months (Table 7.3). GDS improved by a mean of 2.9 (SD 3.0) 
points (40%). The BFM score showed a similar improvement of 18.8 (27.1) points (38%). 
BFM subscores for the upper extremities improved by 45%, while dystonia in the lower 
extremities improved by 33%. GDS and BFM scores decreased during the first six months 
and remained stable thereafter (Figure 7.3A and B). Pain severity measured by the NRS 
decreased from 7.7 to 5.7 (26%) and there was a correlation between the reduction of 
pain and the improvement in the GDS score (Spearman's rho 0.50). The DFL total, mobility, 
transfers, and left/right arm function scores improved by 31, 19, 38, 35 and 33%, 
respectively. The Rivermead mobility index improved by 44%. Out of six patients who 
were completely confined to bed, four changed to using a wheelchair (two of which were 
able to walk short distances with or without walking aids) and one patient became fully 
ambulatory. One explanted patient remained confined to bed. Three of four patients who 
were partially bed-bound changed to full-time wheelchair use. Of the 14 patients who 
were wheelchair-bound, 10 remained unchanged, two still needed a wheelchair but were 
able to walk short distances, and two became fully ambulatory. All four patients with part-
time wheelchair use remained unchanged. Of five patients who needed walking aids, four 
improved to walking without aids. One of three ambulatory patients became part-time 
wheelchair-dependent due to worsening of CRPS symptoms. The other two patients 
remained ambulatory. The Barthel Index improved by 26%. Distribution of the Rankin 
Scale improved; 26 patients had moderate to severe disability at baseline, compared to 15 
patients during follow-up. The EuroQol-index improved from 0.21 to 0.45 while the health 
state improved from 42 to 54. 
 
The pump was explanted in six patients before the endpoint was reached (Figure 7.1, 
mean duration of ITB administration = 6 months, range 2-11). Results of the intention-to-
treat analysis (n=36) did not differ from the on-treatment analysis (n=30). Apart from a 
slight improvement in GDS score, none of the outcome measures in the off-treatment 
group changed significantly. Seventy percent of patients on treatment improved by ≥25% 
on the primary outcome, whereas 47% of the patients improved by ≥50%, and 20% 
improved by ≥75%.  
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Table 7.3 (continued on next page). Open label study: primary and secondary outcomes 
at baseline and 12 months follow-up 
  Intention to treat (n=36) 




Global Dystonia Severity (0-10)  7.3 4.4 -2.9 -3.9 to -1.9 
Burke-Fahn Marsden Scale (0-120)  48.9 30.1 -18.8 -28.0 to -9.6 
Pain - numeric rating scale (0-10)  7.7 5.7 -2.0 -3.0 to -1.0 
Dystonia-related Functional Limitations      
   Total score (0-12)  8.5 5.9 -2.6 -3.8 to -1.5 
   Mobility (0-3)  2.1 1.7 -0.4 -0.6 to -0.1 
   Transfers (0-3)  2.1 1.3 -0.8 -1.1 to -0.4 
   Right hand function
a
 (0-3)  2.3 1.5 -0.8 -1.2 to -0.4 
   Left hand function
a
 (0-3)  2.1 1.4 -0.7 -1.1 to -0.4 
Rivermead Mobility Index (0-15)  5.5 7.9 2.4 0.5 to 4.4 
Barthel Index (0-20)  11.8 14.9 3.1 1.3 to 5.0 
EuroQol-5D    
    Index  (EQ-Tariff) (0-1) 











0.12 to 0.36 
4.4 to 18.7 
a
Right and left hand functions were only assessed in affected hands. Absolute values are 
given in means. Differences in Global Dystonia Severity were tested with the paired 




None of the variables tested in the logistic regression analysis (including patient 
characteristics and screening characteristics, such as time to response and dose at which 
the patient met the responder criteria in the screening phase) predicted the response to 
ITB in the open-label study. The median ITB dose in the follow-up study increased from 




Nineteen ITB-related adverse events were reported in 14 patients (Table 7.4). Most 
frequent ITB-related adverse events were nausea, vomiting, headache, and short-term 
urinary retention at the start of the treatment. Three patients developed baclofen 
intoxication with somnolence, nausea and vomiting, which required temporary 
                   





On treatment (n=30)  Off treatment (n=6) 
0 Mo 12 Mo Change 
from 
baseline 




7.3 4.1 -3.2 -4.4 to -2.1  7.1 6.1 -1.0 -1.8 to -0.2 
50.5 27.2 -23.3 -33.3 to -13.3  40.8 44.8 3.9 -12.0 to 20.4 
7.7 5.4 -2.3 -3.4 to -1.2  7.4 7.4 0 -1.5 to 1.5 
         
8.6 5.3 -3.3 -4.5 to -2.1  8.2 8.8 0.6 -1.1 to 2.3 
2.1 1.6 -0.5 -0.8 to -0.2  2.1 2.4 0.3 -0.2 to 0.8 
2.1 1.2 -0.9 -1.3 to -0.5  2.0 2.1 0.1 -0.5 to 0.7 
2.3 1.3 -1.0 -1.4 to -0.6  2.3 2.3 0 -0.6 to 0.7 
2.1 1.2 -0.9 -1.3 to -0.5  1.8 2.0 0.2 -0.3 to 0.7 
5.7 8.3 2.7 0.4 to 4.9  4.6 5.6 1.0 -1.8 to 3.8 











0.13 to 0.41 











-0.03 to 0.14 
-10.9 to 41.3 
 
 
discontinuation of baclofen. Persistent baclofen-related headache and vomiting, which 
cleared after lowering ITB dose to a minimum rate, led to pump explantation in one 
patient. Three patients had psychiatric adverse events (two with psychosis and one with 
depression), which were probably caused by ITB, as symptoms cleared after lowering or 
stopping ITB. This led to explantation in one of these patients. 
 
Device-related complications were common: 43 catheter-related complications occurred 































































Figure 7.3. Dystonia severity during open-label study.  
Mean (SD) scores of Global Dystonia Severity (GDS, panel A) and the Burke-Fahn-Marsden 
scale (BFM scale, panel B) before and after 3, 6, 9, 12 months of ITB infusion in the on-
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Five patients, who initially responded to ITB, experienced a gradual worsening of dystonia 
over a period of 1-2 weeks. Catheter dysfunction was found in these patients and dystonia 
improved after a variable delay of days to months after catheter revision. 
Nine pump-related adverse events occurred in eight patients. Two patients experienced 
refractory pain at the site of the pump pocket, which led to explantation in one of these 
patients. The pump was explanted in three of four patients who developed a pocket 
infection. The pump was not re-implanted in two of these patients due to a questionable 
effect of ITB. The third patient improved to her former level after re-implantation.  
 
Table 7.4. Adverse events in open-label study 
Adverse events Type of event  n 












  3 
  3 
  3 
  2 
  2 
  1 
  1 
  1 
  3 
Device–related, catheter (n=43) Post-dural puncture headache 
Dislodgment 
Subcutaneous fluid collection/CSF leak 
Occlusion/kink 






Device–related, pump (n=9) Pump pocket infection 
Pain at pump site 
Migration of pump 









Excessive weight loss 
Gastro-intestinal problems (unrelated to ITB) 










psychosis: n=2, depression and anxiety disorders: n=1 
b
diplopia, dizziness, anorgasmia 
c
confusional state: n=2, reactive depression: n=1, reactive psychosis: n=1 
d
anemia, elevated liver enzymes, electrolyte changes   
 




Dystonia is characterised by impaired inhibition of sensorimotor circuitry at multiple levels of 
the central nervous system.
28-30
 Findings on dystonia in CRPS are in line with this and 
showed a loss of spinal and cortical inhibition.
30-32
 The dose-escalation study showed that 
ITB reduces dystonia in patients with CRPS. The fact that baclofen is infused around the spinal 
cord where it is known to stimulate presynaptic GABAB and possibly postsynaptic 
receptors,
20,21
 may indicate that loss of spinal GABA-ergic inhibition is an important 
mechanism in this type of dystonia. However, since baclofen may diffuse more rostrally, we 
cannot rule out that part of the effect is mediated at a supraspinal level.  
The open-label study showed marked improvement of patient and assessor-rated dystonia 
after one year. The largest improvement in dystonia was seen after three months, with a 
smaller further improvement after 6 months after which dystonia remained stable (Figure 
7.2). A similar response pattern was observed in deep brain stimulation (DBS) in patients 
with primary generalised dystonia
33
 and contrasts with the more rapid response to DBS of 
other movement disorders, possibly indicating a typical response characteristic of 
dystonia. A direct antinociceptive effect of baclofen cannot be ruled out since pain 
reduction was only partly explained by a decrease in dystonia severity.
20
 The median 
baclofen dose of 615 µg/day after one year of follow-up was similar to doses used in other 
types of dystonia,
22,34
 but higher than those reported for spasticity (mean 290 µg/day),
35,36
 
possibly due to differences in the pathophysiology of both disorders.  
We found improvement in arm function (DFL, 35/33%), transfers (DFL, 38%), and mobility 
(DFL 19%, Rivermead Mobility Index 44%) on the disability level. The largest changes in 
mobility were observed in patients confined to bed. The improvements in the impairment 
and disability levels paralleled those in the QoL. The efficacy of ITB in CRPS-related dystonia 
is emphasised by the observation that, contrary to the on-treatment group, the off-treatment 
group failed to change significantly in all measures but the GDS. However, the small change in 
GDS was not paralleled by a change in the BFM dystonia rating scale.   
One may postulate that the benefits reported by the patients on ITB reflect placebo 
effects, but we consider this unlikely for the following reasons. Firstly, all patients had 
long-term, progressive dystonia despite numerous interventions, including rehabilitation 
programs and invasive procedures (e.g. spinal cord stimulation).  Secondly, only a small 
placebo response (7%) was found in the dose-escalation study, which was similar in 
magnitude to our earlier study.
19
 Thirdly, catheter dysfunction led to obvious worsening of 
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dystonia in initial responders when these patients were unaware of the immediate cause. 
This worsening of dystonia also highlights that ITB acts on a symptomatic level.  
All patients had met the 25% responder criteria in the dose-escalation study, but only 70% 
of the on-treatment patients experienced a ≥25% reduction in dystonia, which was not 
anticipated. Malfunctioning of the pump-catheter system or a subtherapeutic dose of ITB 
could not explain this failure to respond. Pump-catheter system integrity was verified 
postoperatively in all patients and again in non-responders when a minimal dose of 1000 
microgram per day was reached. The cause of the discrepancy between both our studies 
therefore remains uncertain. A possible explanation is the difference in ITB flow rates 
between both studies since the flow rate during the dose-escalation study was almost six 
times higher than the rate in the open-label study. Flow-rate dependent effects of 
intrathecal administration may influence the drug's distribution along the spinal canal
37
 
and are currently being evaluated in a new study. We encountered a high percentage of 
adverse events during the follow-up period, which were related to the surgical procedure, 
drug delivery system and to baclofen. Particularly, PDPH occurred more frequently (86%) 
than commonly reported for pump implantation in other disorders (up to 42%
38
). A 
previous study reported high frequency of CSF leakage in patients with dystonia.
22
 CSF 
leakage related to PDPH was evident in three of our implanted patients, but we cannot 
rule out CSF leakage at a subclinical level in those patients lacking clear signs of CSF 
leakage. Migration of the pump leading to failure of drug delivery occurred in two patients 
with a body mass index of over 30. ITB likely caused psychosis in two patients and 
depression in one, since lowering the dose resulted in symptoms clearing. The higher 
number of device-related adverse events compared to ITB-treated patients with spasticity, 
can possibly be explained by the greater mobility in patients with CRPS-related dystonia.      
Although the female to male ratio of CRPS is 3-4 in most studies, our patient group 
included a very high percentage (95%) of female patients. This finding is in line with other 
studies in patients with CRPS-related dystonia where the percentage of females is much 
higher (84-86%).
14,17,39
 To date, no satisfactory explanation has been provided for this 
female predominance. 
There is an ongoing controversy over whether dystonia related to peripheral trauma with or 
without CRPS is caused by organic or psychogenic factors. Seventy-four percent of patients in 
our study also participated in a case-control study, in which their psychological 
characteristics were compared with those of patients with affective and conversion 
disorders.
40
 In line with other case-control studies,
16,39
 this study found no evidence to 
support a distinct psychological profile in patients with CRPS-related dystonia.  
 
122 | I n t r a t h e c a l  b a c l o f e n  i n  d y s t o n i a  i n  C R P S  
 
In conclusion, this placebo-controlled dose-escalation study showed that ITB reduces dystonia 
in CRPS and lends further support to the role of GABA-ergic mechanisms in this cause of 
dystonia. ITB also improved disability and QoL and remained efficacious over a period of one 
year. However, ITB is associated with a high complication rate and therefore methods to 
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Abstract 
Since glycinergic neurotransmission plays an important inhibitory role in the processing of 
sensory and motor information, intrathecal glycine (ITG) administration may be a potential 
therapy for both pain and movement disorders in patients with complex regional pain 
syndrome (CRPS). Aims of the current study, which is the first report on ITG in humans, 
were to evaluate its safety and efficacy. ITG treatment during 4 weeks was studied in CRPS 
patients with dystonia in the period before they received intrathecal baclofen treatment. 
Twenty patients were assessed and after exclusion of one patient, the remaining 19 
patients were randomised in a double-blind placebo-controlled crossover study. Safety 
was assessed by clinical evaluation, blood examinations and electrocardiograms. Efficacy 
measures involved pain (numeric rating scale, McGill pain questionnaire), movement 
disorders (Burke-Fahn-Marsden dystonia rating scale, unified myoclonus rating scale, 
tremor research group rating scale), activity (Radboud skills questionnaire, walking ability 
questionnaire), and a clinical global impression (CGI) and patient's global impression score 
(PGI). Treatment-emergent adverse events were generally mild to moderate and not 
different from placebo treatment. During ITG treatment growth hormone levels were 
slightly increased. Although there was a trend to worsening on the CGI and PGI during ITG 
treatment, there were no significant differences between ITG and placebo treatment in 
any of the outcomes. ITG given over 4 weeks was ineffective for pain or dystonia in CRPS. 
Although no serious adverse events occurred, further studies are required to rule out 
potential neurotoxicity of ITG. 
                   





Complex regional pain syndrome type 1 (CRPS), which is more common in women and 
often preceded by a trauma, is characterised by spontaneous pain, oedema, changes in 
skin temperature and colour, hyperhidrosis, and motor disturbances.
1,2
 The latter mainly 
include fixed dystonia of the distal extremities.
3,4
 The pathophysiology of CRPS is still 
unclear but over the last decade there is increasing evidence showing that different 
mechanisms may contribute to its broad clinical spectrum.
1,5,6
  
The initial symptoms of CRPS have been attributed to a perturbed regulation of 
inflammation in which both C and Aδ sensory nerve fibers (neurogenic inflammation) and 
the immune system of the skin are involved.
7-10
 Peripheral inflammation or injury may in 
turn lead to profound changes in the processing of sensory input at the spinal level, a 
process known as central sensitisation.
11,12
 As a result, pain may become chronic and 
allodynia and hyperalgesia may develop. Additionally, these central changes may corrupt 
the normal control of motor circuits.
13,14
 
Compelling evidence from neurophysiological studies that focused at the spinal or cortical 
level in patients show that disinhibition is a key characteristic in the involvement of the 
central nervous system in CRPS patients with and without dystonia.
15-18
 Cutaneous C and 
Aδ afferents are linked to spinal interneuronal circuits that mediate nociceptive 
withdrawal reflexes (NWRs).
19
 Interestingly, both sensitised NWRs in animal models and 
pain and dystonia in CRPS patients respond to the intrathecal administration of the GABAB 
agonist baclofen (ITB), which enhances spinal GABA-ergic inhibition.
20-22
 
In addition to GABA-ergic circuits, glycinergic circuits may also be involved in central 
sensitisation. In rats, peripheral inflammation-induced central sensitisation has been 
associated with loss of glycinergic inhibition.
23
 Following peripheral inflammation or spinal 
PGE2 injection, mice with a glycine receptor deficiency showed a reduced pain 
sensitisation.
24,25





 hyperalgesia. Besides involvement in afferent processing, 
glycine may play a prominent role in the control of motor functions. Strychnine is a glycine 
receptor antagonist, and poisoning with this drug results in overwhelming muscle spasms, 
rigidity and tremor.
29
 Glycine receptor mutations in both humans and animals result in 
spasms, tremor and myoclonia,
30,31
 motor features that bear a remarkable similarity to 
those reported in CRPS. 
In view of the important role of disinhibition in chronic CRPS and the potential role of 
glycinergic mechanisms in pain and motor processing, drugs such as glycine that enhance 
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glycinergic inhibition may provide a new mode of treatment in CRPS. Because glycine is 
abundantly present in food, it would seem plausible that this potentially dangerous 
inhibitory neurotransmitter has limited access to the CNS. Indeed, two animal studies 
have reported a poor blood-brain barrier (BBB) passage of glycine.
32,33
 As a consequence, 
glycine requires intrathecal administration (ITG) to explore its role in the management of 
pain and dystonia in CRPS. 
Aims of the current study were to evaluate the safety and efficacy of ITG in patients with 
CRPS. We here report the results of a double-blind randomised placebo-controlled 




Subjects were male or female out-patients, at least 18 years of age, with a clinical 
diagnosis of CRPS with dystonia who were referred to the movement disorders outpatient 
clinic of the Department of Neurology and were candidates for ITB treatment. Patients 
who qualified for ITB treatment were requested to participate in the current study, which 
was performed in the period before ITB treatment started. Patients were referred by 
physicians throughout the Netherlands. Inclusion criteria were CRPS 1 according to the 
diagnostic criteria of the International Association for the Study of Pain,
34
 clinically significant 
fixed dystonia in one or more extremities, and symptoms for at least 1 year. Exclusion criteria 
were satisfactory relief of symptoms with conventional treatments including oral baclofen, 
pregnancy, breastfeeding, childbearing potential without using effective contraception, 
clinically significant psychiatric illness, suspicion of poor compliance, or involvement in legal 
proceedings concerning compensation for CRPS. All patients were evaluated by a psychiatrist 
to exclude psychiatric comorbidity. In all subjects a programmable SynchroMed pump 
(Medtronic, Minneapolis, MN) for continuous IT administration was implanted. The catheter 
was introduced in the subarachnoid space (L2-L3) under X-ray guidance with the distal tip 
of the catheter placed in the midthoracic region. The catheter was then tunneled 
subcutaneously and connected to the pump. Pump-catheter system integrity was verified 
post-operatively. We aimed to recruit 20 patients, which was considered a reasonable 
sample size for a first safety study. Patient consent was obtained according to the 
Declaration of Helsinki and the study was approved by the Ethics Committee of the Leiden 
University Medical Centre. 
 
 
                   




To date no published studies on ITG in humans are available. The dose schedule of ITG in 
the current study was based on our experiences in one CRPS patient who progressed to 
generalised dystonia and did not respond to ITB. After consent was obtained from both 
the local Ethics Committee and the patient, a last resort therapy with ITG was started. We 
noted a sustained and prominent decrease in pain with moderate effects on dystonia at a 
dose of 30 mg/24 h. ITG was administered for 1 year and no side-effects occurred.  
 
Study design 
We used a double-blind randomised placebo-controlled crossover design. Randomization 
was done by a computer-generated list and took place at the Department of Pharmacy. 
Treatment allocation remained concealed from patients and investigators (including those 
who performed the assessments) throughout the study. Every subject received two 
intrathecal treatments: 21 mg/mL glycine solution during 4 weeks, and sodium chloride 
0.9% (w/v) during 4 weeks (placebo), with a tapering and wash-out period in-between 
both treatments: tapering in 1 week (3 equal dose reductions with an interval of 48 h), 
followed by a wash-out period of 1 week. The carry-over between treatments was considered 
minimal because the plasma half-life of IV glycine ranges from 30-60 min
35
 (the half-life of ITG 
is unknown). Placebo and ITG have the same watery appearance, which made unblinding by 
inspection of the administered substances impossible. Treatment was started at 8 mg/24 h 
and was increased weekly with 8 mg/24 h. Unless side-effects occurred, glycine 
administration reached a daily dose of 32 mg/24 h in the last week of the glycine period. 
Higher dose administrations were not studied because of the associated short filling interval 
(<1 month) of the pump, which was considered not feasible in clinical practice.  
 
An independent data safety board monitored the study. The committee monitored the 
safety of the patients by evaluating the treatment-emergent adverse events (AEs). The 
study is registered with the Netherlands Trial Register, number NTR499. 
 
Outcome measures 
Safety assessments included history taking, physical examination and routine blood 
assessments (every other week) and electrocardiograms (every other week). Pain was 
evaluated with a numeric rating scale (NRS) for pain, and the McGill pain questionnaire.
36
 
A TSA-II thermal sensory analyzer (Medoc Ltd., Ramat Yishai, Israel), using a thermode 
placed on both hands (thenar eminences), was used to assess detection thresholds of 
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temperature change (method of limits).
37
 Efficacy on movement disorders was studied with 
the Burke-Fahn-Marsden (BFM) dystonia rating scale,
38
 unified myoclonus rating scale 
(sections 2, 3, and 4)
39
 and tremor research group rating scale (items 1-8).
40
 Assessment of 
activity level included the Radboud skills questionnaire
41
 (if arms were involved) and the 
walking ability questionnaire
42
 (if legs were involved). Change of CRPS signs and symptoms 
was rated on a global impression scale: both the investigator (clinical global impression, CGI) 
and the patient (patient's global impression, PGI) assessed the change during treatment on a 
scale ranging from -3 (very poorly) to +3 (very well). 
Success of the blinding was investigated by asking both the patient and investigator to guess 
which treatment was administered. 
 
Plasma glycine and growth hormone analysis 
Blood samples for glycine measurement were taken at the last day of treatment (before 
tapering). Blood was collected in EDTA (ethylene diamine tetraacetic acid) tubes and 
directly cooled with melting ice. Plasma was isolated after centrifugation at 20°C for 7 min 
at 1,500g and stored at -20°C until analysis. Glycine was determined on a Biochrom 30 
automated amino acid analyzer (Biochrom, Cambridge, UK) as previously described;
43
 
however 250 µM L-methionine sulfone (Sigma, St Louis, MO) was used as the internal 
standard and a short buffer program of 50 min was used. 
Because in a previous study in children, IV glycine increased growth hormone (GH) 
levels,
44




To study differences between 4 weeks of ITG treatment and 4 weeks of placebo treatment, 
the paired t-test (if data were normally distributed) or Wilcoxon test (if not) were used. 
Significance was assumed at the 0.05 level. For all tests, the SPSS software package version 




No patients refused to participate in the study in the period before their ITB treatment 
started. Patients were aged 26-58 years (19 women, 1 man). One patient withdrew her 
consent after implantation. The remaining 19 patients entered the study (Table 8.1). In 
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one patient, the study was ended prematurely because participation was experienced as 
too burdensome (she received ITG during 21 days, and no placebo). 
 
 
Table 8.1. Baseline characteristics - before pump implantation (n=19) 
Characteristic Value 
Gender (F/M) 18/1 
Age (yr; median, IQR) 41 (34-51) 
Duration of CRPS (yr; median, IQR) 9 (5-17) 
Number of dystonic extremities (%)  
 1 0 
 2 6 (31) 
 3 3 (16) 
 4 10 (53)) 
Modified Rankin scale (%)
45 
 
 No significant disability 0 
 Slight disability 7 (37) 
 Moderate disability 5 (26) 
 Moderately severe disability 7 (37) 
 Severe disability 0 




Treatment-emergent AEs were found in 15 patients. The most frequently reported AEs 
were drowsiness, headache, dysesthesia and nausea and vomiting (Table 8.2). The 
proportion of patients with one or more AEs was similar during ITG (12/19 = 63%; 18 AEs) 
and placebo treatment (9/18 = 50%; 13 AEs; χ
2
 = 0.23, df = 1, P=0.63). 
Serious AEs did not occur. Other AEs during ITG treatment were categorized as mild to 
moderate. In one patient, a mild but persistent exacerbation of pain and dystonia 
occurred, which began at the first day of ITG treatment.  
 
Plasma glycine and GH measurements 
Mean plasma glycine concentrations were not different between ITG treatment (242 μM, 
range 106-461) and placebo treatment (241 μM, range 105-499) at 28 days of treatment 
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Table 8.2. Treatment-emergent adverse events 
Adverse event ITG (n=19) Placebo (n=18) 
Drowsiness 3 2 
Headache 2 2 
Dysesthesia 1 3 
Dysgeusia 1 - 
Photopsia - 1 
Restless legs 1 - 
Nervousness 1 - 
Emotional liability 2 - 
Nausea or vomiting 1 3 
Palpitations - 1 
Polyuria 1 - 
Unpleasant feelings 1 2 
Myalgia 2 - 
Fever (1 day) 1 - 
CRPS exacerbation 2 - 
Total 19 14 
CRPS = complex regional pain syndrome type 1; ITG = intrathecal glycine. 
 
 
At baseline, four patients had GH values (8.8, 9.8, 25.9 and 70.6 mU/L) above the normal 
range (0.0-5.0 mU/L). GH was significantly increased at day 29 of ITG treatment (median 
2.1, interquartile range [IQR] 0.7-5.3, maximum 30.7 mU/L) compared to day 29 of 
placebo (median 0.9, IQR 0.5-4.2, maximum 13.4 mU/L; P=0.031, Wilcoxon test). There 
were no significant abnormalities in other clinical laboratory tests or electrocardiograms. 
 
Efficacy 
There were no significant differences in any of the outcome measures, between ITG and 
placebo treatment (table 8.3). During ITG treatment, one patient reported improvement 
(PGI +2), and nine reported worsening (PGI -3 in one patient, -2 in four, and -1 in four). 
The CGI score showed improvement in one patient during ITG treatment (+2), and 
worsening in five (-3 in one, and -1 in four). During placebo treatment, two patients 
reported improvement (PGI +2), and four reported worsening (-2 in three, and -1 in one), 
the CGI showed improvement in none, and worsening in one (-1). The effect of placebo 
was 0% for the pain NRS and -15% for the BFM dystonia rating scale. 
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Table 8.3. Summary of secondary outcome events (medians (interquartile ranges) are 
presented) 




Intrathecal glycine Placebo P
b
 
Baseline 4 weeks Baseline 4 weeks 
Pain (numeric rating 
scale) 
0-10 6 (4-8) 6 (5-8) 7 (5-8) 7 (5-7) 1.0 
McGill pain 
questionnaire 
      
 Number of words 
chosen 
0-20 12 (7-13) 13 (8-14) 12 (8-14) 12 (8-14) 0.20 










analyzer  (°C) 
      







































      
 Myoclonus at rest 0-128 0 (0-8) 0 (0-5) 0 (0-1) 0 (0-1) 0.35 
 Stimulus sensitivity 0-17 0 (0-1) 0 (0-0) 0 (0-1) 0 (0-1) 0.13 
 Myoclonus with action 0-160 10 (0-20) 0 (0-16) 3 (0-20) 4 (0-17) 0.96 
Tremor research group 
rating scale (items 1-8) 
0-76 2 (0-6) 2 (0-6) 1 (0-6) 2 (0-6) 0.96 
Radboud skills 
questionnaire (total) 
1-5 4 (3-5) 4 (3-4) 4 (3-4) 4 (3-4) 0.18 
Walking stairs 
questionnaire 
      
 Walking in the house 0-10 9 (8-10) 9 (6-10) 9 (6-10) 9 (7-10) 0.77 
 Walking outside 0-10 10 (7-10) 10 (7-10) 10 (9-10) 10 (8-10) 0.23 
Patient's global 
impression 
-3-+3  0 (-1-0)  0 (0-0) 0.32 
Clinical global 
impression 
-3-+3  0 (-2-0)  0 (0-0) 0.74 
a
Best score is underlined.  
b
ITG at 4 weeks versus placebo at 4 weeks (Wilcoxon signed rank test). 
Patient's and investigator's guesses of which treatment was administered were incorrect 
in 57% and 59%, respectively. There was no significant effect of sequence (ITG-placebo or 
placebo-ITG) on the pain NRS and BFM dystonia rating scale baseline scores. 
 
 




Central disinhibition plays an important role in CRPS and enhancing the GABA-ergic 
inhibitory status through intrathecal administration of baclofen has proven beneficial in 
the treatment of dystonia and to a lesser extent on pain.
21,22,46
 Against this background, 
we were interested if similar results could be obtained by enhancing glycinergic inhibition 
in CRPS patients. Because no information is available on the tolerability of this mode of 
glycine administration in humans, this study firstly focussed on the safety of ITG and 
secondly evaluated its efficacy in doses up to 32 mg/24 h. No major AEs occurred in 19 
CRPS patients treated with ITG over 4 weeks. The proportion of most frequently reported 
AEs (drowsiness, headache, dysesthesia and nausea and vomiting) was similar for ITG and 
placebo treatment. Compared to placebo, median GH values increased during ITG 
treatment (0.9 versus 2.1 mU/L). GH levels still remained in the normal range of 0-5.0 
mU/L, and were smaller than the increases that are observed with intravenous GH. 
Notably, the absence of functional disturbances in our patients is at best only a surrogate 
marker for the absence of neurotoxicity of ITG.
47
 Evolving deficits may not be revealed by 
functional indices for an extended period of time, whereas histological examination 
demonstrates a continuing event.
48
 Consequently, our findings are insufficient to assume 
that ITG is not associated with neurotoxicity and further studies are required to address 
this issue. 
 
Over the dose-escalation period of 4 weeks with doses up to 32 mg/24 h we did not find 
evidence of efficacy of ITG. Several explanations for this lack of efficacy of ITG are 
possible. First, it is possible that not glycinergic but GABA-ergic mechanisms play a key role 
in central disinhibition of CRPS. Second, ITG may have been administered in an insufficient 
dose, although GH-increases indicate that the doses were pharmacologically active. Third, 
effective synaptic concentrations of glycine are regulated by glycine transporters which 
mediate its uptake into nerve terminals and adjacent glial cells.
49
 Hence, the lack of 
efficacy of ITG could result from a compensatory ITG-mediated increased activity of 
glycine reuptake transporter mechanisms. In this case, selective inhibitors of glycine 
transporter could be more efficacious. Finally, however, our patient and clinician-based 
impression scores may hint at another explanation. Although the primary outcomes 
showed no difference, there was a trend on the patient and clinician-based impression 
scores to show deterioration during ITG. Nine patients worsened during ITG, versus four 
during placebo treatment according to the patient-based PGI score. In line with this, the 
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investigator-based CGI indicated that five patients got worse during ITG, versus one 
patient during placebo treatment. Although, the PGI and CGI were not significantly 
different from zero, the trend towards a deterioration of signs and symptoms with ITG 
suggests that glycine may play a pathophysiological rather than a therapeutic role in CRPS. 
This could be caused by the dual action of glycine, which serves both as an obligatory co-
activator of the spinal excitatory N-methyl-D-aspartate (NMDA) receptor, and as a 
neurotransmitter at the inhibitory strychnine-sensitive glycine receptor.
50,51
 It is possible 
that the excitatory effects prevailed in the applied dose range. In CRPS, chronic pain, 
allodynia, and hyperalgesia, are assumed to result from central sensitisation, a state 
reflecting enhanced synaptic transmission efficiency of neurons in the dorsal horn of the 
spinal cord.
11
 In central sensitisation, the NMDA receptor is upregulated, and open studies 
using NMDA antagonists memantine and ketamine have reported beneficial effects on 
pain in CRPS .
52-54
 Hence, ITGs efficacy could depend on the state of the NMDA receptor 
and stimulation of the excitatory glycine receptor of the upregulated NMDA receptor may 
potentially worsen symptoms such as pain, explaining the trend of poorer ratings of 
patients and physicians when patients were using ITG.
55-57
 Interestingly, intrathecal 
administration of 2-amino-5-phosphonopentanoate, an NMDA receptor antagonist, 
unmasked the analgesic action of glycine in rats.
58
 Hence, future studies could analyze 
whether or not NMDA inhibition, administered prior to or simultaneously with ITG may 
enhance its therapeutic potential under circumstances of central sensitisation. Because 
intrathecal administration of NMDA inhibitors is neurotoxic,
59
 this hypothesis can only be 
tested with orally or intravenously administered agents. 
 
We studied a population of severely affected CRPS patients with long disease duration. 
Consequently, this patient sample involved a selection of treatment refractory patients, 
who are not representative for all CRPS patients. However, it would be unethical to 
evaluate ITG in acute stage patients, in whom symptoms might resolve spontaneously or 
following less invasive treatment options.  
 
There is no data on the magnitude of the placebo responses in trials evaluating chronic 
treatment in CRPS patients with dystonia until now. In our previous study, placebo 
responses to two intrathecal saline injections were 4% and 8%, respectively.
21
 
Interestingly, there was no detectable placebo response in the current study during 4 
weeks of intrathecal treatment. This finding might be useful for designing future trials on 
this subject. 
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In conclusion, ITG in doses up to 32 mg/24 h during four weeks was not associated with 
serious adverse events, but further studies are required to rule out potential neurotoxicity 
of ITG. Although results from animal studies were promising, this study did not find 
efficacy on pain or dystonia in patients with chronic CRPS. Several potential explanations 
for this finding could be addressed in future studies. 
 
 




The data safety board consisted of Prof.dr. H.J. Guchelaar (Department of Clinical 
Pharmacy, Leiden University Medical Centre), Dr. R.J.E. Grouls (Department of Clinical 
Pharmacy, Catharina Hospital, Eindhoven) and Dr. G.J. Lammers (Department of 
Neurology, Leiden University Medical Centre). 
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Abstract 
Activated immune cells in the spinal cord may play an important role in the development 
and maintenance of neuropathic pain, such as occurs in response to peripheral 
inflammation or tissue injury. Immune activation may therefore serve as a therapeutic 
target for immune modulating drugs like corticosteroids. This double-blind randomised 
placebo-controlled parallel-group trial aimed to investigate the efficacy and safety of a 
single intrathecal administration of 60 mg methylprednisolone (ITM) in chronic patients 
with complex regional pain syndrome (CRPS). The primary outcome measure was change 
in pain (pain intensity numeric rating scale; range 0-10) after 6 weeks. With 21 subjects per 
group the study had a 90% power to detect a clinically relevant difference (≥2 points). After 
21 patients (10 on ITM) were included, the trial was stopped prematurely after the interim 
analysis had shown that ITM had no effect on pain (difference in mean pain intensity 
numeric rating scale at 6 weeks 0.3, 95% CI -0.7 to 1.3) or any other outcome measure. 
We did not find any difference in treatment-emergent adverse events between the ITM 
and placebo group. We conclude that a single bolus administration of ITM is not 
efficacious in chronic CRPS patients, which may indicate that spinal immune activation 
does not play an important role in this phase of the syndrome.   
 
                   





Complex regional pain syndrome type 1 (CRPS) is usually preceded by tissue injury and 
characterized by pain, oedema, skin discoloration, altered temperature, hyperhidrosis, 
and movement disorders.
1,2
 The initial symptoms of CRPS have been attributed to 
aberrant inflammation in which both C and Aδ sensory nerve fibers and the immune 
system of the skin contribute.
3-5
 This peripheral inflammation may lead to profound 
changes in spinal processing resulting in allodynia, hyperalgesia, and the chronification of 
pain (central sensitisation).
6,7
 In turn this process may corrupt sensorimotor network 
function causing motor dysfunction.
8,9
 
The mechanisms underlying central sensitisation in CRPS are still largely unknown. 
Activation of spinal microglia has been implicated in the development and maintenance of 
neuropathic pain states.
5,10,11
 In this process, a range of immune mediators is released, 
among which prostaglandin E2 (PGE2) plays a crucial role.
12
 Cyclooxygenase-2 (COX-2), 




Glucocorticoids have powerful anti-inflammatory effects throughout the whole body with 
COX-2 repression as one of the mechanisms of action.
14
 In CRPS, glucocorticoids may be 
beneficial early in the course of the syndrome,
15
 which most likely is explained by the 
suppression of peripheral inflammation. Because of the poor spinal bioavailability,
16
 oral 
corticosteroids may lack efficacy with respect to the chronic features of CRPS caused by 
central sensitisation. A possible method to circumvent this problem is intrathecal 
administration. In chronic postherpetic neuralgia, another neuropathic pain syndrome, 
intrathecal methylprednisolone (ITM) was shown to be effective.
17
  
The aim of this study was therefore to evaluate the efficacy and safety of a single 




Subjects were male or female outpatients, with a clinical diagnosis of CRPS type 1 who 
were referred to the Movement Disorders outpatients clinic of the Department of 
Neurology. In all cases patients were referred by neurologists and anesthesiologists 
throughout the Netherlands. Patients had to fulfill the diagnostic criteria of the consensus 
report of CRPS 1,
18
 had to be 18-75 years old, have experienced symptoms for more than 6 
months and less than 6 years, and report spontaneous pain of at least five on a pain 
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intensity numeric rating scale (PI-NRS; on which 0 represents no pain, and 10 the worst 
imaginable pain). Patients were excluded if they had experienced satisfactory relief of 
symptoms with conventional treatments, had contraindications for steroid therapy or 
lumbar puncture, were pregnant or breast-feeding women or women of childbearing 
potential not using effective contraception, had clinically significant psychiatric illness, 
were suspected of poor compliance, or were involved in legal proceedings claiming 
compensation for their CRPS. 
 
A review of the literature showed that methylprednisolone acetate (Depo-Medrol) was 
administrated intrathecally in patients in more than 5,900 occasions (see the discussions 
in The Medical Journal of Australia,
19-27
 Archives of Neurology
28-35
 and The Clinical Journal 
of Pain
36-38



















. Most of these side effects were reported in patients with multiple 
sclerosis who received repeated administrations.  
Patients in our study were orally and written informed about these facts. Patient consent 
was obtained according to the Declaration of Helsinki and the study was approved by the 
medical ethics committee of the Leiden University Medical Centre. 
 
Study design 
We used a double-blind randomised placebo-controlled parallel-group design. 
Randomization was done with a computer-generated list and took place at the 
Department of Pharmacy. Treatment allocation remained concealed from patients and 
investigators (including those who performed the assessments) throughout the study. 
Lumbar puncture (20 or 22 gauge needle) was performed by physicians experienced in 
performing lumbar punctures (A.M. or A.P.). Subjects received 60 mg methylprednisolone 
acetate (Depo-Medrol 40 mg/ml) or 1.5 ml sodium chloride 0.9% (placebo). Study 
medication was distributed in opaque syringes, which made unblinding impossible. Clinical 
assessments were scheduled at baseline (1 week before administration of study 
treatment), at 6 weeks and 12 weeks follow-up.  
An independent data monitoring committee was instituted to monitor safety and to 
perform an interim analysis on efficacy halfway during the study. At the interim analysis, 
this committee assessed the probability that efficacy of ITM could be demonstrated at the 
end of the study. The study is registered with the Netherlands Trial Register, number NTR61. 
                   




Pain was evaluated with the PI-NRS,
51
 and the McGill pain questionnaire
52
 and were 
computed as the means of the scores at 09:00, 13:00, 17:00 and 21:00 h at one day. The 
effect of  ITM on movement disorders was studied with the Burke-Fahn-Marsden dystonia 
rating scale (BFM),
53
 unified myoclonus rating scale (UMRS; sections 2-4)
54
 and tremor 
research group rating scale (TRGRS; items 1-8)
55
. Change of CRPS signs and symptoms was 
rated on a global impression scale: both the investigator and the patient assessed the 
change from baseline at the end of the study period on a scale ranging from -3 (very much 
worse) to +3 (very much improved).
51,56
 
The integrity of the blinding procedure was investigated by asking both the patient and 
investigator to indicate which treatment they thought had been administered. 




The primary outcome measure was the change in pain on the PI-NRS at six weeks. It was 
estimated that 21 patients in each treatment group would provide a 90% power to detect a 
mean difference in the mean PI-NRS of ≥2 points between the two groups, which was 
considered clinically relevant,
51
 with a type I error rate of 5%. Based on previous studies,
51,57
 
an SD of 2 was assumed. Independent-samples t-tests were used to compare the PI-NRS 
change between the two groups after 1, 6 and 12 weeks. Mann-Whitney U tests were 
used to compare the patient's and investigator's global impression scores between both 
groups. One-way between groups analyses of covariance (ANCOVA) with the baseline scores 
of the various outcome measures entered as covariates, were used to compare the efficacy of 
ITM to placebo while adjusting for baseline differences between the two groups. For the 
ANCOVA, preliminary checks were conducted to ensure that there was no violation of the 
assumptions of normality, linearity, homogeneity of variances, homogeneity of regression 
slopes, and reliable measurement of the covariate. The relation between the patient's and 
investigator's global impression score was investigated using Spearman rank correlation 
coefficient. Significance was assumed at the 0.05 level. For all tests, the SPSS software 











Twenty-eight patients were screened for enrollment, seven of whom were ineligible: two 
did not meet the inclusion criteria, and five refused to participate (in whom clinical 
characteristics were not different from the remaining patients; Figure 9.1). The other 21 
patients (16 females, 5 males) were randomised; their mean (SD) age was 46 (11) years 
and their mean (SD) duration of CRPS 4.5 (2.2) years. One randomised patient (who had 
received placebo) withdrew from the study because she developed severe post-dural 
puncture headache as well as a major depressive disorder. All male patients (n=5) received 
placebo. Twelve patients had two or more affected extremities, of which eight received 
ITM. Other baseline characteristics were similarly distributed between treatment groups 
(Table 9.1).  
 
Efficacy 
The study was ended prematurely because the interim analysis showed that the chance of 
reaching efficacy on the pre-established primary outcome measure was <1%.  
There was no significant difference in PI-NRS change score between the ITM and the 
placebo group after 6 weeks (t = 0.65, df = 18, P=0.53; difference in means 0.3, 95% CI -
0.7-1.3). PI-NRS change scores in the ITM group were in the range between -0.75 and 
+1.75, thus indicating that none of the patients met the predefined criteria of clinically 
significant improvement. Additionally, adjusting for baseline PI-NRS scores did not yield a 
significant difference (F (1,17) = 0.33, P=0.57, partial eta squared = 0.02) (Table 9.2). There 
was a strong relation between the PI-NRS at baseline and 6 weeks (partial eta squared 
value = 0.73). Contrary to the placebo group, myoclonus deteriorated in the ITM group, 
leading to a significant difference between the groups (F (1,17) = 6.17, P=0.02, partial eta 
squared = 0.27) (Table 9.2). There were no significant differences between ITM and 
placebo treatment in any of the remaining outcome measures. In the ITM group, two 
patients reported improvement (global impression score +1), and three reported 
worsening (-3, -2, and -1), whereas the other 5 remained unchanged. The investigator's 
global impression score showed improvement in one patient in the ITM group (+2) and 
worsening in two (-3, and -1), whereas the other seven remained unchanged. In the 
placebo group, one patient reported improvement (+2), and six reported worsening (-3 in 
one patient, -2 in three, and -1 in two), the investigator's global impression score showed 
improvement in one patient (+2), and worsening in three (-2 in one, and -1 in two). There 
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was a strong positive correlation between patient's and investigator's global impression 
































Figure 9.1. Patient disposition. 
 




  Not meeting inclusion criteria 
(n=2) 




Excluded from analysis (n=0) 
Lost to follow-up (n=0) 





Lost to follow-up (n=1) 
 
 Reason: refused 
Allocated to placebo (n=11) 
 
Received placebo (n=11) 
Analyzed (n=10) 
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 Table 9.1. Baseline characteristics of the 21 patients  
Characteristic Methylprednisolone (n=10) Placebo (n=11) 
Gender (F/M) 10/0 6/5 
Age (yr; mean, SD) 45 (7) 46 (15) 
Duration of CRPS (yr, mean, SD) 5 (2) 4 (2) 
Preceding trauma, n   
 Contusion 5 5 
 Fracture  1 2 
 Surgery 0 4 
 Other 4 0 
Affected extremity    
 Right/left arm 6/7  5/7 
 Right/left leg 7/8  5/4  
Mean PI-NRS (SD) 6.9 (2.1) 7.3 (1.7) 
McGill Pain Questionnaire (SD)   
 NWC 12.2 (6.3) 11.5 (6.0) 
 PRI 24.2 (17.7) 25.5 (18.4) 
Autonomic abnormalities, n 9 10 
 Oedema 9 7 
 Skin discoloration 8 7 
 Altered temperature 9 10 
 Hyperhidrosis 7 7 
Sensory abnormalities, neurological 
examination, n 
9 11 
 Tactile hypesthesia or hypalgesia 5 7 
 Tactile hyperesthesia, hyperalgesia or 
allodynia 
9 7 
Movement disorders, n 10 11 
 Dystonia 9 9 
 Myoclonus 5 6 
 Tremor 5 5 
CRPS = complex regional pain syndrome; NWC = number of words chosen; PI-NRS = pain 
intensity numeric rating scale; PRI = pain rating index. 
 
 
Data at 1 and 12 weeks follow-up showed no significant differences compared to baseline 
(data not presented). Both patient's and investigator's guesses of which treatment was 
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PI-NRS (SD) 0-10 6.9 (2.1) 6.9 (2.0) 7.3 (1.7) 6.8 (1.9) 0.57 
McGill pain questionnaire (SD) 






9.7 (6.1) 0.35 













7.3 (7.6) 9.3 
(12.4) 
0.28 




2.7 (3.6) 2.3 (3.5) 0.02 
TRGRS, items 1-8 (SD) 0-76 2.9 (4.2) 2.5 (3.4) 1.4 (2.1) 1.7 (2.1) 0.89 
PGI -3-+3 -0.4 -0.9 0.42
c
 
CGI -3-+3 -0.3 -0.2 0.83
c
 
BFM = Burke-Fahn-Marsden dystonia rating scale; CGI = clinician's global impression; NWC 
= number of words chosen; PGI = patient's global impression; PI-NRS = pain intensity 
numeric rating scale; PRI = pain rating index; TRGRS = tremor research group rating scale; 
UMRS = unified myoclonus rating scale. 
a
Best score is underlined. 
b





Table 9.3. Treatment-emergent adverse events 
Adverse event Methylprednisolone (n=10) Placebo (n=11) 
Post-dural puncture headache 5 3 
Tension-type headache - 1 
Backache 5 4 
Major depressive disorder - 1 
Constipation 1 - 
Diarrhea - 1 
Flushing 1 - 
Oedema - 2 
Vasovagal syncope - 1 
Decubitus - 1 




Total 13 15 
CRPS = complex regional pain syndrome. 
a
In this patient, worsening of CRPS-related pain occurred. 
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Safety 
Serious AEs did not occur. Non-serious AEs occurred in 16 patients: 13 events in 8 patients 
who received ITM and 15 events in 8 patients who received placebo (Table 9.3). Post-dural 
puncture headache occurred in eight patients (38%), with durations ranging from 2 days 
to the complete study period of 84 days (median 9 days, persistent in three patients). 
Three epidural blood patches were administered in two patients, though, without effect. 
Backache occurred in nine patients (43%), the duration of which ranged from 2 days to the 




Despite the extensive evidence for a role of the immune system in chronic pain 
disorders,
5,10,12,13
 and the favourable findings of ITM in postherpetic neuralgia,
17
 we did 
not find a positive effect of ITM in chronic CRPS patients. Moreover, none of the patients 
met the predefined criteria of clinically significant improvement. There may be several 
explanations for this lack of efficacy. Firstly, the role of the immune system in pain in CRPS 
may be different from other chronic pain disorders. The evidence suggesting increased 
levels of inflammatory mediators in CSF of chronic CRPS patients is inconsistent.
58,59
 
Secondly, the lack of effect of ITM in chronic CRPS may indicate that it is much too late to 
expect effects on glia cell activation mechanisms since these occur early in the process of 
chronification of pain. Patients in Kotani et al.'s study
17
 had a mean (SD) duration of 
postherpetic neuralgia of 3 (2) years. Thirdly, one administration of ITM may have been 
insufficient since Kotani et al.
17
 applied four intrathecal administrations. However, since 
after a single intrathecal administration of methylprednisolone acetate, CSF levels of the 
drug remain measurable for at least 2 weeks, some improvement of symptoms can be 
expected.
60
 In view of the risks associated with repeated ITM administrations (see above), 
a study with repeated intrathecal administrations would only be appropriate if some 
improvement had occurred after a single administration. Finally, it is possible that the 
efficacy of ITM in postherpetic neuralgia is overestimated. Until now, replication of the 
results from Kotani et al.
17
 have not been reported.  
We did not find any difference in treatment-emergent AEs between the ITM and placebo 
group, which is in line with the earlier study on ITM
17
. Post-dural puncture headache 
developed in 38% of patients (n=8), and no relation with the administered treatment was 
found. Additionally, post-dural puncture headache extended beyond the follow-up period 
of 12 weeks in 14% (n=3), which is unusual as compared to published findings in other 
                   





 Indeed, we used fairly wide-bore needles (20 or 22 Gauge) which is common at 
neurology departments, at least in The Netherlands. Although the use of small-bore 
needles may have led to lower rates of post-dural puncture headache, recent observations 
suggest that other mechanisms besides intracranial hypotension may contribute to the 




We cannot rule out that patient selection may have influenced the findings. This partly 
results from the fact that this study was performed at a neurology department, where the 
majority of the randomised patients had movement disorders. However, all patients had 
typical features of CRPS including prominent chronic pain. Since there are no indications 
for a different pain pathophysiology in CRPS patients with or without movement 
disorders, there is no clear reason to assume that patient selection negatively influenced 
our findings. Because all men in this study received placebo, the efficacy of ITM in male 
patients remains unknown, although there are no arguments to assume gender specificity. 
Furthermore, since the mean duration of symptoms in our patients was five years, we 
cannot exclude that ITM may have been efficacious in an earlier phase of the condition. 
The meaning of the significant deterioration of myoclonus in the ITM group is uncertain. 
In conclusion, a single bolus administration of ITM is not efficacious in chronic CRPS 
patients, which may indicate that spinal immune activation does not play an important 
role in this phase of the syndrome. 
 
 





The data monitoring committee consisted of Prof.dr. A. Dahan (Department of 
Anesthesiology, Leiden University Medical Centre), Prof.dr. A.F. Cohen (Centre for Human 
Drug Research, Leiden) and Prof.dr. R. Brand (Department of Medical Statistics and 
Bioinformatics, Leiden University Medical Centre). 
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Abstract 
Objective: To describe the unusual course of post-dural puncture headache after pump 
implantation for intrathecal baclofen administration in patients with complex regional 
pain syndrome related dystonia. Design: Case series based on data collected from 1996-
2005. Setting: Movement disorders clinic, university hospital. Patients: A total of 54 
patients with complex regional pain syndrome related dystonia who were treated with 
intrathecal baclofen. Results: A high incidence (76%) and prolonged course (median 18 
days, range 2 days-36 months) of post-dural puncture headache was found. Radionuclide 
studies performed in 2 patients with long-lasting symptoms (12-16 months) did not reveal 
cerebrospinal fluid leakage. In patients without signs of CSF leakage (n=38), epidural blood 
patches administered in 24 patients were effective in 54%, while ketamine infusions 
administered in 6 patient were effective in 67%. Conclusions: Our observations may 
suggest that other mechanisms besides intracranial hypotension play a role in the 
initiation and maintenance of post-dural puncture headache in complex regional pain 
syndrome and stimulate new directions of research on this topic. 
                   





Complex regional pain syndrome type 1 (CRPS) is characterized by combinations of chronic 
pain, allodynia, hyperalgesia, changes in skin colour and temperature, sweating and 
swelling.
1
 The syndrome predominantly develops in women and usually occurs following a 
tissue injury, for example a fracture or surgery.
1-3
 Approximately 20% of the patients with 
CRPS develop dystonia, which is characterized by fixed flexion postures. 
 
Treatment of dystonia is difficult,
4
 although continuous administration of intrathecal 
baclofen (ITB) was shown to be beneficial in some patients with multifocal or generalised 
dystonia.
5
 Inherent to this mode of drug delivery is the requirement of placement of an 
intrathecal catheter. As a consequence of the catheter's perforation of the spinal dura, 
cerebrospinal fluid (CSF) leakage may occur. Subsequent to this procedure, 0-42% of the 
patients develop headache over the frontal and occipital areas radiating to the neck and 
shoulders.
6-10
 Exacerbation of the headache by adoption of the upright posture, and 
improvement of the pain by lying down is the sine qua non of post-dural puncture 
headache (PDPH).
10
 PDPH is often associated with nausea and vomiting, neck stiffness, 
tinnitus, hypacusia, and photophobia, and after a single small diameter puncture rarely 
lasts longer than a week.
11
 Although a low CSF pressure and meningeal inflammation have 





We have treated patients with CRPS-related dystonia with ITB since 1996. Over this period 
we have noticed an unusual high frequency and prolonged duration of PDPH after pump 
implantation in these patients. Here, we present our experiences and propose a 





The medical records of all CRPS patients who underwent pump implantation in the course 
of studies addressing the efficacy and safety of ITB in CRPS-related dystonia between May 
1996 and December 2005 were evaluated. Therefore, the current study is retrospective, 
not-controlled and observational. All patients met the CRPS type 1 criteria of the 
International Association for the Study of Pain,
14
 either at the time of disease onset or at 
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the time of presentation at the clinic. Subjects were included if they had dystonia in at 
least two extremities, and experienced insufficient relief from oral baclofen or if this 
treatment caused dose-limiting side effects. Before implantation, patients were subjected 
to a screening procedure to determine responsiveness to ITB.
5,15
 The SynchroMed EL or 
SynchroMed II programmable drug infusion system (Medtronic, Minneapolis, MN) was 
implanted under general anesthesia by an experienced neurosurgeon (J.V.). One end of 
the catheter was placed in the intrathecal space through a 17 gauge Tuohy needle 
(direction of the bevel parallel to the longitudinal axis of the spine), with the catheter tip 
placed at the midthoracic level. The other end of the catheter was tunneled into the 
subcutaneous space to the pump, which was positioned in the lower abdomen. 
 
PDPH was diagnosed according to the definition of the International Headache Society: (i) 
headache that worsens within 15 min after sitting or standing and improves within 15 min 
after lying, with at least one of the following: neck stiffness, tinnitus, hypacusia, 
photophobia and nausea; (ii) dural puncture had been performed; and (iii) headache 
developed within 5 days after dural puncture.
11
 It is assumed that the headache resolves 
spontaneously within 1 week or within 48 h after effective treatment of the spinal leak 




PDPH during the post-operative course was treated with bed rest in horizontal position, 
pain killers (acetaminophen or non-steroidal anti-inflammatory drugs), EBP or intravenous 
(IV) ketamine (the latter as from 2004). EBP was administered by experienced 
anesthesiologists who injected 10-20 mL autologous blood one level caudal to the dural 
puncture site. This level was chosen to prevent damaging of the inserted spinal catheter. 
Dose of the ketamine infusion was based on a study from Correll et al.
16
 Instead of 
racemic ketamine, we used S(+) ketamine because (at half the dose) this optical isomere 
has been suggested to be as efficient in reducing pain with fewer cognitive side effects.
17
 
The infusion rate was started at a dose of 4 mg/h and increased with increments of 2 
mg/h or less three times a day if pain relief was insufficient and side effects were 
acceptable to the patient. The maximum dose was 20 mg/hr. Duration of the treatment 
was 7-14 days, or shorter if PDPH symptoms disappeared earlier or severe adverse events 
(as judged by patient or physician) occurred. 
 
Presence, characteristics and duration of PDPH, effectiveness of treatment, as well as 
occurrence of CRPS exacerbation were recorded on a case report form. Exacerbation was 
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defined as a serious increase in CRPS-related pain as judged by the patient, or an increase 
in dystonia or autonomic signs (oedema, changes in skin blood flow or abnormal 
sudomotor activity in the region of the pain) as observed by the physician. 
The frequency of PDPH in patients with and without CRPS exacerbations was compared 
using a, where a P value <0.05 was considered significant. 
 
Two patients who were evaluated for CSF leakage with radionuclide studies, by injecting 
indium
111
 diethylenetriaminepentaacetic acid (DTPA) into the drug reservoir of the 
pump,
18,19
 are described in more detail. 
 
 
Table 10.1. Baseline characteristics (n=54) 
Characteristic Value 
Gender (%)  
 Male 4 (7) 
 Female 50 (92) 
Age  
 Mean, SD (yr) 38.6 ± 12.4 
 Median, IQR (yr) 40.3 (26.8-49.0) 
Duration of CRPS (yr; mean, SD) 10.1 (6.8) 
Number of affected extremities (median, IQR) 3 (2 - 4) 
Number of extremities with dystonia (median, IQR) 3 (2 - 4) 
Preceding trauma, n (%)  
 Contusion 19 (35) 
 Fracture 10 (19) 
 Surgery 7 (13) 
 Soft tissue injury 2 (4) 
 Distorsion 1 (2) 
 Spontaneously 15 (28) 
VAS pain (mean, SD) 7.4 (1.8) 
Sensory abnormalities, n (%)  
 Hyperesthesia, hyperalgesia or allodynia 28 (52) 
 Hypesthesia or hypalgesia 39 (72) 





Fifty-four CRPS patients (50 female) who underwent a pump-catheter implantation were 
identified (7 patients, in whom clinical characteristics where not different from the 
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remaining patients, had dropped out during the screening procedure). Mean (SD) age was 
39 (12.4) years with a range from 17-64 years. The median number of extremities affected 
by CRPS was 3: both sides of the body were involved in 44 patients, only right in 7, and 
only left in 3; upper and lower extremities were involved in 47 patients, only upper in 3, 
and only lower in 4 (Table 10.1). PDPH occurred in 41 patients (76%) after the 
implantation procedure (Figure 10.1). A history of migraine was present in 9 patients. 
Forty-four percent of the migraine patients developed PDPH, against 82% of the patients 
without migraine. 
 
Three patients (7%) showed signs of CSF leakage (i.e., subcutaneous swelling). In one of 
these patients, the subcutaneous swelling with PDPH disappeared spontaneously after 5 
weeks. Because this patient rated the symptoms of PDPH severity as mild, no treatment 
was started. In the second patient, PDPH resolved within 48 h after an EBP that was 
administered 11 days after implantation. In the third patient, PDPH persisted for 12 
months after implantation, in spite of the disappearance of subcutaneous swelling after 
two EBPs administered at 10 and 17 days after implantation. Radionuclide imaging was 
performed three months after pump implantation and showed no signs of CSF leakage. 
PDPH was of such severity that she was confined to bed till six months after implantation. 
At this stage, two IV ketamine treatments were administered over a three week period 
which resulted in a gradual decrease of PDPH allowing the patient to become wheelchair-
bound. Subsequently, PDPH gradually decreased. At 12 months post-implantation PDPH 
had resolved. 
 
Thirty-eight of the 41 PDPH patients (93%) had PDPH without signs of CSF leakage. 
Duration of PDPH in these patients varied from 2 days-36 months, with a median of 18 
days and an interquartile range of 8 days-3 months. Of the 24 cases who received an EBP, 
PDPH resolved within 48 h in 13 (54%). In 9 patients with enduring complaints of PDPH, 
EBPs were repeated once (n=5) or twice (n=4) without any result. One of these patients 
experienced PDPH for 16 months and 3 EBPs were unsuccessful. One month after pump 
implantation, radionuclide imaging was performed which showed no signs of CSF leakage. 
She was not treated with IV ketamine because PDPH resolved before 2004 (when IV 




                   


























Figure 10.1. Study population flow chart. 
CRPS = complex regional pain syndrome; CSF = cerebrospinal fluid; PDPH = post-dural 
puncture headache. 
*Persistent symptoms in 2; 
†
persistent symptoms in 1. 
 
 
Six patients with PDPH but without overt signs of CSF leakage received IV ketamine (Table 
10.2). PDPH resolved in four patients (67%) during 2-10 days of treatment. In two of these 
patients a prior EBP had had no effect. IV ketamine gave no improvement in two patients, 
one of whom also had had a prior EBP without effect. Non-serious adverse events related 





Range: 11 days - 12 months 
Median: 1 month 
n=41 
Range: 2 days - 36 months* 




Range: 2 days - 36 months* 
Median: 18 days 
n=14 
Range: 2 days - 36 months
†
 
Median: 19 days 
n=13 
Range: 3 - 21 days 
Median: 10 days 
n=24 
Range: 3 days - 24 months
†
 




Range: 19 days - 25 months
†
 
Median: 4 months 
No CSF leakage 
PDPH 
Unsuccessful  EBP 
EBP 
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A 4 days + - 8 days + 24 months
a
 
B 4 days - + 4 
months 
+ 3 months 
C 7 days + - 17 days - NA 
D 9 days - - 3 
months 
+ 3 months 
E 12 days + + 19 days + 32 months
a 
F 13 days + + 19 days + unknown 
CRPS = complex regional pain syndrome; EBP = epidural blood patch; NA = not applicable; 





Following pump implantation, 15 patients (28%) experienced an exacerbation of CRPS. 
Fourteen of these patients also had PDPH without signs of CSF leakage. One patient had 
an exacerbation of CRPS without PDPH. Compared to patients without PDPH, patients 
with PDPH, but without signs of CSF leakage (n=51), more often experienced an 
exacerbation of CRPS (χ
2
 = 3.964, df = 1, P=0.046, difference in proportions 29%, 95% CI 
0.2-46.2%). The exacerbation lasted 7 days-51 months, with 4 patients still experiencing 




In this study, 76% of the CRPS patients developed PDPH after pump implantation for 
intrathecal drug delivery. In 38 of the 41 PDPH patients, there were no overt clinical signs 
of CSF leakage. The duration of symptoms clearly exceeded the usual duration of PDPH 
known for patients that have been implanted, with 50% of the cases experiencing PDPH 
that lasted between 18 days to 36 months. 
An EBP was effective in 54% of the patients. An explanation for the high incidence of PDPH 
in our population may be that needles with a large diameter, which are associated with a 
greater risk for PDPH,
20
 were used. This explanation seems less likely because several 
earlier studies that used a catheter for ITB with a similar diameter, have reported PDPH in 
0-42%,
6-9
 which clearly differs from the 76% encountered in our population. 
                   




An EBP to reduce CSF leakage is the standard treatment of PDPH, but evidence of its 
efficacy (in comparison with a sham procedure) is still lacking.
11,21
 Although the loss of CSF 
and subsequent decrease of CSF pressure is not disputed, the actual mechanism 
underlying the symptoms in PDPH is still unclear.
10
 CSF leakage related PDPH was evident 
in some of our implanted patients and we cannot exclude that CSF leakage occurred at a 
subclinical level in those patients without overt signs of CSF leakage. However, both 
prevalence and duration of symptoms of PDPH in CRPS patients without CSF leakage 
deviated conspicuously from the values that are reported in patients implanted for other 
indications. Additionally, in two of our cases with long-lasting (12-16 months) PDPH, 
radionuclide studies did not reveal CSF leakage. Together, our findings suggest that, in 
CRPS at least, other causes than a reduced CSF pressure may underlie the initiation or 
maintenance of PDPH. 
 
Compared to patients without PDPH, patients with PDPH more often experienced an 
exacerbation of CRPS. This may suggest that biological mechanisms involved in CRPS play a 
role in the initiation or maintenance of PDPH as well. Compelling evidence suggests that 
aberrant inflammation, in which both neurogenic and immunogenic components play a 
role, underlie the clinical features of the acute phase of CRPS.
22-24
 Patients with CRPS may 
also develop symptoms and signs of vasomotor dysregulation, in which both a decreased 
central sympathetic activity and disturbed endothelium mechanisms play a role. As a 
consequence, vessels show a reduced vasomotor tone.
25-27
 According to the Monro-Kellie 
doctrine, the sum of volumes of the brain, CSF and intracranial blood is constant with an 
intact skull.
10
 It has been suggested that in PDPH a loss of CSF is compensated by 
vasodilatation
28
 which has been illustrated by pachymeningeal gadolinium enhancement 
on magnetic resonance imaging.
12
 Surgery or needle punctures are both well-known 
triggers of CRPS, but may also incite an exacerbation in patients with established 
disease.
29,30
 If, and to what extent CRPS may cause an inflammatory response as well as a 
vasomotor dysregulation of meningeal structures is unknown. Nevertheless, increased 
pooling of blood in possibly sensitised meningeal vessels with disturbed vasomotor 
regulation may have contributed to PDPH in CRPS. 
 
IV ketamine had a beneficial effect on PDPH in four of our six patients. This finding may 
suggest that ketamine elevated CSF pressure, as has been reported previously,
31
 which 
consequently leaded to resolution of PDPH. However, this explanation is unlikely because 
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there is compelling evidence to suggest that even in larger dosages, ketamine does not 
effect or even lower CSF pressure.
32,33
 Our patients had long-lasting CRPS with sensory and 
motor features reflecting central involvement. Allodynia and hyperalgesia, present in half 
of our patients, are well-known features of central sensitisation.
34
 Dystonia in CRPS has 
been attributed to a disinhibition of nociceptive withdrawal reflexes, likely also a 
reflection of central sensitisation.
34
 Key in central sensitisation, is the activation of the N-
methyl-D-aspartate (NMDA) receptor
35
 and ketamine is a powerful suppressor of central 
sensitisation.
36
 In CRPS patients, several open studies using ketamine have found 
beneficial effects on pain.
16,37,38
 So, the beneficial response of PDPH to ketamine could be 
explained by its action as a non-competitive NMDA receptor antagonist in reversing 
central sensitisation. Alternatively, meningeal inflammation has been demonstrated in 
PDPH
12,13
 and ketamine has an anti-inflammatory effect.
39-41
 This may suggest that PDPH 
in CRPS reflects an aberrant meningeal inflammatory response induced by the insertion of 
an intrathecal catheter.   
 
Obviously, there are a number of limitations in this study. First, we performed 
radionuclide imaging to exclude CSF leakage in only two patients and the reliability of this 
technique in demonstrating or excluding a leakage has not been established. However, 
this limitation is applicable for any other method used for this purpose. The most 
appropriate diagnostic study for evaluating intracranial hypotension would probably be 
measurement of CSF opening pressure. However, additional lumbar punctures potentially 
may further exacerbate the condition and were therefore not considered. Otherwise, 
PDPH is a clinical diagnosis.
11
 Second, the efficacy of EBP and IV ketamine was evaluated in 
a small population (n=6) and in a non-randomised way, which may have led to bias. Third, 
retrospective studies are subject to misclassification and information on the exact 
duration of symptoms is less accurate than those that would have been obtained in a 
prospective study. 
 
Nevertheless, our observations on PDPH may suggest that other mechanisms besides low 
CSF pressure play a role in the initiation and maintenance of PDPH in CRPS and stimulate 
new directions of research on this topic. 
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This thesis described studies on the pathophysiology and therapy of complex regional pain 
syndrome (CRPS) related movement disorders. 
 
Chapter 1. General introduction and aims  
A short overview about the current knowledge on CRPS-related movement disorders is 
given in chapter 1. The syndrome is frequently associated with sensory and autonomic 
disturbances. It is often preceded by a limb trauma. The current theory is that the 
syndrome is caused by a combination of trauma related peripheral and central 
neuroimmunological changes. A key neurophysiological finding is a lack of central 
inhibition. CRPS is a severe and disabling condition, and treatment options are limited. 
 
Chapter 2. How psychogenic is dystonia? Views from past to present  
In the last few centuries there has been a constant sway between organic and psychogenic 
explanations for dystonia. In chapter 2 we investigate this history, assuming the 
perspective of a spectrum from organic to psychogenic, between which ideas were 
moving. We have focussed on (i) primary generalised dystonia; (ii) cervical dystonia; (iii) 
writer's cramp; and (iv) fixed dystonia related to CRPS. We have studied medical texts 
published since the 19
th
 century and their references. Jean-Martin Charcot advocated the 
concept of hysteria: disorders in which, besides predisposition, environmental factors 
were involved in its pathogenesis. Sigmund Freud introduced psychoanalysis as an 
explanatory therapy for psychic disorders. Previous theories, together with the lack of an 
organic substrate for dystonia, made a strong case for psychogenic explanations. 
Consequently, many dystonia patients were told that they suffered from psychological 
conflicts and were treated for them. However, after the description of new hereditary 
cases in the 1950s, the limited efficacy of psychotherapy in torsion dystonia, the effects of 
surgical treatments and the lesion studies in the 1960s, more physicians became 
convinced of the organic nature. The culminating point was the discovery of the DYT1 
gene in 1997. In the meantime, experts had already convinced the neurological 
community that cervical dystonia and writer's cramp were focal dystonias, i.e. minor 
forms of generalised dystonia, and therefore organic disorders. In contrast, the 
pathophysiology of fixed dystonia related to CRPS remained controversial. Knowledge of 
this history, which played on the border between neurology and psychiatry, is instructive 
and reflects the difficulty in discriminating between them. Today, new insights from 
functional imaging and neurophysiological studies again challenge the interpretation of 
these disorders, while the border between psychogenic and organic has become more 
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blurred. Abnormalities of sensorimotor integration and cortical excitability that are 
currently supposed to be the underlying cause of dystonia bring us back to Sherringtonian 
physiology. We suggest that this may lead to a common explanation of the four afflictions 
of which we have traced the history. 
 
Chapter 3. Thermal hypesthesia in patients with complex regional pain syndrome related 
dystonia  
The quantitative thermal test showed cold and warmth hypesthesia without increased 
heat pain sensitivity in the affected limbs of CRPS patients with tonic dystonia (n=44) in 
comparison with healthy controls with a similar age and gender distribution (n=35). The 
degrees of cold and warmth hypesthesia were strongly correlated. We conclude that 
dysfunction in small nerve fiber (i.e., C and Aδ) processing is present in patients with CRPS-
related dystonia. 
 
Chapter 4. Fixed dystonia in complex regional pain syndrome: a descriptive and 
computational modelling approach  
Background: CRPS may occur after trauma, usually to one limb, and is characterized by 
pain and disturbed blood flow, temperature regulation and motor control. Approximately 
25% of cases develop fixed dystonia. Involvement of dysfunctional GABA (gamma 
aminobutyric acid)-ergic interneurons has been suggested, however the mechanisms that 
underpin fixed dystonia are still unknown. We hypothesised that dystonia could be the 
result of aberrant proprioceptive reflex strengths of position, velocity or force feedback. 
Methods: We systematically characterized the pattern of dystonia in 85 CRPS patients 
with dystonia according to the posture held at each joint of the affected limb. We 
compared the patterns with a neuromuscular computer model simulating aberrations of 
proprioceptive reflexes. The computer model consists of an antagonistic muscle pair with 
explicit contributions of the musculotendinous system and reflex pathways originating 
from muscle spindles and Golgi tendon organs, with time delays reflective of neural 
latencies. Three scenarios were simulated with the model: (i) increased reflex sensitivity 
(increased sensitivity of the agonistic and antagonistic reflex loops); (ii) imbalanced reflex 
sensitivity (increased sensitivity of the agonistic reflex loop); and (iii) imbalanced reflex 
offset (an offset to the reflex output of the agonistic proprioceptors). Results: For the arm, 
fixed postures were present in 123 arms of 77 patients. The dominant pattern involved 
flexion of the fingers (116/123), the wrists (41/123) and elbows (38/123). For the leg, fixed 
postures were present in 114 legs of 77 patients. The dominant pattern was plantar 
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flexion of the toes (55/114), plantar flexion and inversion of the ankle (73/114) and flexion 
of the knee (55/114). Only the computer simulations of imbalanced reflex sensitivity to 
muscle force from Golgi tendon organs caused patterns that closely resembled the 
observed patient characteristics. In parallel experiments using robot manipulators we 
have shown that patients with dystonia were less able to adapt their force feedback 
strength. Conclusions: Findings derived from a neuromuscular model suggest that 
aberrant force feedback regulation from Golgi tendon organs involving an inhibitory 
interneuron may underpin the typical fixed flexion postures in CRPS patients with 
dystonia.  
 
Chapter 5. Analysis of cerebrospinal fluid inflammatory mediators in chronic complex 
regional pain syndrome related dystonia 
There is compelling evidence of central nervous system involvement in neuropathic pain 
and movement disorders in patients with CRPS. Previously, elevated cerebrospinal fluid 
(CSF) levels of interleukin-1β and interleukin-6 were found in CRPS patients with and 
without movement disorders. The aim of the study in chapter 5 was to replicate these 
findings and to search for additional CSF biomarkers in chronic CRPS patients with 
dystonia. CSF samples of 20 patients and 29 subjects that underwent spinal anaesthesia 
for surgical interventions were used. We measured interleukin-1β, interleukin-6, 
interferon-γ inducible protein-10, RANTES (regulated upon activation, normal T-cell 
expressed and secreted), complement C3, mannose-binding lectin, complement C1q, 
soluble intercellular adhesion molecule-1, endothelin-1, nitric oxide, human lactoferrin 
and hypocretin-1 levels in these samples. No differences in the CSF levels of these effector 
mediators between patients and controls were found. Our CSF findings do not support a 
role of a variety of inflammatory mediators or hypocretin-1 in chronic CRPS patients with 
dystonia.  
 
Chapter 6. Clinical and neurophysiological characterisation of myoclonus in complex 
regional pain syndrome  
The origin of myoclonus in patients with CRPS is unknown. Eight patients with CRPS-
related myoclonus were clinically evaluated and studied with intermuscular and 
corticomuscular coherence analysis. Jerks were present at rest, aggravated during action 
and were frequently associated with tremulousness or dystonia. Electromyography 
demonstrated a burst duration ranging from 25-240 ms with burst frequencies varying 
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from <1 jerk/s during rest-20 Hz during action. Coherence studies showed increased 
intermuscular coherence in four patients in the 6-12 Hz band, as reported in patients with 
enhanced physiological tremor. In two patients side-to-side coherence was observed, 
pointing to a central oscillatory drive. Significant coherence entrainment was detected in 5 
patients. We conclude that the characteristics of myoclonus in CRPS are different from 
other forms of myoclonus. 
 
Chapter 7. Intrathecal baclofen for dystonia of complex regional pain syndrome  
Dystonia in CRPS responds poorly to treatment. Intrathecal baclofen (ITB) may improve 
this type of dystonia, but information on its efficacy and safety is limited.  A single-blind, 
placebo-run-in, dose-escalation study was carried out in 42 CRPS patients to evaluate 
whether dystonia responds to ITB. Thirty-six of the 38 patients who met the responder 
criteria received a pump for continuous ITB administration and were followed for 12 months 
to assess long-term efficacy and safety (open-label study). Primary outcome measures 
were Global Dystonia Severity (both studies) and Dystonia-related Functional Limitations 
(open-label study). The dose-escalation study showed a dose-effect of baclofen on 
dystonia severity in 31 patients in doses up to 450 µg/day. One patient did not respond to 
treatment in the dose-escalation study and three patients dropped out. Thirty-six patients 
entered the open-label study. Intention-to-treat analysis revealed a substantial 
improvement in patient and assessor-rated dystonia scores, pain, disability and quality
 
of 
life (QoL) at 12 months. The response in the dose-escalation study did not predict the 
response to ITB in the open-label study. Eighty-nine adverse events occurred in 26 
patients and were related to baclofen (n=19), pump/catheter system defects (n=52), or 
could not be specified (n=18). The pump was explanted in 6 patients during the follow-up 
phase. Dystonia, pain, disability and QoL all improved on ITB and remained efficacious 
over a period of one year. However, ITB is associated with a high complication rate in this 
patient group and methods to improve patient selection and catheter-pump integrity are 
warranted. 
 
Chapter 8. Intrathecal glycine for pain and dystonia in complex regional pain syndrome  
Since glycinergic neurotransmission plays an important inhibitory role in the processing of 
sensory and motor information, intrathecal glycine (ITG) administration may be a potential 
therapy for both pain and movement disorders in patients with CRPS. Aims of the study 
described in chapter 8, which is the first report on ITG in humans, were to evaluate its 
safety and efficacy. ITG treatment during 4 weeks was studied in CRPS patients with 
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dystonia in the period before they received ITB treatment. Twenty patients were assessed 
and after exclusion of one patient, the remaining 19 patients were randomised in a 
double-blind placebo-controlled crossover study. Safety was assessed by clinical 
evaluation, blood examinations and electrocardiograms. Efficacy measures involved pain 
(numeric rating scale, McGill pain questionnaire), movement disorders (Burke-Fahn-
Marsden dystonia rating scale, unified myoclonus rating scale, tremor research group 
rating scale), activity (Radboud skills questionnaire, walking ability questionnaire), and a 
clinical global impression (CGI) and patient's global impression score (PGI). Treatment-
emergent adverse events were generally mild to moderate and not different from placebo 
treatment. During ITG treatment growth hormone levels were slightly increased. Although 
there was a trend to worsening on the CGI and PGI during ITG treatment, there were no 
significant differences between ITG and placebo treatment in any of the outcomes. ITG 
given over 4 weeks was ineffective for pain or dystonia in CRPS. Although no serious 
adverse events occurred, further studies are required to rule out potential neurotoxicity of 
ITG. 
 
Chapter 9. Efficacy and safety of a single intrathecal methylprednisolone bolus in chronic 
complex regional pain syndrome  
Activated immune cells in the spinal cord may play an important role in the development 
and maintenance of neuropathic pain, such as occurs in response to peripheral 
inflammation or tissue injury. Immune activation may therefore serve as a therapeutic 
target for immune modulating drugs like corticosteroids. This double-blind randomised 
placebo-controlled parallel-group trial aimed to investigate the efficacy and safety of a 
single intrathecal administration of 60 mg methylprednisolone (ITM) in chronic patients 
with CRPS. The primary outcome measure was change in pain (pain intensity numeric 
rating scale; range 0-10) after 6 weeks. With 21 subjects per group the study had a 90% 
power to detect a clinically relevant difference (≥2 points). After 21 patients (10 on ITM) 
were included, the trial was stopped prematurely after the interim analysis had shown 
that ITM had no effect on pain (difference in mean pain intensity numeric rating scale at 6 
weeks 0.3, 95% CI -0.7 to 1.3) or any other outcome measure. We did not find any 
difference in treatment-emergent adverse events between the ITM and placebo group. 
We conclude that a single bolus administration of ITM is not efficacious in chronic CRPS 
patients, which may indicate that spinal immune activation does not play an important 
role in this phase of the syndrome.   
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Chapter 10. Post-dural puncture headache in complex regional pain syndrome: a 
retrospective observational study  
Objective: To describe the unusual course of post-dural puncture headache after pump 
implantation for ITB administration in patients with CRPS-related dystonia. Design: Case 
series based on data collected from 1996-2005. Setting: Movement disorders clinic, 
university hospital. Patients: A total of 54 patients with CRPS-related dystonia who were 
treated with ITB. Results: A high incidence (76%) and prolonged course (median 18 days, 
range 2 days-36 months) of post-dural puncture headache was found. Radionuclide 
studies performed in 2 patients with long-lasting symptoms (12-16 months) did not reveal 
CSF leakage. In patients without signs of CSF leakage (n=38), epidural blood patches 
administered in 24 patients were effective in 54%, while ketamine infusions administered 
in 6 patients were effective in 67%. Conclusions: Our observations may suggest that other 
mechanisms besides intracranial hypotension play a role in the initiation and maintenance 





Prior to the start of the studies included in this thesis, the mechanisms underlying the 
development of movement disorders in CRPS were poorly understood. Moreover, 
randomised controlled trials were lacking. 
 
Studies on pathophysiology 
Although thermal hypesthesia was earlier shown in CRPS patients without dystonia, its 
presence in those with dystonia was unknown. We found thermal hypesthesia in CRPS 
patients with dystonia. Apparently, dysfunction in small nerve fiber (i.e. C and Aδ) 
processing is present in these patients. Since similar findings have been documented in 
CRPS without dystonia, it remains unclear whether this sensory abnormality is involved in 
the causal pathway to dystonia. 
By systematically evaluating the extremities of 85 patients with CRPS-related dystonia, we 
identified a dominant pattern of fixed dystonia. Fixed flexion of the fingers was observed 
in 95% of affected arms and a multisegmental pattern of finger flexion, wrist and/or elbow 
flexion and shoulder internal rotation/adduction, was observed in 66% of affected arms. A 
similar pattern was observed in affected legs: plantar flexion/inversion of the ankle was 
observed in 88% of affected legs, and a multi-segmental pattern of ankle plantar 
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flexion/inversion, toe and knee flexion, internal rotation of the hip, was observed in 66% 
of affected legs. Our modelling study showed that aberrant force feedback from Golgi 
tendon organs may be related to these postures. 
Our CSF findings did not support a role of a variety of inflammatory mediators in chronic 
CRPS patients with dystonia. A search for CSF biomarkers involved in molecular pathways 
that play a role in neuroplasticity may be more fruitful. 
 
We evaluated eight patients with CRPS-related myoclonus. Both clinically and 
electrophysiologically, myoclonus was diverse. The significant coherence entrainment that 
was detected in five patients may point to central nervous system disinhibition. However, 
coherence entrainment has also been suggested as clue for psychogenic movement 
disorders. Further studies towards the value of entrainment are warranted.  
 
Studies on intrathecal therapy 
A single intrathecal administration of 60 mg methylprednisolone was not efficacious in 
chronic CRPS. Furthermore, continuous ITG in doses up to 32 mg/24 h was not efficacious 
in CRPS-related dystonia. In contrast, ITB reduced severity of CRPS-related dystonia, 
improved quality of life and remained efficacious over a period of one year (median dose 
of 615 µg/day). Unfortunately, ITB was associated with a high complication rate and 
therefore methods to improve patient selection and catheter-pump integrity are 
warranted to enhance its therapeutic potential. Collectively, the findings from these 




Hitherto, studies on the pathogenesis of dystonia in CRPS have focused on the role of 
single biochemical CSF components and distinct neurophysiological characteristics. 
Instead, modern 'omics' approaches are able to measure the overall metabolic or 
proteomic content of biological samples. The output of these experiments may be 
interpreted as a signature, or 'endophenotype', of the disease. Extrapolation on other 
'omics' data potentially uncovers mechanisms of disease. Currently, such studies using 
different body fluids from CRPS patients with dystonia are ongoing. 
The central nervous system controls the behaviour of the musculoskeletal system through 
many feedback loops. Their dynamic behaviour can be quite unpredictable from the 
individual components. The results from our modelling study suggest that it may be 
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worthwhile to study dystonia with closed loop system identification techniques. Currently, 
such studies are employed in the evaluation of CRPS-related dystonia. 
 
Through intrathecal delivery of drugs, we have focused on modulation of predominantly 
spinal mechanisms in CRPS-related dystonia. Results of these studies confirmed the 
findings of neurophysiological studies which showed that disinhibition plays an important 
role. Enhancing central GABA, but not glycine, mediated inhibition seemed to decrease 
the severity of dystonia. However, in view of the large number of complications related to 
the delivery technique required to administer baclofen, new GABA-ergic drugs with a 
better blood-brain barrier passage, are desirable. 
 
Pain and dystonia presumably are disorders of neural circuits as opposed to disorders of a 
single nervous system structure. Hence, neuromodulation techniques that target 
supraspinal regions of interest, like repetitive transcranial stimulation or epidural cortical 
stimulation, may also provide new therapeutic possibilities for CRPS-related movement 
disorders. 
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Dit proefschrift beschrijft de resultaten van een aantal studies naar de pathofysiologie en 
behandeling van complex regionaal pijnsyndroom (CRPS) gerelateerde bewegings-
stoornissen. 
 
Hoofdstuk 1. Algemene inleiding en doelen 
Een korte samenvatting van de huidige kennis over CRPS gerelateerde 
bewegingsstoornissen wordt gegeven in hoofdstuk 1. Het syndroom komt meestal in 
combinatie met sensibele en autonome stoornissen voor. Het wordt vaak voorafgegaan 
door een trauma aan een ledemaat. De huidige theorie is dat het syndroom wordt 
veroorzaakt door een combinatie van trauma gerelateerde perifere en centrale neuro-
immunologische factoren. Een belangrijk neurofysiologisch kenmerk is gebrek aan 
inhibitie. CRPS is een ernstige en invaliderende aandoening en de behandelings-
mogelijkheden zijn beperkt. 
 
Hoofdstuk 2. Hoe psychogeen is dystonie? Inzichten van vroeger naar nu 
In de afgelopen eeuwen waren er afwisselend organische en psychogene verklaringen 
voor dystonie. In hoofdstuk 2 onderzoeken we deze geschiedenis en gaan daarbij uit van 
een spectrum van organisch naar psychogeen. We hebben ons gericht op (i) primair 
gegeneraliseerde dystonie; (ii) cervicale dystonie; (iii) schrijverskramp; en (iv) gefixeerde 
dystonie gerelateerd aan CRPS. We bestudeerden medische teksten vanaf de 19e eeuw 
inclusief de referenties. Jean-Martin Charcot was aanhanger van het concept van hysterie: 
stoornissen waarin naast predispositie omgevingsfactoren een belangrijke rol spelen. 
Sigmund Freud introduceerde de psychoanalyse: een inzichtgevende therapie voor 
psychische stoornissen. Deze ontwikkelingen, tezamen met de afwezigheid van een 
organisch substraat voor dystonie, waren destijds aanleiding voor een nadruk op 
psychogene verklaringen. Dientengevolge werd vele dystonie patiënten verteld dat ze 
leden aan psychologische conflicten en werd hun behandeling daarop gericht. Echter, 
door nieuwe beschrijvingen van families met meerdere aangedane personen in de jaren 
50, de teleurstellende resultaten van psychotherapie bij torsie dystonie, de effectiviteit 
van chirugische behandelingen en de lesie-studies in de jaren 60, raakten meer en meer 
artsen overtuigd van de organiciteit van dystonie. Het ultieme moment was de ontdekking 
van het DYT1 gen in 1997. Inmiddels hadden experts de neurologische gemeenschap al 
overtuigd dat focale dystoniëen zoals cervicale dystonie en schrijverskramp partiële 
uitingen van generaliseerde dystonie waren en dus een organische basis hadden. De 
pathofysiologie van CRPS gerelateerde gefixeerde dystonie bleef echter controversieel. 
                   
S a m e n v a t t i n g  e n  c o n c l u s i e s | 179 
 
 
Kennis van deze ontwikkelingen die zich afspeelden op de grens tussen neurologie en 
psychiatrie is leerzaam en toont hoe ingewikkeld het is een onderscheid te maken. 
Vandaag de dag laten functionele imaging en neurofysiologische studies zien hoe onzeker 
het verschil tussen neurologische en psychiatrische stoornissen is en vervaagt de grens 
tussen organisch en psychogeen. Tegenwoordig wordt verondersteld dat gestoorde 
sensomotorische integratie en corticale exciteerbaarheid een belangrijke rol spelen in het 
ontstaan van dystonie. In feite verklaart het alle onderzochte dystonie varianten en brengt 
het ons terug naar de fysiologie van Sherrington. 
 
Hoofdstuk 3. Thermische hypesthesie bij patiënten met complex regionaal pijnsyndroom 
gerelateerde dystonie 
De kwantitatieve thermische test toonde koude en warmte hypesthesie zonder 
toegenomen hitte pijn sensitiviteit in de aangedane ledematen van CRPS patiënten met 
tonische dystonie (n=44) in vergelijking met gezonde controles met een zelfde leeftijds- en 
geslachtsopbouw (n=35). De mate van koude en warmte hypesthesie was onderling sterk 
gecorreleerd. Deze bevindingen vormen een aanwijzing voor gestoorde verwerking van 
dunne zenuwvezel (dat wil zeggen C en Aδ vezels) informatie bij patiënten met CRPS 
gerelateerde dystonie. 
 
Hoofdstuk 4. Gefixeerde dystonie bij complex regionaal pijnsyndroom: een beschrijvende 
en een modelmatige benadering 
CRPS kan optreden na een trauma, meestal van een ledemaat, en wordt gekenmerkt door 
pijn en stoornissen in bloeddoorstroming, temperatuurregulatie en motorische controle. 
Ongeveer 25% van de patiënten ontwikkelt een gefixeerde dystonie. Betrokkenheid van 
dysfunctionele GABA (gamma-aminoboterzuur)-erge interneuronen wordt verondersteld, 
echter, de mechanismen zijn onzeker. De hypothese in deze studie was dat de dystonie 
het gevolg is van afwijkende proprioceptieve reflexen namelijk een gestoorde 
terugkoppeling van positie, snelheid of kracht. We onderzochten de dystone patronen bij 
85 CRPS patiënten met dystonie systematisch door de houdingen van de gewrichten van 
de aangedane ledemaat te bestuderen. We vergeleken de patronen met een 
neuromusculair computer model dat gestoorde proprioceptieve reflexen simuleerde. Het 
computer model bestaat uit twee antagonistische spieren met een expliciete bijdrage van 
het musculotendineuze systeem, reflexpaden vanuit de spierspoeltjes en Golgi 
peeslichaampje en met tijdsvertragingen die neurale latentietijden vertegenwoordigen. 
Drie scenario's werden met het model gesimuleerd: (i) verhoogde reflex sensitiviteit 
 
180 | S a m e n v a t t i n g  e n  c o n c l u s i e s  
 
(verhoogde sensitiviteit van de reflexboog van zowel agonist als antagonist; (ii) 
onevenwichtige reflex sensitiviteit (verhoogde sensitiviteit van de reflexboog van de 
agonist); en (iii) onevenwichtige reflex uitgangswaarde (verhoogde uitgangswaarde van de 
proprioceptor van de agonist). Gefixeerde houdingen werden gevonden in 123 armen van 
77 patiënten. Het dominante patroon bestond uit flexie van de vingers (116/123), de 
polsen (41/123) en de ellebogen (38/123). Gefixeerde houdingen werden gevonden in 114 
benen van 77 patiënten. Het dominante patroon was plantairflexie van de tenen (55/114), 
plantairflexie en inversie van de enkel (73/114) en knieflexie (55/114). Alleen de simulaties 
met onevenwichtige reflex sensitiviteit voor kracht, afkomstig van Golgi peeslichaampjes, 
leidden tot patronen die veel gelijkenis vertoonden met de houdingen bij patiënten. In 
parallel experimenten met robotarmen is aangetoond dat dystonie patiënten minder goed 
in staat zijn de grootte van de krachtterugkoppeling aan te passen. De bevindingen van 
het huidige neuromusculaire model suggereren dat afwijkende regulatie van 
krachtterugkoppeling van Golgi peeslichaampjes, met betrokkenheid van een inhiberend 
interneuron, ten grondslag liggen aan de karakteristieke gefixeerde flexie houdingen bij 
CRPS patiënten met dystonie. 
 
Hoofdstuk 5. Analyse van ontstekingsmediatoren in de liquor cerebrospinalis bij chronische 
complex regionaal pijnsyndroom gerelateerde dystonie 
Er is overtuigend bewijs voor betrokkenheid van het centrale zenuwstelsel bij 
neuropathische pijn en bewegingsstoornissen bij patiënten met CRPS. Eerder werden 
verhoogde liquorconcentraties van interleukine-1β en interleukine-6 gevonden bij CRPS 
patiënten met of zonder bewegingsstoornissen. Het doel van de studie in hoofdstuk 5 was 
om deze liquor bevindingen te bevestigen en om onderzoek te doen naar eventuele 
nieuwe liquor biomarkers bij chronische CRPS patiënten met dystonie. Liquormonsters 
van 20 patiënten en 29 mensen die spinale anesthesie ondergingen vanwege een 
chirurgische ingreep werden gebruikt. We bepaalden interleukine-1β, interleukine-6, 
interferon-γ induceerbare proteïne 10, RANTES ("regulated upon activation, normal T-cell 
expressed and secreted"), complement C3, mannose-bindend lectine, complement C1q, 
oplosbaar intercellulair-adhesiemolecuul-1, endotheline-1, stikstofoxide, humaan 
lactorferrine en hypocretine-1 concentraties in deze monsters. Er werd geen verschil in 
liquorconcentratie van deze effector mediatoren tussen patiënten en controles gevonden. 
Onze liquorbevindingen ondersteunen een rol van diverse ontstekingsmediatoren of 
hypocretine-1 bij chronische CRPS patiënten met dystonie niet. 
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Hoofdstuk 6. Klinische en neurofysiologische karakterisering van myocloniëen bij complex 
regionaal pijnsyndroom 
De oorsprong van myocloniëen bij patiënten met CRPS is onbekend. Acht patiënten met 
CRPS gerelateerde myocloniëen werden klinisch geëvalueerd en bestudeerd met 
intermusculaire en corticomusculaire coherentieanalyse. De schokken waren in rust 
aanwezig, verergerden tijdens actie en waren vaak geassocieerd met tremor of dystonie. 
Electromyografie toonde een variabele burst duur van 25-240 ms met burst frequenties 
welke varieerden tussen <1 schok/s in rust tot 20 Hz tijdens actie. Coherentie studies 
toonden toegenomen intermusculaire coherentie in de 6-12 Hz band bij vier patiënten, 
zoals ook gerapporteerd is bij patiënten met een versterkte fysiologische tremor. Bij twee 
patiënten werd coherentie tussen de twee lichaamshelften gevonden, wijzend op een 
centrale oorzaak. Significante coherentie entrainment werd gevonden bij 5 patiënten. We 
concluderen dat kenmerken van myocloniëen bij CRPS anders zijn dat bij andere typen 
myocloniëen. 
 
Hoofdstuk 7. Intrathecale baclofen voor dystonie bij complex regionaal pijnsyndroom 
Dystonie bij CRPS reageert slecht op behandeling. Intrathecale baclofen (ITB) kan dit type 
dystonie doen verbeteren, maar de informatie omtrent effectiviteit en veiligheid is 
beperkt. Een enkel-blinde placebo run-in dosis-escalatie studie werd uitgevoerd bij 42 
CRPS patiënten om te onderzoeken of de dystonie ITB-responsief was. Zesendertig van de 
38 patiënten die voldeden aan de responder-criteria ontvingen een pomp voor continue 
ITB toediening en werden 12 maanden vervolgd om de lange termijn effectiviteit en 
veiligheid te onderzoeken (open-label studie). Primaire uitkomstmaten waren Globale 
Dystonie Ernst (beide studies) en Dystonie-gerelateerde Functionele Beperkingen (open-
label studie). De dosis-escalatie studie toonde een dosis-afhankelijk effect van ITB op 
dystonie ernst bij 31 patiënten in doseringen tot 450 µg/dag. Eén patient reageerde niet 
op de behandeling in de dosis-escalatie studie en drie patiënten vielen uit. Zesendertig 
patiënten startten de open-label studie. Intention-to-treat analyse toonde een 
aanzienlijke verbetering bij de door zowel patiënt als onderzoeker gescoorde mate van 
dystonie, pijn, handicap en kwaliteit van leven na 12 maanden. De respons in de dosis-
escalatie studie voorspelde de respons op ITB in de open-label studie niet. Negenentachtig 
bijwerkingen traden op bij 26 patiënten en waren gerelateerd aan baclofen (n=19), 
pomp/catheter systeem defecten (n=52), of konden niet worden gespecificeerd (n=18). De 
pomp werd geëxplanteerd bij 6 patiënten tijdens de follow-up fase. Dystonie, pijn, 
handicap en kwaliteit van leven verbeterde allemaal onder ITB en bleef stabiel over een 
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periode van een jaar. Echter, bij ITB komen in deze patiëntengroep veel complicaties voor 
en verbetering van patiëntenselectie en pomp/catheter-integriteit zijn gewenst. 
 
Hoofdstuk 8. Intrathecale glycine voor pijn en dystonie bij complex regionaal pijnsyndroom 
Omdat glycinerge neurotransmissie een belangrijke inhiberende rol speelt bij het 
verwerken van sensibele en motorische informatie is intrathecale glycine (ITG) toediening 
een potentiële therapie voor zowel pijn als bewegingsstoornissen bij CRPS patiënten. 
Doelen van de studie beschreven in hoofdstuk 8 zijn het onderzoeken van de veiligheid en 
effectiviteit van ITG bij CRPS patiënten met dystonie. ITG behandeling gedurende 4 weken 
werd onderzocht bij CRPS patiënten met dystonie in de periode voorafgaand aan ITB 
behandeling. Twintig patiënten werden beoordeeld en na exclusie van één patiënt werden 
de overgebleven 19 patiënten gerandomiseerd in een dubbel-blinde placebo-
gecontroleerde crossover studie. Veiligheid werd beoordeeld door klinische evaluatie, 
bloedonderzoeken en electrocardiogrammen. Effectiviteitsmaten waren pijn (numerieke 
beoordelingsschaal, McGill pain questionnaire), bewegingsstoornissen (Burke-Fahn-
Marsden dystonia rating scale, unified myoclonus rating scale, tremor research group 
rating scale), activiteiten (Radboud skills questionnaire, walking ability questionnaire), en 
een clinical global impression (CGI) en patient's global impression score (PGI).  ITG-
gerelateerde bijwerkingen waren over het algemeen licht tot matig-ernstig en niet anders 
dan tijdens behandeling met placebo. Tijdens ITG behandeling waren de groeihormoon 
concentraties licht verhoogd. Hoewel er een trend naar verslechtering op de CGI en PGI 
tijdens ITG behandeling was, waren er geen significante verschillen tussen ITG en placebo 
behandeling in elk van de uitkomstmaten. ITG gedurende 4 weken was niet effectief op 
pijn en dystonie bij CRPS. Hoewel er geen ernstige bijwerkingen optraden zijn er meer 
studies nodig om potentiële neurotoxiciteit van ITG uit te sluiten. 
 
Hoofdstuk 9. Effectiviteit en veiligheid van een eenmalige intrathecale methylprednisolon 
toediening bij chronisch complex regionaal pijnsyndroom 
Geactiveerde immuuncellen in het ruggenmerg kunnen een belangrijke rol spelen in de 
ontwikkeling en instandhouding van neuropathische pijn, zoals gebeurt in reactie op een 
perifere ontsteking of weefselschade. Immuunactivatie kan daarom dienen als 
aangrijpingspunt voor immunomodulerende medicijnen zoals corticosteroïden. Deze 
dubbel-blinde gerandomiseerde placebo-gecontroleerde parallel-groep studie onderzocht 
de effectiviteit en veiligheid van een eenmalige intrathecale toediening van 60 mg 
methylprednisolon (ITM) bij chronische patiënten met CRPS. De primaire uitkomstmaat 
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was verandering in pijn (numerieke beoordelingsschaal; bereik 0-10) na 6 weken. Met 21 
personen per groep had de studie een power van 90% om een klinisch relevant verschil 
(≥2 punten) te vinden. Nadat 21 patiënten (10 met ITM) waren geïncludeerd, werd de studie 
voortijdig beëindigd omdat de interim analyse had getoond dat ITM geen effect op pijn 
(verschil in gemiddelde numerieke beoordelingsschaal op 6 weken 0,3, 95% 
betrouwbaarheidsinterval -0,7 tot 1,3) of een van de andere uitkomstmaten had. We vonden 
geen verschil in bijwerkingen tijdens behandeling met ITM en placebo. We concluderen dat 
behandeling met een eenmalige toediening van ITM niet effectief is bij chronische CRPS 
patiënten, wat zou kunnen betekenen dat spinale immuunactivatie geen rol speelt tijdens 
deze fase van het syndroom. 
 
Hoofdstuk 10. Post-punctie hoofdpijn bij complex regionaal pijnsyndroom: een 
retrospectieve observationele studie 
Doel: beschrijving van het ongewone beloop van post-punctie hoofdpijn na een pomp-
implantatie voor ITB toediening bij patiënten met CRPS gerelateerde dystonie. Opzet: 
Patiëntenserie gebaseerd op gegevens welke verzameld werden van 1996 tot 2005. 
Setting: polikliniek bewegingsstoornissen, academisch ziekenhuis. Patiënten: 54 patiënten 
met CRPS gerelateerde dystonie die behandeld werden met ITB. Resultaten: een hoge 
incidentie (76%) en langdurig beloop (mediaan 18 dagen, bereik 2 dagen-36 maanden) van 
post-punctie hoofdpijn werd gevonden. Radionuclide studies werden gedaan bij 2 
patiënten met langdurige symptomen (12-16 maanden) waarbij geen lekkage van liquor 
cerebrospinalis werd gevonden. Bij patiënten zonder tekenen van liquor lekkage (n=38), 
werd een epidurale bloedpleister ('blood patch') aangebracht bij 24 patiënten welke niet 
effectief bleek bij 54%, terwijl ketamine infusie toegediend bij 6 patiënten effectief was bij 
67%. Conclusie: Onze observaties suggereren dat andere mechanismen dan intracraniële 
hypotensie een rol spelen bij het ontstaan en instandhouden van post-punctie hoofdpijn 




Voorafgaand aan de studies in dit proefschrift waren de mechanismen welke ten 
grondslag liggen aan CRPS gerelateerde bewegingsstoornissen slecht begrepen. Eveneens 
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Pathofysiologische studies 
Hoewel thermische hypesthesie eerder werd gevonden bij CRPS patiënten zonder 
dystonie, was dit niet eerder onderzocht bij CRPS patiënten met dystonie. We vonden 
thermische hypesthesie bij CRPS patiënten met dystonie. Kennelijk is er een gestoorde 
verwerking van dunne zenuwvezel (dat wil zeggen C en Aδ vezels) informatie bij deze 
patiënten. Omdat dezelfde afwijkingen werden gevonden bij CRPS zonder dystonie is het 
onzeker of deze afwijking een causale relatie met het ontstaan van dystonie heeft. 
Door de ledematen van 85 patiënten met CRPS gerelateerde dystonie systematisch te 
evalueren, vonden we een dominant patroon van gefixeerde dystonie. Gefixeerde flexie 
van de vingers werd gevonden bij 95% van de aangedane armen en een multisegmentaal 
patroon  van vinger, pols- en/of elleboogflexie en endorotatie/adductie van de schouder 
werd gevonden bij 66% van de aangedane armen. Een vergelijkbaar patroon werd 
gevonden bij aangedane benen: plantairflexie/inversie van de enkel werd gevonden bij 
88% van de aangedane benen en een multisegmentaal patroon van enkel 
plantairflexie/inversie, teen- en/of knieflexie en endorotatie van de heup werd gevonden 
bij 66% van de aangedane benen. Onze modellering studie toonde dat afwijkende 
krachtterugkoppeling van Golgi peeslichaampjes gerelateerd kan zijn aan deze houdingen. 
Onze bevindingen in liquor cerebrospinalis zijn geen ondersteuning van een rol van 
ontstekingsmediatoren bij chronische CRPS patiënten met dystonie. Een zoektocht naar 
liquor biomarkers welke betrokken zijn bij moleculaire paden die een rol spelen bij 
neuroplasticiteit is mogelijk meer succesvol. 
We onderzochten ook acht patiënten met CRPS gerelateerde myocloniëen. Zowel de 
klinische als de neurofysiologische kenmerken waren gevariëerd. De significante 
coherentie entrainment die gevonden werd bij vijf patiënten kan duiden op een gebrek 
aan inhibitie van het centrale zenuwstelsel. Echter, coherentie entrainment wordt ook 
geduid als aanwijzing voor psychogene bewegingsstoornissen. Meer studies naar de 
waarde van entrainment zijn nodig. 
 
Intrathecale therapie studies 
Een eenmalige intrathecale toediening van 60 mg methylprednisolon was niet effectief bij 
chronische CRPS. Ook was continue ITG in doseringen tot 32 mg/24 u niet effectief bij 
CRPS gerelateerde dystonie. ITB verminderde wel de ernst van CRPS gerelateerde 
dystonie, verbeterde de kwaliteit van leven en bleef effectief gedurende een periode van 
een jaar (mediane dosis 615 µg/dag). Helaas was ITB geassocieerd met vele complicaties; 
voor een grotere toepasbaarheid is zowel een betere patiëntenselectie als een betere 
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pomp/catheterintegriteit gewenst. De bevindingen van deze studies ondersteunen een rol 




Studies naar de pathofysiologie van CRPS gerelateerde dystonie hebben zich tot nu toe 
gericht op bepaalde mediatoren in de liquor cerebrospinalis en een aantal 
neurofysiologische kenmerken. 
In tegenstelling hiermee kunnen moderne 'omics technieken tegelijkertijd alle 
metabolieten of eiwitten van biologische monsters bepalen. De uitkomst kan beschouwd 
worden als handtekening of 'endofenotype' van een ziekte. Extrapolatie naar andere 
'omics' data kan helpen bij het ontraadselen van ziektemechanismen. Momenteel worden 
deze studies met gebruikmaking van verschillende lichaamsvloeistoffen van CRPS 
patiënten met dystonie uitgevoerd. 
Het centrale zenuwstelsel reguleert het gedrag van het bewegingsapparaat via vele 
terugkoppelingslussen. Het voorspellen van dat gedrag kan moeilijk zijn. De resultaten uit 
onze modellering studie suggereren dat het zinvol is dystonie te bestuderen met closed-
loop systeem identificatie technieken. Momenteel wordt deze benadering gebruikt in 
klinische studies naar CRPS gerelateerde dystonie. 
Via intrathecale toediening van medicatie, hebben we ons gericht op modulatie van 
voornamelijk spinale mechanismen bij CRPS gerelateerde dystonie. Resultaten van deze 
studies bevestigen de bevindingen van neurofysiologische onderzoeken dat disinhibitie 
een belangrijke rol speelt. Versterking van de centrale GABA-erge, maar niet glycinerge, 
inhibitie lijkt de ernst van de dystonie te kunnen verminderen. Echter, met het oog op de 
vele complicaties van het toedieningsmechanisme dat nodig is voor ITB, zijn GABA-erge 
medicijnen met een betere bloed-hersenbarrière passage wenselijk. 
Pijn en dystonie zijn vermoedelijk stoornissen van neurale circuits en niet het gevolg van 
een enkel defect. Vandaar dat neuromodulatie technieken die aangrijpen op supraspinale 
structuren, zoals repetitieve transcraniële magneet stimulatie of epidurale corticale 
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